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1. Introduction 
 
Adenosine signaling has long been a target for drug development, with adenosine itself or its derivatives 
being used clinically since the 1940s. In the 1970s it became clear that there are receptors for adenosine, and 
there was evidence that methylxanthines such as caffeine, the most commonly consumed drug in the world, 
produces many of its actions by acting as antagonists at adenosine receptors. Towards the end of the 
twentieth century it became clear that there are subtypes of adenosine receptors, now recognized as a family 
of four, that are present in most vertebrates. In fact, extracellular adenosine exerts its actions via specific G 
protein-coupled receptors (GPCRs) divided into four adenosine receptor (AR) subtypes termed A1, A2A, A2B 
and A3. Since the heterogeneity of ARs and their widespread expression throughout the body, the 
development of drugs that selectively affect specific AR subtypes and/or specific components of adenosine 
signaling will hopefully provide new therapeutic opportunities for a large variety of human diseases. The 
knowledge of the complexity of regulatory mechanism controlling the receptor biological response under 
physiological and pathological conditions (1) (2) represent a crucial starting point in the development of 
adenosine-based drugs.  In fact, these receptors are widely expressed and it was demonstrated that they are 
implicated in several biological functions, both physiological and pathological. These include cardiac rhythm 
and circulation (3) (4), lipolysis, renal blood flow (5) (6), immune function (7), sleep regulation (8) (9), 
angiogenesis (10), inflammatory diseases (11) (12), ischemia-reperfusion (13) and neurodegenerative 
disorders (14). Adenosine itself is used clinically (15) for the treatment of supraventricular tachycardia (16) 
(15), and many clinically used drugs (including dipyridamole and methotrexate) may exert their effects by 
altering extracellular adenosine concentrations and signaling. In fact, several pharmacological compounds 
specifically targeting individual ARs have now entered the clinic or clinical studies are ongoing. However, only 
one AR specific agent, the A2A AR agonist regadenoson (Lexiscan; Astellas Pharma), has so far gained approval 
from the US Food and Drug Administration (FDA). Many research programs focused on the adenosine 
signaling in order to identify bioactive compounds that could be useful for the therapy of many AR-mediated 
diseases (17). The complexity of adenosine signaling was primarily responsible for the failure of one of the 
largest clinical trials for an A1 receptor antagonist so far (18) (19). Moreover, since its discovery in the 1983, 
A2B AR lack a selective and potent full agonist that could be helpful in order to deepen the physiopathological 
properties of this receptor (20). In fact, until now NECA, a non-selective AR agonist, has been used as elected 
ligand for the activation of the A2B AR for the understanding of the signaling pathway mediated by this 
receptor, but, obviously with scarce results (21). 
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1.1 G-Protein Coupled Receptors 
 
The superfamily of seven transmembrane domain (7TM) G-protein coupled receptors (GPCRs) represent the 
largest family of membrane proteins in the human genome and nowadays the richest source of targets and 
then drugs for the pharmaceutical industry. There has been remarkable progress in the field of GPCR biology 
during the past three decades. Notable milestones include the cloning of the first GPCR genes, and the 
sequencing of the human genome revealing the size of the GPCR family and the number of orphan GPCRs. In 
fact, a recent and detailed analysis of the human genome reveals over 800 unique GPCRs, of which 
approximately 460 are predicted to be olfactory receptors (22). Based on sequence similarity within the 7TM 
segments, these receptors could be described by belonging to five families (23): 
 the rhodopsin family (701 members) 
 the adhesion family (24 members) 
 the frizzled/taste family (24 members)  
 the glutamate family (15 members) 
 the secretin family (15 members).  
The physiologic function of a huge part of these 800 GPCRs is nowadays unknown: these receptors are 
referred to as orphan GPCRs. However, deorphanization of non-olfactory GPCRs is tough process (24), as they 
are a promising group of targets for the pharmaceutical industry. Actually, the number of still orphan GPRS 
is significantly decreasing, highlighting the efforts of scientific community on this task.  
 
1.1.1 Structure and ligands 
 
GPCRs bear a common structural signature made of seven hydrophobic transmembrane (TM) segments, with 
an extracellular amino terminus and an intracellular carboxyl terminus (Figure 1). The most variable 
structures among the family of GPCRs are the COOH terminus, the intracellular loop between TM5 and TM6, 
and the NH2 terminus, where the greatest diversity is observed. This sequence is relatively short (10–50 
amino acids) for monoamine and peptide receptors, and much larger (350–600 amino acids) for glycoprotein 
hormone receptors, and the glutamate family receptors. The largest amino terminal domains are observed 
in the adhesion family receptors. Interestingly, this structural and functional similarity of GPCRs stands in 
contrast to the structural diversity of the natural GPCR ligands (25).  
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Figure 1: GPCRs diversity in NH2 and COOH termini and ligand binding position. 
 
In fact, ligands can range from subatomic particles (a photon), to ions (H+ and Ca2+), to small organic 
molecules, to peptides and proteins. While many small organic agonists bind within the TM segments, 
peptide hormones and proteins often bind to the amino terminus and extracellular sequences joining the TM 
domains. However, size of the ligand alone cannot be used to predict the location of the binding site: for 
instance, glycoprotein hormones, glutamate, and Ca2+ all activate their respective receptors by binding to 
relatively large amino terminal domains (25) (26). Furthermore, it has been possible to identify small 
allosteric modulators that bind at the TM domains for many GPCRs that bind their native agonists on the 
extracellular loops or the NH2 terminus (27) (28) (29). Our understanding of GPCR structure is based largely 
on the high-resolution structures of the inactive state of rhodopsin (Figure 2). Rhodopsin is commonly used 
for structural studies than most other GPCRs because it is possible to obtain large quantities of highly 
enriched protein from bovine retina and it is also a remarkably stable GPCR, retaining function under 
conditions that denature many other GPCRs. 
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Figure 2: Crystallographic structure of rhodopsin co-crystallized with 11-cis-retinal 
 
Moreover, there are many evidences that let to affirm that GPCRs exist as dimers (or oligomers) and that 
these dimers may be important for G protein activation. Dimerization is an important mechanism of receptor 
activation for the glutamate family of GPCRs (26) (30), where ligand-induced changes in the dimer interface 
of the amino terminal ligand binding domain has been demonstrated by crystallography (31) (32). However, 
the role of dimerization in the activation of rhodopsin family members is less clear and it remains to be seen 
if a receptor dimer is required for G protein activation in some cases. The effect of agonist binding on the 
formation or disruption of dimers is not consistent among the rhodopsin family members that have been 
examined (33). Moreover, ligands interact with individual receptor monomers, and there is currently no 
evidence that ligands could stand in between receptor dimers or span the dimer. If changes in dimerization 
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occur, it is likely a frequently occurring secondary consequence of ligand-induced changes in the arrangement 
of the TM segments. Evidence in support of this comes from biophysical studies on leukotriene B4 
homodimers demonstrating that ligand binding to one protomer leads to conformational changes in its 
partner (34). While dimers may be important for G protein activation, it is essential to understand the 
agonist-induced structural changes that occur in the context of individual GPCR monomers.  
 
1.2 Purinergic Signaling 
 
Adenosine receptors or P1 receptors belong to the large family of purinergic receptors, described and divided 
in two subtypes, P1 and P2, by Geoffrey Burnstock in 1972 (35). Burnstock introduced the concept of 
purinergic signaling after it was shown that ATP was a transmitter in non-adrenergic, non-cholinergic 
inhibitory nerves in the guinea-pig taenia coli (36) and the term purinergic receptor was introduced only to 
describe specific membrane protein that mediate relaxation of gut smooth cells activated by adenosine 
triphosphate (ATP) (P2) or adenosine (P1). P2 receptors have further been divided into two families, P2Y and 
P2X. P2X receptors are ligand-gated ion channels, whereas the P1 or adenosine receptors (ARs) A1, A2A, A2B 
and A3 and P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14) are GPCRs. P2X receptors are 
nonselective cation channels responsible for mediating excitatory postsynaptic responses, similar to nicotinic 
and ionotropic glutamate receptors. P2X receptors are distinct from the rest of the widely known ligand-
gated ion channels, as the genetic encoding of these particular channels, indicates the presence of only two 
transmembrane domains within the channels. These purinergic receptors have been shown to be widely 
distributed throughout the CNS, being present early in evolution in neurons and glia; therefore, are arguably 
the most abundant receptors in living organisms (37). ATP acts as neurotransmitter while interacting with P2 
receptors mainly as a fast excitatory response mediator or as a potent mediator in long-term processes like 
cell proliferation, growth and development, diseases and cytotoxicity. Nowadays, it is not fully clarified 
whether various physiological nucleotide-receptor agonists (e.g. ATP, ADP, UTP, UDP, UDP sugars and NAD+) 
are released by common mechanisms or not. The main ways through which ATP is released extracellularly at 
this moment known are: 
 Exocytotic neuronal vesicular release, (38)  
 Vesicular release of ATP from astrocytes, (39) which perhaps involves lysosomes, (40)  
 ATP binding cassette transporters, (41)  
 Connexin or pannexin hemichannels, (42)  
 Plasmalemmal voltage-dependent anion channels, (43)  
 P2X7 receptors, (44) 
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 Vesicular nucleotide transporter (VNUT), secretory and synaptic vesicles in which ATP can be 
accumulated and released by a Cl- dependent vesicular nucleotide transporter. (45)  
ATP and other nucleotides undergo rapid enzymatic degradation by ectonucleotidases after release. 
Ectonucleotidases are divided in several families and each everyone of these families are expressed in the 
brain:  
 Ectonucleoside triphosphate diphosphohydrolases E-NTPDases, hydrolyze ATP and ADP to AMP, 
 Ectonucleotide pyrophosphatase and/or phosphodiesterases E-NPPs hydrolyze ATP and ADP to AMP 
and Dinucleoside polyphosphates, NAD+ and UDP sugars, 
 Ecto-5'-nucleotidase also called CD73 (Cluster of Differentiation 73) hydrolyze AMP to adenosine, 
 Alkaline phosphatases equally hydrolyze nucleoside tri, di and monophosphates. (37) 
 
1.2.1 Purinergic Transimission  
 
Nucleotides and nucleosides signaling that define the purinergic transmission can be seen as a temporal 
sequence. (46) Nucleotides released physiologically or pathologically from intracellular sources provide 
either an immediate or a delayed response to a local challenge to tissues or cells. (47) The released 
nucleotides can act on the same or on neighboring cells, either to open fast cation channels or for signaling 
on a slower time scale at metabotropic GPCRs. On a more prolonged time scale, the adenine nucleotides are 
converted by the sequential action of ectonucleotidases to the nucleoside adenosine for activation of the 
ARs (Figure 3). Thus ectonucleotidases control the lifetime of nucleotide transmitters and additionally, by 
degrading or interconverting the originally released ligands, they also produce mediators for additional P2 
receptors and nucleosides. Besides the catabolic pathways, nucleotide interconverting enzymes exert their 
action by nucleotide re-phosphorylation and extracellular synthesis of ATP (e.g. ectonucleoside diphosphate 
kinase and adenylate kinase). Furthermore, adenosine can also be sourced intracellularly, through 
subpopulations of neurons and/or astrocytes that release adenosine directly (48). These transformations and 
sequential receptor effects are related to overall biological functions irregularly occurring, such as 
cytoprotection, vascular adaptations, and immune effects, which may be effects in contrast at different 
points in the time sequence (e.g. the rapid effects of nucleotides on P2 receptors tend to boost the immune 
response, while the slower AR effects generally attenuate the immune response). (46)  
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Figure 3: Mechanisms of ATP release, degradation and reception. Abbreviations: Alk-Phos, alkaline phosphatase; Myok, myokinase (adenylate 
kinase); NDK, nucleoside diphosphate kinase; NPPs, nucleotide pyrophosphatase and/or phosphodiesterases; 50-Nuc, 50-nucleotidase; VNUT, 
vesicular nucleotide transporter. (37)  
 
 
 
1.3 Adenosine Receptors 
 
As previously said the adenosine receptors subtypes (A1, A2A, A2B and A3) are members of the superfamily of 
GPCRs belonging to the subfamily of rhodopsin-like receptors and thus, show the typical heptahelical 
structure. Within the rhodopsin-like family A GPCRs, the TM domain is more highly conserved than the 
extracellular loops (ELs). TM helices, consisting of 25-30 amino acid residues each, are connected by six loops, 
three intracellular (IL) loops and three ELs. A disulfide link is formed between two cysteine residues present 
in TM3 and EL2, which are conserved in most GPCRs in order to promote packing and stabilization of a 
restricted number of conformations of these 7 TMs. Extracellular regions contain sites exerting post-
translational modifications, such as glycosilation. The A1 and A3 contain also sites for palmitoylation in the C-
terminus domain. The A2A AR has a long C-terminal segment of more than 120 amino acid residues, which is 
not required for coupling to Gs, probably useful as a binding site for “accessory” proteins. The sequence 
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identity between the human (h) A1 and A3 ARs is 49%, and the hA2A and hA2B ARs are 59% identical. Some of 
these particular conserved residues point to specific functions. In deep, there are two peculiar His residues 
in TMs 6 and 7 of A1, A2A, and A2B ARs: in the A3 AR, this His residue is lacking but another His residue can be 
found in TM3. All this His residues have been indicated by mutagenesis studies to be important in recognition 
and/or activation of the receptor (1) (49). In the beginning, adenosine receptors were divided in subtypes A1 
and A2 following their ability to increase or decrease the activity of adenylate cyclase (AC), respectively (50) 
(51). Then, A2 receptors were further classified, by Daly and coworkers (52), relying on their affinity for the 
endogenous ligand adenosine: A2A with high affinity (0.1-1 μM) and A2B with low affinity (>10 μM). Moreover, 
A3 AR was identified in 1991 through a polymerase chain reaction (PCR) performed on rat cDNA encoding a 
GPCR that showed high affinity (58%) with A1 and A2A AR (53). This “new” receptor revealed an 
unconventional low homology between its homologous in other species (e.g. 72% versus rat A3 AR) 
considering the other ARs (85-95 % of homology versus rat).  
 
1.3.1 Crystallographic structure 
 
Despite 25 years were passed since the discover of all AR subtypes, nowadays only the crystal structure of 
A2A AR has been determined. Nevertheless, ARs characterization began long before the determination of the 
crystal structure of A2A AR: prior to the report of the crystallographic structure of the A2A AR (54), the only 
method to represent the 3D structure of the ARs passed through molecular modeling studies. This approach 
relied on information from convergent sources: homology modeling of the protein and ligand docking, 
receptor mutagenesis (1995) (55), and both qualitative and quantitative structure activity relationship (SAR) 
of ligands. The structure of the A2A AR was determined in multiple forms with different ligands. Both 
antagonist-bound and agonist-bound states of the receptor were solved initially by the Stevens’s group using 
the stabilizing fusion protein T4 lysozyme. Jaakola and coworkers (54), obtained the 2.6 Å crystal structure of 
A2A AR engineered the receptor to improve on thermostability by the insertion of the very stable lysozyme 
from T4 bacteriophage (T4L) for most of the third intracellular loop (Leu209-Ala221), and by deletion of the 
larger part of the very flexible C terminus (Ala317-Ser412) (Figure 4). This construct (A2A-T4L-C) was further 
stabilized during purification with high concentrations of sodium chloride and cholesterol and a receptor-
saturating concentration of the antagonist theophylline, which was replaced by the high affinity agonist 4-
(2-(7-amino-2-(2-furyl)-1,2,4-triazolo[2,3-a]-1,3,5-triazin-5-yl)amino)ethyl)phenol (ZM241385, Figure 14) in 
the final purification step. A2A AR complexes crystallized by Heptares Therapeutics using thermostabilized 
receptors by systematic scanning mutagenesis (StaRs) include several other agonists and antagonists (56).  
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Figure 4: Crystal structure of A2A-T4L-ΔC. (A) Overall topology of A2A-T4L-ΔC. The transmembrane part of A2A-ΔC structure is colored brown 
(helices I to VIII), and the T4L is in cyan. The structure is viewed perpendicular to the plasma membrane. ZM241385 is colored blue, and the five 
lipid molecules bound to the receptor are colored red. The four disulfide bonds are yellow. The sulfate ions are omitted. The extracellular loops 
(ECL1 to 3) are colored green, and the intracellular loops are colored blue (54). 
 
 
The differences in the particular architecture of agonist- and antagonist-bound conformations have been 
analyzed in detail for the A2A AR and by analogy to other ARs (57). The conformation of the A2A AR complex 
with UK-432097 (Figure 5) (57), although lacking a G-protein or equivalent, displays features of an active-like 
conformation, e.g., ionic lock spreading. TMs 5, 6, and 7 engage in most of the conformation movement that 
leads to receptor activation, while the only pronounced movement within TMs 1-4 is a piston-like upward 
movement of TM3 to accommodate an agonist. 
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Figure 5: Ligand UK-432097 and its binding cavity. (A) Overall view of the ligand-binding cavity. The transmembrane part of A2AAR is shown as 
ribbon and colored gray (helices I to VII). Ligand UK-432097 is shown as bright green stick. For comparison, ligand ZM241385 (gray stick) is also 
shown at the position when the two complex structures were superimposed. The binding cavity is represented by orange. (B) Schematic 
representation of the hydrogen-bonding interactions (green dashed lines) between A2AAR and UK-432097. (C) Molecular interactions within the 
ligand-binding cavity for UK-432097 around the adenine moiety. Interacting residues are shown as sticks with side chains colored orange. 
Hydrogen bonds between A2AAR and ligand are shown as black dotted lines. (D) Molecular interactions around the ribose moiety. (E) Molecular 
interactions around the ligand substitution sites. A water molecule is shown as purple sphere. In (B)-(E), residue mutations reported to disrupt 
agonist and/or antagonist binding are indicated with orange squares (57). 
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The agonist-bound structure of A2AAR features a contracted ribose binding region in which hydrophilic 
residues (His) of the pocket are drawn toward H bonding groups of the ribose (Figure 6).201 
 
Figure 6: Structures of the hA2AR in cartoon representation are shown bound to the following ligands: (a) ZM241385; (b) NECA; and (c) 
adenosine.20a 
 
1.3.2 Homomers and Heteromers 
 
Adenosine receptors, like other class A GPCRs, have been thought to exclusively occur in a monomeric state 
for a long time. Monomeric receptors are enough to induce signaling. At least some studies suggest signaling 
via dimers occurs only at higher receptor densities. More recently, however, evidence is accumulating that 
adenosine receptors can form dimeric or, more generally speaking, multimeric or oligomeric structures. 
Through self-association, homo-oligomers (“homomers”) can be formed. Hetero-oligomerization leading to 
“heteromers” may be the consequence of the association between adenosine receptors and preferred 
partners, mostly other GPCRs, including other adenosine receptor subtypes. This phenomenon has been 
demonstrated through a variety of experimental techniques, mostly in artificial cell lines. The use of 
overexpressed recombinant receptors may result in the creation of many more oligomers than naturally 
exist. In some cases, bioluminescence resonance energy transfer (BRET) may detect interactions between 
receptors that are in close proximity in a compact structure such as a coated pit, rather than forming true 
molecular dimers. Furthermore, GPCRs contain hydrophobic regions that can oligomerize, even after 
solubilization in sodium dodecyl sulfate (SDS). Hence, receptor dimerization or oligomerization may occur 
after solubilization in detergent and not be representative of receptor structure and organization in the 
membrane (1).  
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In theory, four homomeric pairs can be predicted for adenosine receptors, but only reports with experimental 
evidence for the occurrence of A1-A1 and A2A-A2A homomers have been published. 
A1-A1. Both Ciruela (58) and Yoshioka (59) used antibodies against the wild-type adenosine A1 receptor to 
show how immunoprecipitation experiments analyzed with Western blotting revealed higher order bands in 
some instances. In another recent study by Briddon (60), A1-A1 homomers, predominantly located at the cell 
surface, were identified with Bimolecular Fluorescence Complementation (BiFC) techniques in CHO cells 
expressing yellow fluorescent protein (YFP) tagged receptors. 
A2A-A2A. The first evidence for A2A receptor homodimerization was provided by Canals et al. (2004)60. The 
authors used both FRET and BRET techniques as well as immunoblotting to show that in transfected HEK293 
cells, overexpressed recombinant A2A AR exist as both homodimers and monomers. They demonstrated, by 
means of cell surface biotinylation experiments, that after detergent solubilization, approximately 90% of 
the cell surface recombinant A2A AR species exists as a homodimer. The same pattern of dimer formation was 
observed for an engineered A2A AR lacking the C terminus, whereas this receptor mutant was no longer able 
to dimerize with the dopamine D2 receptor. A2A AR homodimerization was also demonstrated with BiFC 
techniques by Vidi (61), who also used a combination of fluorescence resonance energy transfer (FRET) and 
BiFC techniques to  demonstrate that recombinant A2A AR exist as higher order oligomers, consisting of at 
least three monomers, at the plasma membrane of differentiated neuronal cells.  
Available evidence points to the interaction of both A1 and A2A ARs with other GPCRs, however no direct data 
have been reported for adenosine A2B and A3 ARs. 
A1-A2A. The two receptors are co-localized in striatal glutamatergic nerve terminals, both pre- and post-
synaptically. This was demonstrated in immunogold blotting and, after detergent solubilization, co-
immunoprecipitation experiments (62). In HEK293 cells transfected with tagged A1 as well as A2A ARs, 
evidence in BRET and FRET experiments was found for a direct interaction between the two recombinant 
receptors. Radioligand binding studies in membranes of these Human Embryonic Kidney 293 cells (HEK293) 
demonstrated that agonist binding to the A2A AR influenced the affinity of (R)-N6-phenylisopropyladenosine 
(R-PIA, Figure 11) for the A1 AR, but not vice versa. These findings constitute a mechanism for fine-tuning the 
release of glutamate by adenosine.  
Nevertheless, heteromerizations such as A1-P2Y1 (59), A1-P2Y2, A1-D1, A2A-CB1 (61) and A2A-D2-CB1, A2A-D3, , 
and A1-Thromboxane A2 (1) have been demonstrated in many studies in literature. 
A2A-D2 The heteromeric pair of A2A AR and D2 receptors is probably the most studied combination. In fact, 
double immunofluorescence experiments with confocal laser microscopy showing substantial co-localization 
of recombinant A2A AR and dopamine D2 receptors in cell membranes of SH-SY5Y human neuroblastoma cells 
stably transfected with human D2 receptor, as well as in cultured striatal cells have been performed (63) (64) 
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There are evidences that heteromerization may also occur between adenosine receptors and proteins 
belonging to other superfamilies, in particular adenosine deaminase and calmodulin, like A1-D1 with 
adenosine deaminase and A2A-D2 with calmodulin. There is thus very good evidence that recombinant 
adenosine receptors can form homo- and heteromultimers. It is less clear, however, whether this has 
important pharmacological consequences in physiological tissues. In a dimeric complex, both receptors may 
not be simultaneously active and signaling. This implies that the signaling pathway and consequentially the 
derived response can be very complex. It is unclear which rules determine how partnerships are formed. 
Thus, the fact that adenosine receptors can form multimeric complexes with different members will 
necessitate much more work on signaling in intact cells in vivo (65).  
 
1.3.3 Desensitization 
 
Continued or repeated exposures to an agonist usually result in a flat receptor-mediated response followed 
by decreasing of this response despite the continual presence of agonist. Kinetically, this process is called 
desensitization (66). GPCRs undergo desensitization through a complex phenomenon involving multiple and 
temporally distinct components. The mechanisms underlying a rapid desensitization frequently involve 
receptor phosphorylation by a family of G protein-coupled receptor kinases (GRKs) resulting in their 
preferential binding to arrestins, that promote desensitization by uncoupling the receptor from its G-protein, 
leading to impaired receptor function (67). Following desensitization, many GPCRs internalize by an arrestin-
dependent process via clathrin-coated pits which leads to the subsequent intracellular dephosphorylation of 
the receptor, and its re-insertion into the cell membrane leading to a resensitized state (68). More prolonged 
agonist activation generally leads to a subsequent down-regulation by lysosomes (69). These processes that 
form the physiological life of a receptor are deeply involved in the receptor-related response. It has been 
already shown that activation of all four AR subtypes eventually leads to their desensitization by different 
mechanisms. Actually, most of these observations are made following administration of non-hydrolysable 
agonists to cell cultures and animals and it is yet unclear how significant a role receptor desensitization plays 
in regulation of ARs by adenosine in vivo under physiological conditions. Studies have shown that upon 
addition of agonists, the A1 AR is phosphorylated and internalized slowly, with a half-life of several hours. In 
contrast, A2A and A2B ARs demonstrate a more rapid rate of down-regulation, usually lasting about an hour. 
Finally, the down-regulation and desensitization of the A3 AR occurs within minutes (70). Thus, it is important 
to understand their regulation in order to design drugs that can exploit or avoid the receptor-mediated 
signaling to treat diseases. 
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A1 AR: Several studies have been carried out to understand the molecular mechanisms underlying A1 AR 
desensitization. In an early study, Parson and Stiles (71) showed that the A1 AR in rat adipocytes desensitized 
upon chronic administration of A1 AR agonist R-PIA (Figure 11), over a period of six days by Alzet minipumps 
(Alza Corporation, Vacaville, CA, USA). A decrease in A1 AR levels and reduced inhibition of isoproterenol-
stimulated adenylyl cyclase activity was detected following R-PIA treatment. These changes were associated 
with decreased levels of pertussis-sensitive G proteins, but an increase in Gs proteins in the plasma 
membranes. Furthermore, adipocyte membranes obtained from R-PIA-treated rats showed enhance 
isoproterenol and forskolin-stimulated adenylyl cyclase. These studies suggest that adipocytes increase the 
stimulatory response (i.e., increase in adenylyl cyclase activity) because of a chronic activation of the A1 AR. 
A subsequent study performed in cultured adipocytes confirmed the in vivo findings and further 
demonstrated that desensitization of the A1 AR was associated with desensitization of insulin-dependent 
glucose transport (72). This suggests a common link between desensitization of the A1 AR and insulin 
receptor. A later study by Longabaugh and coworkers (73) confirmed the previous findings that 
desensitization of the A1 AR to R-PIA was linked to reductions in A1 AR and Gi proteins and an increase in Gsα 
proteins, but showed that the changes in Giα proteins were not dependent by alternations in their mRNA 
levels. Jajoo et al. (74) deepened the role of β-arrestin 1/extracellular signal-regulated kinase (ERK1/2) MAPK 
pathway in the regulation of A1 AR desensitization and recovery in ductus deferens smooth muscle (DDT1-
MF2) cells. They reported that applying the A1 AR agonist R-PIA for 24 h resulted in a decrease of A1 AR on 
the membrane which was associated with an unexpected 11-fold increase in A1 AR mRNA. This effect was 
dependent on β-arrestin 1, knocked-down by siRNA blocked R-PIA-mediated down-regulation of the A1 AR. 
In addition, β-arrestin 1 knockdown by siRNA suppressed R-PIA-dependent ERK1/2 and activator protein-1 
(AP-1) activities and reduced the induction of A1 AR mRNA. Interestingly, withdrawal of the agonist after a 24 
h exposure resulted in rapid recovery of plasma membrane A1 AR, which was dependent on the de novo 
protein synthesis and on the activity of ERK1/2 but independent of β-arrestin1 and NF-κB. These findings 
suggest that the β-arrestin 1/ERK1/2 pathway, which contributes to the desensitization and down-regulation 
of A1 AR, is also able to prime the transcriptional machinery for rapid synthesis of the A1 AR after withdrawal 
of the agonist. Chick embryo retina cultures of eight days treated for 48 h with CGS 21680 and N6-(2(3,5-
dimethoxyphenyl)-2-(2-methylphenyl)ethyl)-adenosine (DPMA), selective A2A AR agonists, showed an 
increased expression of A1AR. This effect was blocked by the selective A2A AR antagonist, ZM 241385 (Figure 
14), and PKA inhibitor N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide (H89) 
(75). These in vitro findings were confirmed in an in vivo study where chick embryo retinas were treated for 
48 h with A1 AR agonist CGS 21680 (Figure 13). In this study, CGS 21680 was able to increase the expression 
of A1 AR which was blocked by selective A2AAR antagonists, SCH 58261 and ZM 241385. Interestingly, under 
normal conditions, endogenous adenosine produced and released into the environment of the retina appears 
to control A2A AR-mediated 
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expression of A1 AR, since the treatment with ZM 241385 and SCH 58261 aa alone was capable of reducing 
the expression of A1 AR (76). These findings indicate that up-regulation of A1 AR by long-term activation of 
A2A AR depends on classical AR signaling pathway.  
A2A AR: Short-term agonist exposure induced a rapid desensitization of A2A AR-stimulated AC activity which 
was associated with a diminished receptor-Gs coupling, and agonist-stimulated phosphorylation of the A2A 
AR. Longer agonist treatment, on the other side, resulted in down-regulation in total receptor number and 
up-regulation of α-subunits of Gi (77). The structural requirements necessary for the agonist-induced 
desensitization of A2A AR resides in its COOH-terminus. Palmer and Stiles (78) introduced various mutations 
in the 95 amino acid sequence of the COOH-terminus of A2A AR which contains ten different phosphorylation 
sites and identified Thr298 to be essential in agonist-induced receptor phosphorylation and short-term 
desensitization, being, at the same time, not involved in long-term desensitization of A2A AR function. These 
findings confirm that short-term and long-term desensitization of A2A AR could be mediated by structurally 
distinct regions of the receptor protein and may involve different mechanisms. 
A2B AR: A serine residue (Ser329), close to the COOH-terminus, was revealed as critical for the rapid agonist-
induced desensitization and internalization of the receptor (79) through point mutation or deletion studies 
of rat A2B AR stably expressed in CHO cells. Due to a GRK-2 and arrestin-dependent mechanism, A2B AR 
undergoes rapid agonist-induced desensitization and internalization. Expression of a dominant negative 
mutant of GRK-2 in NG108-15 cells (80) or antisense-induced inhibition of non-visual arrestins (arrestin-2 and 
-3) in human embryonic kidney (HEK-293) cells (81) efficiently reduced the rate of agonist-induced 
desensitization and internalization of endogenous A2B AR. In another study, A2B AR was shown to internalize 
in an arrestin- and dynamin-sensitive manner (82). On the other hand, second messenger-dependent kinases, 
such as PKA and PKC, did not seem to be involved in agonist-mediated phosphorylation and subsequent 
desensitization of A2B AR (83). Human astrocytoma cells which endogenously expressed A2BAR showed that 
tumor necrosis factor α (TNFα), a pro-inflammatory cytokine, markedly reduced agonist-dependent receptor 
phosphorylation on threonine residues and attenuated agonist-mediated A2B AR desensitization (84). TNFα-
induced inhibition of A2B AR desensitization could result in prolonged A2B AR responsiveness and may 
contribute unregulated activation of astrocytes that eventually occurs in neurodegenerative diseases. In a 
recent study, it was proposed that A2A AR is involved in the expression of A2B AR in human embryonic kidney 
cell line, AD-293, transfected simultaneously with mouse A2A AR and A2B AR. It was found that newly 
synthesized A2B AR is retained in the endoplasmic reticulum (ER) and is eventually targeted for degradation 
by the proteasomes that, when inhibited, was not sufficient to enhance maturation and surface expression 
of the receptor. These findings support the notion that A2A AR and A2B AR form heterodimer complexes for 
trafficking and function (85). 
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A3 AR: A3 AR undergoes rapid desensitization of receptor function after prolonged application of an agonist, 
as a result of phosphorylation of the receptor protein by members of the family of GRKs (86) (87). It was 
demonstrated (88) that a triple mutant, Thr307/Ala307, Thr318/Ala318 and Thr319/Ala319 within the COOH-
terminus, showed marked reduction in agonist-stimulated phosphorylation and desensitization of rat A3 AR. 
Individual mutations of each residue showed that Thr318 and Thr319 are the two major sites for 
phosphorylation where Thr318 appeared to be necessary to observe phosphorylation at Thr319, but not vice 
versa. Moreover, mutation of two palmitoylation sites of rat A3 AR within the COOH-terminus, Cys302 and 
Cys305, which controls the GRK phosphorylation sites, revealed basal phosphorylation even in the absence 
of an agonist. This suggests an important regulatory role of these palmitoylation sites in receptor 
desensitization. Receptor kinetics of A3 AR was studied (89) in human astrocytoma cells. Short-term exposure 
to the agonist 2-chloro-N6-(3-iodobenzyl)-N-methyl-5'-carbamoyladenosine (Cl-IBMECA, Figure 17) caused 
rapid receptor desensitization followed by internalization within 15 and 30 min, respectively. Agonist removal 
resulted in recycling of the A3 ARs to the cell surface within 120 min. Long-term exposure (1–24 h) resulted 
in a higher receptor down-regulation and the restoration of receptor levels was also slow (24 h). MAPK was 
shown to regulate agonist-induced phosphorylation of A3 AR where its stimulation mediated activation of 
ERK1/2 within 5 min of agonist exposure in CHO cells stably expressing A3 AR. Treatment with PD98059, a 
well-characterized MAPK kinase inhibitor, showed impaired receptor phosphorylation, desensitization and 
internalization by inhibiting GRK-2 translocation from cytosol to the plasma membrane. These data suggest 
that A3 AR activation is regulated by ERK1/2 in a feedback mechanism which controls GRK-2 activity and 
prevents receptor phosphorylation (90). These findings could explain the dual and opposite role of A3 AR in 
neuroprotection and neurodegenerative diseases. 
 
1.3.4 Physiopathological role of ARs 
 
Receptor 
name 
Human 
gene 
G proteins Localization 
Potency of 
adenosine* 
A1 AR ADORA1 Gi,o 
Broad distribution: high in nerves, heart, kidney and 
adipose tissue 
10−8 to 10−7 
A2A AR ADORA2A Gs/olf 
Broad distribution: very high in basal ganglia; high in 
nerves, blood vessels and immune cells 
10−8 to 10−7 
A2B AR ADORA2B 
Gs (Gq/11; 
G12/13) 
Broad distribution, but generally low abundance 3 × 10−7 to 10−5 
A3 AR ADORA3 Gi,o 
Restricted distribution, varying in different species: 
high in mast cells 
10−8 to 10−7 
 
Table 1: Adenosine receptors distribution and signaling. *The potency (in mol/l) is determined by the effect of the agonist in cells expressing 
approximately 2 × 105 receptors per cell. 
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Adenosine is fully considered a homeostatic regulator due to the wide range of effects mediated the binding 
at adenosine receptors. ARs play an important role in several key physiological processes, ranging from 
neuromodulation to immune regulation, and from vascular function to metabolic control. One approach that 
has proved to be particularly effective in uncovering the normal physiological roles of adenosine receptors is 
genetic knockout mouse models (91) for all four adenosine receptors (Adora1, Adora2a, Adora2b and Adora3 
are the genes encoding A1, A2A, A2B and A3 ARs, respectively, see Table 1 above) generated by the targeted 
deletion of either of the two critical exons of the adenosine receptors (92). Although detection of the 
pathophysiological roles of adenosine signaling requires models of disease in the genetically modified 
organism, the available genetic knockout mouse models have actually provided important evidences. Two 
lines of Adora1-knockout mice have been generated (93) and Adora1-knockout mice exhibit decreased 
fertility, a significant decrease in lifespan and an increased risk of seizures (6). In the kidney, studies 
conducted on knockout mice have confirmed that the stimulation at A1 AR on the glomerular afferent 
arteriole reduces renal blood flow and the glomerular filtration rate, and stimulation of the A1 receptor on 
the proximal tubules increases sodium and water reabsorption. These studies led to the rational approach 
for developing A1 receptor antagonists to control renal dysfunction in patients with acute heart failure. A2A 
AR are expressed at high levels in the dorsal striatum, a critical basal ganglia structure involved in motor 
control, where they are co-localized with dopamine D2 receptors: they inhibit D2 receptor binding in the 
striatum and immediate-early gene expression. The behavioral effect given by the application of A2A AR 
antagonists partly overlap with those of D2 receptor agonists, useful for the treatment of Parkinson’s disease 
(PD), in which D2 receptors are fully involved, and also influencing working memory (94), reversal learning 
(95) and goal-oriented behavior (96), although leaving spatial reference memory, motor function and 
anxiety-like behaviors intact. Regarding A2A AR, three strains of Adora2a-knockout mice have been generated 
exhibiting reduced exploratory behavior and an higher score in anxiety tests, with male mice being much 
more aggressive towards intruders (97). Due to the reduced activity they gain weight, especially as fat. Their 
response to acute pain stimuli is slower and their blood pressure and heart rate are elevated (98). Genetic 
Adora2a-knockout models have uncovered complex roles of the A2A AR in tissue protection: in fact, A2A AR 
activation confers tissue protection in peripheral organs (99), while its inactivation confers neuroprotection 
against brain injury (100). Genetic knockout models have shown that both A1 and A2A AR are involved in 
mediating the sleep-promoting properties of adenosine in the brain (101) and the arousal effects of caffeine 
seen in wild-type animals are dampened in Adora2a-knockout mice (9) lead to consider that AR ligands could 
be used as normal cognitive enhancers or sleep promoters. Moving on A2B AR, several strains of Adora2b-
knockout mice have also been generated (102) (103). Assumed A2B AR as a low-affinity receptor that is mostly 
expressed at low levels, it could be quiet unexpected that Adora2b-knockout mice have very strong 
phenotypes, especially in relation to the vasculature (103). Adora2b-knockout mice show reduced 
inflammation of the vascular tissue at the baseline and suffer from increased vascular leakiness in several 
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organs (104). A major reason for this evident effect of A2B AR could be that local adenine nucleotide signaling 
is fully involved in this compartment and thus adenosine levels can transitorily be considerably high (104). 
However, an increased susceptibility to ischemic and inflammatory wounds is observed in the intestine, liver, 
kidney, lung and heart of Adora2b-knockout mice (105) (106), with disorders characterized by higher 
extracellular adenosine levels. Under such conditions, studies in Adora2b-knockout mice have shown that 
A2B receptor signaling is implicated in attenuating hypoxia-driven inflammation and in the adaptation of 
tissues to conditions of limited oxygen availability. Moreover, activation of the A2B AR has been shown to 
promote bone cell differentiation, control glucose homeostasis and regulate hyperlipidemia and 
atherosclerosis (107) (108). On the other hand, some harmful effects of A2B AR activation have also been 
reported, including promotion of tumor growth in the bladder and breast, renal fibrogenesis and 
inflammatory damage in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis 
(109) (110). 
Knockout of the A3 AR in mice was similarly surprising, resulting in marked phenotypes even at locations 
where the receptors have a low density (for example, the brain) and where ligands have little effect. (111) 
Interestingly A3 AR knockout mice shown an increased protection from the ischemic damage both in 
Langendorff heart and in vivo coronary occlusion model versus wild type mice (112). These evidences lead to 
hypothesize that the proinflammatory role of A3 AR may be strictly connected with this deletion related 
effect. Moreover, unknown compensatory changes due to the adora3 knockout may contribute to the 
paradox finding of an ischemia-tolerant phenotype (113). A3 KO animals benefit of hemodynamic changes 
due to the increase of A2A and A2B ARs signaling and the conjugated increasing in cAMP release. Nevertheless, 
they suffer of a more pronounced drop of blood pressure than wild-type mice (114). A3 AR KO mice shown 
actually protection from renal failure caused by ischemia-reperfusion injury or by myoglobinuria (115): this 
effect was confirmed by application of A3 AR antagonist, that could be candidate for the renal failure 
treatment. Targeted deletion of A3 AR confirmed the hypothesis that this receptor is involved in glaucoma 
opening to the treatment of this condition, one of the leading cause of blindness (116). 
Adenosine signaling is not largely noticeable in physiological condition, but aberrant adenosine signaling is 
implicated as a common disease mechanism underlying inflammatory and ischemic tissue damage (117). This 
includes excessive inflammatory tissue damage such as in acute liver injury, ischemic kidney injury, acute 
lung injury, traumatic brain injury, ischemic brain injury, epilepsy and some neurodegenerative disorders 
such as Parkinson’s disease and Huntington’s disease (91) (118) (100). As such, enhanced adenosine signaling 
is crucial in these pathological conditions associated with tissue inflammation and remodeling.  
Together with dramatic increases in extracellular adenosine levels, conditions of tissue hypoxia are 
associated with enhanced expression of adenosine receptors, particularly the A2A AR (119) and A2B AR, and a 
marked induction of ENTPD1 (120) (121) and NT5E, as these pathways are tightly controlled on a 
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transcriptional level. During ischemia, activation of A2B AR has been shown to promote ischemia tolerance, 
improve oxygen-efficient metabolism and protect against ischemia-reperfusion injury of the heart, kidneys 
or intestine (122). Triggering A2B AR can reduce the activation and transmigration of inflammatory cells into 
post-ischemic tissues and protect against sepsis-induced mortality by dampening an excessive inflammation 
response to the damage (123). Moreover, activation of A2A receptors on inflammatory cells invading the 
tissue can be an efficient treatment for reperfusion injury (124) (125): for example, activation of A2A AR 
expressed on T cells or dendritic cells (126) has been associated with the attenuation of organ injury during 
hepatic or renal ischemia, respectively. Moreover, A1 AR are downregulated by hypoxia in C6 glioma cells 
(127). 
Adenosine receptor expression may be different as physiological levels in cancer cells, but the significance of 
this is yet unclear. Hypoxia in solid tumors is associated with increased levels of ENTPD1-and NT5E-dependent 
adenosine, causing A2A AR-mediated attenuation of the immune response against cancer. On the other hand, 
A2A AR inactivation in the brain has been consistently associated with protection against brain damage after 
ischemia, excitotoxicity, traumatic brain injury (128) (129) and neurodegeneration in Parkinson’s disease 
(130) and Alzheimer’s disease (131). In some cases, both sides of the A2A AR modulation have a protective 
effect, including in animal models of Huntington’s disease (132) (133) and spinal cord injury.  
Several transcriptional mechanisms contribute to the induction of A2A AR, A2B AR and ecto-nucleotidase 
expression in response to stress, hypoxia and inflammation and other pathological insults as well as a local 
increase in adenosine levels. Hypoxia is associated with a transcriptional program that results in the induction 
of ENTPD1 and NT5E thereby elevating the production of extracellular adenosine production. Moreover, 
ENTPD1 and NT5E have been implicated in the conversion of ATP and ADP to adenosine on regulatory T cells, 
thereby providing an autocrine feedback loop to enhance the anti-inflammatory functions of this subset of T 
cells (134).  
 
1.3.5 Adenosine receptors as therapeutic targets 
 
In the last decades many efforts have been made in order to fully understand AR signaling pathways and 
many AR ligands have been developed as potential therapeutics useful for a wide range of diseases. Many of 
the synthetized compounds nowadays are very potent (in the low nanomolar range or even subnanomolar) 
and selective (100 to 300 times more potent versus the others AR subtypes). However, the biggest issue 
regards druggability, in particular what may concern tissue distribution and bioselectivity. In fact, ARs have a 
broad distribution in the human body and some tissues have a larger “receptor reserve” than other tissues 
(e.g. adipocytes). Decades of expertise and clinical studies gave the chance to better understand how ARs 
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ligands could be useful in therapy and give a clearer view of a very complex scenario, concerning the openly 
wide physiopathological range of effects in which ARs are involved in. In theory, ARs ligands application in 
therapy are partially summarized in Figure 7 and in Table 2 but few of these disease or therapeutic indications 
are targeted by clinical studies and even less are AR ligands in therapy. 
 
 
 
Figure 7: disease targets for selective adenosine receptor ligands (16). 
 
Summarizing, ARs are potential therapeutic targets for Parkinson’s disease, chronic heart failure, 
Inflammatory diseases, autoimmune disorders, chronic neuropathological pain, sickle cell disease and 
cancer.  
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Effects Physiology and pathophysiology 
Adenosine A1 receptors 
Decreased renal blood flow, tubuloglomerular 
feedback and inhibition of renin release 
Physiology 
Inhibition of lipolysis Physiology 
Vasoconstriction Pathophysiology? 
Bronchoconstriction Pathophysiology? 
Inhibition of neurotransmitter release Extreme physiology* 
Inhibition of insulin and glucagon release Physiology 
Reduced heart rate Physiology 
Osteoclast activation and bone resorption Physiology? 
Reduced respiration Extreme physiology* 
Sleep Physiology 
Analgesia Extreme physiology* 
Cardiac preconditioning Pathophysiology 
Adenosine A2A receptors 
Wakefulness and locomotion Physiology 
Neurodegeneration (including Parkinson’s disease, 
stroke, traumatic brain injury and Alzheimer’s 
disease) 
 
Pathophysiology 
Immunosuppression Extreme physiology* or pathophysiology 
Vasodilation and hypotension Physiology or extreme physiology* 
Blood–brain barrier integrity Pharmacology 
Coronary vasodilation Physiology or extreme physiology* 
Inhibition of platelet aggregation Extreme physiology* 
Angiogenesis Extreme physiology* 
Sickle cell disease Pathophysiology 
Fibrosis Pathophysiology 
Adenosine A2B receptors 
Vascular integrity Physiology or extreme physiology* 
Cardiac preconditioning Extreme physiology* 
Sickle cell disease Pathophysiology 
Pro-inflammation (acute injury) and 
antiinflammation 
(some chronic disease states) 
Physiology and pathophysiology 
Fibrosis Pathophysiology 
Adenosine A3 receptors 
Increased mast cell activation Extreme physiology* or pathophysiology 
Airway contraction Pathophysiology 
Inflammatory pain Extreme physiology* or pathophysiology 
White cell chemotaxis Extreme physiology* or pathophysiology 
Chronic neuropathic pain relief Pathophysiology 
Anticancer (melanoma) Pathophysiology 
 
Table 2: Physiological and pathological effects of adenosine receptors (135). *Refers to such conditions such as heavy exercise, being at high 
altitude and unusually high activity in the pathways of the nervous system. 
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A1 AR:  
 Chronic heart failure 
In patients with acute heart failure is definitely common an impaired renal function directly contributing to 
deterioration of the heart and associated with an adverse outcome, including increased mortality. 
Measurement of local adenosine production showed that is often increased in the kidneys of patients with 
heart failure as a result of hypoxia caused by reduced renal perfusion and by stimulation with diuretics (136). 
Based on the demonstrated control of renal function and the implication of A1 AR in the mechanisms 
associated with renal dysfunction, A1 AR antagonists were developed. These antagonists reduced the risk of 
persistent worsening renal failure by more than 50% in a Phase IIb study involving 301 patients with acute 
heart failure, and improved renal plasma flow in 63 ambulatory patients with chronic heart failure (137). 
Thus, a placebo-controlled, randomized Phase III trial involving 2,033 patients with acute heart failure (the 
PROTECT study) was carried out with the A1 AR antagonist rolofylline (Figure 129; this was the largest study 
to date involving the use of A1 AR antagonists targeting renal function. Unfortunately, the results were 
disappointing and rolofylline did not prevent persistent worsening renal function (18) (138). The reason for 
this absence of the kidney protective effects is possibly to be due to an enhanced diuretic effect (as evident 
by more pronounced weight loss), which may have counterweighted the positive effects of rolofylline on the 
preservation of renal function (19). Moreover, pharmacological and genetic studies have extensively 
demonstrated that A1 AR exerts protective effects against ischemic kidney injury and brain injury, which is 
consistent with the increased frequency of stroke and seizure activity in clinical trials of A1 AR antagonists 
(19), thus leading to assert that A1 AR antagonist develop as chronic heart failure therapeutics should proceed 
with caution. It is under this framework where a partial A1 AR agonist could be useful for a potentially 
hemodynamically neutral therapy that could simultaneously improve cardiomyocyte energetics, cardiac 
structure and function, and prevent further tissue injury while being well tolerated when added to 
background medical therapy. Although drug development of a partial A1 AR agonist remains at an early stage, 
compelling biologic rationale and encouraging preclinical evidence support continued attention be given to 
ongoing and future trials with these agents in heart failure (139).  
 Cardiovascular system 
A1 AR activation has many effects in the cardiovascular system, including a reduction in heart rate and atrial 
contractility, and the attenuation of the stimulatory actions of catecholamines on the heart (140) (141). 
Activation of the A1 AR by intravenous infusion of adenosine is used to restore normal heart rhythm in 
patients with paroxysmal supraventricular tachycardia (PSVT). However, for more long-term indications, 
selective A1 AR modulators are needed to avoid side effects related to other AR subtypes such as hypotension. 
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(2S,3S,4R,5R)-5-[6-(cyclopentylamino)purin-9-yl]-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide 
(Selodenoson, DTI0009, GR 56072, RG 14202; Aderis Pharmaceuticals) is a potent and selective A1 AR agonist 
able to control heart rate without lowering blood pressure (142), although it has been reported to have renal 
toxicity during Phase II clinical trials for its capacity to slow heart rate in atrial fibrillation. A1 AR selective non-
nucleoside derivative capadenoson (BAY68-4986, Figure 11) is in trials for treatment of persistent atrial 
fibrillation and is now available as a research tool (143). 
 Pain 
Adenosine exerts multiple influences on pain transmission at peripheral and spinal sites. At peripheral nerve 
terminals in rodents, A1 AR activation produces antinociception by decreasing cAMP levels in the sensory 
nerve terminal (144), thus A1 AR could be useful for neuropathic pain treatment. The functionally important 
regulation of membrane in channels seems to be the domain of A1 AR. Activation of A1 AR enhances K+ and 
Cl- conductance in neurons, leading to membrane hyperpolarization and postsynaptic reduction of neuronal 
Ca2+ influx through voltage- and N-methyl D-aspartate receptor-dependent channels. This counteracts, 
through synaptic and extrasynaptic receptors, nerve cell depolarization (145). A study of 2005 (146) reported 
that capsaicin-induced glutamate release from rat spinal synaptosomes was inhibited by adenosine and 
adenosine A1 AR agonists. These studies suggest that the hyperpolarizing effect of adenosine can inhibit 
excitation of sensory nerves and ameliorate neuropathic pain at the spinal cord level. Moreover, a 2010 study 
by Horiuchi et al. (147) showed how hyperalgesia induced by spinal cord injury (SCI) was significantly inhibited 
by the intrathecal application of 10 nmol Cl-adenosine, a nonselective adenosine receptor agonist. Cl-
adenosine significantly inhibited SCI-induced hyperalgesia at concentrations between 10 and 30 nmol in a 
dose-dependent way. The effect of Cl-adenosine on hyperalgesia after SCI was blocked by the simultaneous 
application of 8-cyclopentyl- 1,3-dipropylxanthine (DPCPX, Figure 12), an A1 AR antagonist. This result 
suggests that the anti-hyperalgesic action of Cl-adenosine is mediated by the stimulation of A1 AR. Intrathecal 
application of R-PIA (10 nmol), an A1 AR agonist (Figure 11), inhibited SCI-induced hyperalgesia. On the other 
hand, intrathecal application of CGS21680, a selective adenosine A2A AR agonist, did not inhibit SCI-induced 
hyperalgesia. These results suggest that adenosine inhibited SCI-induced hyperalgesia through the 
stimulation of A1 AR. A 2015 study by Imlach et al. (148) investigated the changes in adenosine tone and A1 
AR signaling, together with the actions of a novel A1 AR positive allosteric modulator (PAM), VCP171 [(2-
amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone], on excitatory and inhibitory 
neurotransmission at spinal cord superficial dorsal horn synapses in a rat partial nerve-injury model of 
neuropathic pain. In the absence of A1 AR agonists, superfusion of the A1 AR antagonist, DPCPX, produced a 
significantly greater increase in electrically evoked α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor–mediated synaptic current (eEPSC) amplitude in both laminae I and II neurons from nerve-injured 
animals than in controls, suggesting that endogenous adenosine tone is increased in the dorsal horn. 
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Inhibitory GABAergic and glycinergic synaptic currents were also significantly increased by DPCPX in controls 
but there was no difference after nerve injury. The A1 AR agonist, N6-cyclopentyladenosine, produced greater 
inhibition of eEPSC amplitude in lamina II but not lamina I of the spinal cord dorsal horn in nerve-injured 
versus control animals, suggesting a functional increase in A1 AR sensitivity in lamina II neurons after nerve 
injury. The A1 AR PAM, VCP171, indeed produced a greater inhibition of eEPSC amplitude of nerve-injury 
versus control animals in both lamina I and lamina II neurons. Enhanced adenosine tone and A1 AR sensitivity 
at excitatory synapses in the dorsal horn after nerve injury suggest that new generation PAMs of the A1R can 
be effective treatments for neuropathic pain. 
 Parkinson’s disease 
For what may concern Parkinson’s disease (PD), A1 AR is also expressed in the striatum; based on anatomical 
and in vivo microdialysis studies, A1 ARs appear to be localized presynaptically of dopamine axon terminals 
where they inhibit dopamine release. A1 AR antagonists facilitate dopamine release in the striatum, and like 
A2A ARs potentiate dopamine mediated responses (149). Antagonism of both the A2A and A1 AR would be 
synergistic (see Figure 8): inhibition of the A1 receptor will facilitate dopamine release, while inhibition of the 
A2A AR will enhance postsynaptic responses to dopamine. Interestingly, the A1 receptor is also concentrated 
in neocortical and limbic system structures that are important for cognitive function. Pharmacological 
inhibition of A1 receptors enhances neurotransmitter release in the hippocampus and enhances performance 
in animal models of learning and memory (150). 
 
Figure 8: Adenosine receptor implication in the direct and indirect pathways in the motor circuit (151). 
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A2A AR:  
 Parkinson’s disease 
A2A AR antagonists have emerged as leading non-dopaminergic drugs for the treatment of Parkinson’s 
disease, due to many evidences accumulating in the last decades like the concentrated striatal expression of 
A2A AR, the antagonistic A2A-D2 receptor interaction and many preclinical studies demonstrating motor 
benefit in rodent and non-human primate models of Parkinson’s disease (94) (152) (153) (154). Six double-
blind, placebo controlled clinical Phase IIb and Phase III trials of istradefylline (KW-6002, Figure 14), involving 
a total of >2,000 patients with advanced Parkinson’s disease, and one Phase IIb trial with preladenant 
(SCH420814, Figure 14), involving 253 patients with advanced Parkinson’s disease, have been reported (155). 
These clinical Phase IIb and Phase III trials have shown a little but significant reduction in the average ‘off-
time’ by about 1.7 hours compared to the optimal l-DOPA (l-3,4-dihydroxyphenylalanine) dose regimen (154). 
However, another similar Phase III clinical trial with istradefylline in patients with Parkinson’s disease did not 
demonstrate a significant reduction in the ‘off-time’ compared to placebo (156). These relatively modest 
motor effects differed from the unambiguously motor benefit of the preclinical studies in which MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was used in order to cause permanent symptoms of Parkinson's 
disease by destroying dopaminergic neurons in the substantia nigra of the primates’ brain. Clearly, further 
clinical investigation of A2A AR antagonism is necessary to fully understand its potential as a treatment for 
Parkinson’s disease, strengthened by encouraging and consistent finding in the clinical trials of A2A AR 
antagonists for Parkinson’s disease showing that both istradefylline and preladenant had an excellent safety 
profile (154) (155). In April 2007, Kyowa Hakko Kirin Pharma filed a new drug application (NDA) for 
istradefylline for the treatment of advanced Parkinson’s disease; however, the FDA issued a non-approval 
letter in 2008, citing the need for additional efficacy data. Nowadays is ongoing a Phase III long term clinical 
study in subjects with moderate to severe Parkinson's disease. Currently, several Phase IIb and Phase III trials 
for A2A AR antagonists (other than istradefylline) are still underway and these agents remain one of the 
leading non-dopaminergic treatment candidates for Parkinson’s disease (157). 
 Fibrosis 
Both A2A and A2B AR signal for regulation of matrix production via classic GS-mediated activation of cAMP and 
its downstream signaling molecules. The regulatory actions of the receptors likely involve multiple 
interconnected pathways (Figure 9), and one of the more interesting aspects of this regulation is the opposing 
effect of the different levels of cAMP generated (158). Whether this relates to incorporation of alternative 
signaling pathways at higher levels of cAMP or the activation of discrete signaling pathways at different sites 
in the cell remains a subject for further investigation. Additionally, adenosine signaling also contributes to 
fibrosis in organ-specific ways and may have opposite effects in different organs. The deposition of collagen 
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by fibroblasts is an essential part of wound healing but also contributes to pathologic remodeling of organs, 
which can lead to substantial morbidity and mortality. Many small molecules contribute to the pathogenesis 
of fibrosis including the purine adenosine which signals primarily through A2A and A2B AR. These receptors are 
helpful in order to reduce inflammation and promote wound healing. On the other side, excessive activation 
leads to architectural disruption and loss of organ integrity in a variety of fibrosing disorders. The 
development of drugs that selectively target these receptors will disrupt the pathogenesis of fibrosis and 
slow or arrest the progression of these important diseases. 
 
Figure 9: Cross-talk of adenosine receptor signaling pathways leading to collagen deposition and fibrosis. Collagen III is separately regulated by 
p38, inhibition of ERK via PKA, and Akt pathways. Collagen I is shown being positively regulated by Epac2. Additionally, A2AR inhibits Fli1, which 
promotes CTGF transcription and fibrosis (158). 
 
 Sickle cell disease 
Treatment with an A2A AR agonist has been indicated to attenuate sterile inflammation and T cell activation 
in this disorder (159). A clinical trial in patients with sickle cell disease is currently being conducted using the 
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FDA-approved A2A AR agonist 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-
yl]purin-2-yl]- N-methylpyrazole-4-carboxamide (Regadenoson, CVT-3146). 
 Pain 
Assumed that A2A AR is known to exert an hyperalgesic modulation in spinal cord (see A1 AR above), another 
study of 2007 by Hussey et al. (160) deepen the role of A2A AR concerning peripheral nociception, monitoring 
the response of NMDA and NK1 receptor in adora2 knockout mice. The results showed that there was a 
significant reduction in nociceptive behaviour as measured by both bites/licks and flinches in response to 
formalin injection. This pattern was similar when using the selective A2A AR antagonist 5-amino-7-(2-
phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine (SCH58261). Although the response 
to SCH58261 observed in this study was not dose-dependent, 3 mg/kg and 10 mg/kg were chosen on the 
basis of their selectivity for the A2A AR. In our study this is also suggested by the lack of significant difference 
between results obtained using the A2A AR knockout mice and SCH58261. There was a significant reduction 
in time spent biting/licking the formalin-injected paw during the first phase only, with a reduced number of 
flinches observed during both the first and second phases of the test. Although the mechanisms underlying 
the formalin test are complex it was chosen as it consists of two distinct phases, with the first phase being 
generally accepted to be mediated primarily by direct stimulation of peripheral sensory nerves whilst the 
second phase is due to an inflammatory component and involves more complex pain circuitry. The reduced 
response observed during the first phase in A2A AR knockout mice further suggests that peripheral adenosine 
A2A AR are involved in stimulation of nociceptive afferent fibres projecting to the spinal cord. This contrasts 
with Borghi et al. (161) who showed that administration of the selective A2A AR agonist CGS21680 (Figure 13) 
caused a reduction in nociceptive behavior during the first phase which might suggest that the receptor has 
an antinociceptive role. The reduced response as measured by flinches observed during the second phase of 
the formalin test in both A2A AR knockout mice and mice treated with SCH58261 further implicates the A2A 
AR in nociceptive circuits and could be linked to altered NMDA glutamate receptor signalling. The NMDA 
glutamate receptor is a key proponent of central sensitization which is a feature of the formalin test and 
occurs as a result of repetitive stimulation of afferent fibres projecting to the spinal cord. This repetitive 
stimulus induces activation of the NMDA glutamate receptor and leads to calcium entry through the receptor 
and the consequent changes in the post-synaptic membrane. Thus, the loss or blockade of A2A AR causing a 
reduction in nociceptive behaviour in the first phase will be associated with reduced direct activation of 
primary afferent fibres and therefore decreased activation of NMDA glutamate receptors located centrally 
and this is likely to result in a reduction of the central sensitization which characterizes the second phase. In 
conclusion, the decrease in NMDA glutamate receptor binding in A2A AR knockout mice and the reduced 
response to the formalin test in A2A AR knockout mice and mice treated with the selective A2A AR antagonist 
SCH58261 were most probably caused by changes occurring in peripheral nociceptive transmission as a 
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consequence of the genetic knockout or blockade of A2A AR at sensory terminals. These results support a key 
role for the A2A AR in peripheral nociceptive pathways. 
 
A2B AR:  
 Inflammation 
Much research has focused on the regulation of the inflammatory response by the A2B AR. In a study of 2006, 
was generated an A2B AR knockout (KO) mouse model (103) showing that the A2B AR is highly expressed on 
macrophages and that A2B AR KO mice have a mild increase in plasma levels of the pro-inflammatory 
cytokines, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6), and decreased plasma levels of the 
anti-inflammatory cytokine, IL-10, following lipopolysaccharide (LPS) stimulation as compared to wild type 
(WT) mice. These results suggest that the A2B AR dampens the inflammatory response. Further studies have 
shown an anti-inflammatory role for the A2B AR. For example, activation of the A2B AR with BAY60-6583, a 
specific A2B AR agonist, inhibits superoxide generation by neutrophils (162). Importantly, in vivo studies have 
elucidated mechanisms in addition to alteration of cytokine levels that explain how the A2B AR affects the 
pathogenesis of inflammation. A2B AR KO mice have increased expression of adhesion molecules intracellular 
adhesion molecule (ICAM-1) and E-selectin, which increases leukocyte rolling and adhesion (103). 
Furthermore, A2B AR KO mice exhibit enhanced neutrophil infiltration into tissues under hypoxic conditions 
(104). These studies suggest that the A2B AR prevents inflammatory cell transmigration into the tissue of 
interest, one of the first steps in the inflammatory response. In addition, the A2B AR affects alternative 
macrophage activation. Adenosine and NECA enhance the expression of markers of alternative macrophages 
(arginase 1, tissue inhibitor of matrix metalloproteinase-1, and macrophage galactose-type C-type lectin-1). 
Pharmacologic inhibition of the A2B AR or genetic lack of the A2B AR prevents NECA-induced expression of 
these alternative macrophage markers (163), suggesting that A2B AR promotes alternative macrophage 
development. Furthermore, Ryzhov et al. generated an A2B AR KO mouse using a different targeting construct 
and determined the ability of the A2B AR to mediate two actions of NECA: (1) stimulation of IL-6 release and 
(2) inhibition of LPS-induced TNF-a release (164). In this study, NECA increases plasma IL-6 levels in WT but 
not A2B AR KO mice, suggesting that the A2B AR promotes inflammation by increasing IL-6 levels. They also 
found that NECA decreases LPS-induced TNF-a levels in both WT and A2B AR KO mice, suggesting that the A2B 
AR does not dampen inflammation in response to LPS. Despite these results that suggest that A2B AR 
activation by NECA promotes inflammation, this study also found that macrophages derived from A2bAR KO 
mice secrete more TNF-a than WT mice. These studies underlie important considerations in studying the A2B 
AR as well as other receptors. First, genetic lack of a receptor does not always predict the results of 
pharmaceutical modulation of the receptor. Knockout mouse models are helpful in determining the role of 
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a receptor in pathologic processes; however, developmental effects of genetic alteration can impact the 
interpretation of the results. Lack of the A2B AR throughout development may upregulate other proteins to 
compensate for lack of the A2B AR. Pharmacologic modulation of a receptor, unlike knockout mouse models, 
determines how alteration of cellular signaling affects a particular point in time, but may not mimic lifelong 
lack of a receptor. Second, use of pharmacologic modulators requires thorough understanding of the action 
of the agents on potentially other targets. The presence and activity of other receptors may influence the 
effect of A2B AR on particular process. In fact, NECA is a non-specific adenosine receptor agonist that can 
activate all four of the adenosine receptors, which makes it more difficult to conclude which receptor is 
responsible for certain actions of the compound. Different cell types, each expressing the A2B AR may have 
opposing downstream outcomes in response to modulation of the receptor. The initial in vivo studies that 
supported an anti-inflammatory role for the A2B AR showed that TNF-α levels following LPS injection are 
greater in A2B AR KO mice, than control counterparts (103). In a different disease model, that of cecal ligation 
and puncture-induced sepsis, A2B AR signaling on non-hematopoietic cells was the main contributor to 
reducing cytokine and chemokine production (123). Furthermore, the A2B AR is protective in acute 
inflammation as evidenced by the findings that A2bAR KO mice have increased pulmonary inflammation 
following acute injury from hypoxia (104) or ventilator-induced lung injury (107). Overall, when interpreting 
studies on the role of the A2B AR in inflammation-induced processes, it is important to consider timing of A2B 
AR activation or inhibition (pharmacologic or genetic), specificity of pharmacologic agents, model systems, 
and cell types as well as acute versus chronic responses studied. In addition, when studying inflammation in 
vivo, the influence of housing facilities with potentially somewhat different pathogen screens, could impact 
experimental outcomes. 
 Cancer 
Growing evidence indicates that A2B AR potentially plays a pathophysiological role in human cancer (Figure 
10) and might serve as a target for novel therapies or co-therapies for cancer. First, A2B AR is highly expressed 
in various types of tumor cell sort issues and promotes tumor-cell proliferation. For instance, A2B AR was 
found to be overexpressed in colorectal carcinoma cells and tissues, and inhibition of A2B AR blocked the 
proliferation of colon cancer cells (165). In prostate cancer, A2B AR increased cancer-cell proliferation in both 
ligand- dependent, and ligand-independent manners (166) (167). In human oral cancer, A2B AR was shown to 
be upregulated in oral squamous carcinoma cells, and A2B AR knockdown reduced the proliferation of oral 
cancer cells through HIF-1a activation (168). Moreover, A2B AR was reported to foster bladder and breast 
tumor growth in syngeneic mice (110). Second, A2B AR modulates tumor-cell metastasis. A2B AR was 
implicated in promoting breast cancer cell migration in vitro and lung metastasis in vivo (169) (170), although 
the underlying molecular mechanism was not fully elucidated. However, the results of a subsequent study 
suggested a possible explanation: A2B AR activation suppressed the prenylation of the small GTPase Rap1B 
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and diminished Rap1B-mediated cell adhesion, which promoted cell migration (171). Third, A2B AR might 
regulate the tumor microenvironment, including the surrounding blood vessels, immune cells, fibroblasts, 
and the extracellular matrix. Ryzhov and colleagues provided the first genetic evidence indicating that A2B AR 
regulates vascular endothelial growth factor (VEGF) production from tumor-infiltrating host immune cells 
and thereby promotes tumor growth (172). Concomitantly, other groups suggested that A2B AR alters 
angiogenesis by regulating the production of a wide array of pro- or anti-angiogenic factors such as basic 
fibroblast growth factor (bFGF), angiopoietin 2, and a subset of cytokines (173) (174) (175). In addition to 
affecting angiogenesis, A2B AR regulates dendritic-cell differentiation and function (176) (177) and alternative 
macrophage activation (163) and thus contributes to cancer progression. Thus, A2B AR exerts various effects 
on tumor progression and metastasis. Notably, most of the aforementioned evidence was collected using in 
vitro systems, and it is critical to further confirm the role of A2B AR in cancer by using in vivo models before 
A2B AR is used as a potential cancer therapeutic target. 
 Cardiovascular system 
Cardiovascular disease (CVD) comprehends coronary artery disease (myocardial infarction, angina pectoris, 
heart failure), cerebrovascular disease (stroke, transient ischemic attack), peripheral artery disease, and 
aortic atherosclerosis and aneurysm. CVD is the leading cause of death in the world (178). Atherosclerosis is 
an underlying etiologic factor in many types of cardiovascular disease. The pathogenesis of atherosclerosis 
involves endothelial dysfunction, subendothelial accumulation of low density lipoprotein (LDL) and 
subsequent oxidation (179). Oxidized LDL promotes endothelial cell expression of adhesion molecules (like 
ICAM-1 and E-selectin) and secretion of chemokines (like TNF-a), leading to the intimal accumulation of lipid-
laden macrophages, called foam cells. Further accumulation of cholesterol, inflammatory cells, and apoptotic 
cells forms the necrotic core of the atheroma, which is encapsulated by collagen and proliferating smooth 
muscle cells (179). Intervention at one or several of these steps in the development of atherosclerosis may 
prevent subsequent thrombotic events. The function of the A2B AR in the pathogenesis of atherosclerosis has 
been studied. In one approach it was investigated the effect of adenosine on foam cell formation (180) in 
hypoxic conditions (1% O2) using an in vitro model of foam cell formation, which involved differentiating the 
human myelomonocytic cell line U937 or human peripheral blood mononuclear cells into macrophages and 
then incubating the cells with oxidized LDL to form foam cells. The authors found that hypoxia selectively 
induces A2B AR expression in U937 cells, differentiated macrophages, and foam cells. Moreover, adenosine 
promotes hypoxia-inducible factor-1a (HIF-1a) protein and HIF-1a induces expression of vascular endothelial 
growth factor (VEGF) and promotes foam cell formation via the A2B AR and A3 AR specifically (180). These 
results suggest that antagonists to the A2B AR and A3 AR may be beneficial in preventing atherosclerotic 
plaque formation. In contrast, a later study using an in vivo mouse model of atherosclerosis found that the 
A2B AR is protective against plaque formation (109). To promote atherosclerosis development, A2bAR KO 
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mice were bred onto an ApoE background (A2B AR, ApoE double KO) and the mice were fed Western diet. A2B 
AR, ApoE double KO mice have increased plasma and liver cholesterol and triglycerides and larger 
atherosclerotic plaque lesions as compared to ApoE mice. Importantly, injection of the A2B AR specific agonist, 
BAY60-6583 (Figure 15), into ApoE mice reduces atherosclerotic plaque formation and plasma lipid levels. As 
a mechanism to explain the effect of the A2B AR on lipid metabolism, hepatocytes isolated from A2B AR, ApoE 
double KO mice express higher levels of sterol regulatory element binding protein-1 (SREBP-1), a key 
transcription factor in lipogenesis and cholesterol synthesis, while BAY60-6583, reduces hepatocyte 
expression of SREBP-1. As such, this study identified the A2B AR as atheroprotective secondary to modulation 
of lipid metabolism and plaque formation. 
In addition, adenosine signaling has been implicated in mediating cardioprotective cellular responses to 
myocardial ischemia (181). Ischemic preconditioning, which involves repeated short episodes of ischemia 
and reperfusion prior to myocardial infarction (MI), has been shown to reduce infarct size after MI (182). 
Interestingly, A2B AR gene expression is elevated in the hearts of individuals with ischemic heart disease as 
compared to healthy controls (102) and A2B AR expression increases after ischemic preconditioning (183). 
Using a model of murine in situ preconditioning, Eckle et al. (184) showed that A2B AR signaling is necessary 
for the cardioprotective effect of ischemic preconditioning. Ischemic preconditioning reduces infarct size in 
WT, A1 AR KO, A2A AR KO, and A3 AR KO mice, but not in A2B AR KO mice after 2 hours of reperfusion. 
Furthermore, activation of the A2B AR with BAY60-6583 reduces infarct size after ischemia. Further studies 
by the same group showed that A2B AR signaling stabilizes the circadian rhythm protein, period 2 (Per2) within 
2 hours to promote a protective metabolic switch in carbohydrate utilization (102). The group also showed 
that A2bAR signaling in bone marrow-derived cells is primarily responsible for the cardioprotective effect in 
ischemia-reperfusion injury, suggesting an additional role for A2B AR regulation of inflammation in mediating 
cardioprotective effect (185). In contrast, amore recent study did not find a role for the A2B AR in acute 
ischemic preconditioning (186). The authors report no difference in infarct size following ischemic 
preconditioning in A2B AR KO mice as compared to WT mice. However, consistent with the original report, 
they find that treatment with BAY60-6583 reduces infarct size and conclude that the A2B AR may play a role 
in a later phase of ischemic preconditioning. 
Moreover, the current management of symptomatic coronary artery disease includes coronary reperfusion 
with percutaneous coronary intervention (PCI), which involves balloon angioplasty and stent placement at 
the site of the previous arterial blockage. The pathogenesis of restenosis is believed to involve arterial injury 
and neointimal proliferation with macrophage accumulation (187). Research into medical therapy that can 
reduce the rate of restenosis after PCI has gathered interest. One such agent that is being investigated is 
cilostazol, a phosphodiesterase inhibitor that results in an increase in intracellular cyclic AMP (cAMP). The 
A2B AR, which when activated also increases cAMP levels, has been studied as a therapeutic target in 
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restenosis. The A2B AR has been shown to be protective against restenosis following vascular injury. In a 2008 
study, a guidewire-induced femoral artery injury model in mice was used to mimic angioplasty (188) A2B AR 
KO mice have increased neointimal formation following femoral artery injury as compared to WT mice. In 
addition, the chemokine receptor CXCR4, which promotes cell migration and neointimal hyperplasia, is 
upregulated in platelets, macrophages, and leukocytes derived from A2B AR KO mice. Furthermore, the A2B 
AR plays a role in vascular smooth muscle cell (VSMC) proliferation, one of the pathologic steps of restenosis, 
as VSMCs from A2B AR KO mice proliferate faster than those derived from WT mice. These studies suggest 
that A2B AR activation may be beneficial in preventing restenosis following PCI, a conclusion that was recently 
tested. In accordance, a study of 2012 by Bot et al. (189) showed that activation of the A2B AR with BAY60-
6583, the A2B AR specific agonist, for 18 days following wire-induced vascular injury of the left common 
carotid artery in Apolipoprotein E (ApoE) deficient mice reduces lumen stenosis and media size. As a 
mechanism to explain this result, the authors noted that in vivo and in vitro treatment with BAY60-6585 
decreases VSMC proliferation. Moreover, the authors also demonstrated that BAY60-6583 increases collagen 
content, which suggests that A2B AR activation may also promote plaque stability. Overall, these studies show 
promising effects of A2B AR agonism on reducing restenosis.  
Vascular smooth muscle cells (VSMCs) are important in the regulation of vascular tension and have high 
expression of the A2B AR (103). VSMCs contract or dilate in response to changes in calcium (Ca2+) levels that 
result from ligand stimulation of surface receptors (190). It is known that activation of the A2B AR by coupling 
to Gs and Gq results in downstream increases in cAMP and IP3, respectively. IP3 results in elevated cytosolic 
Ca2+ and contraction of VSMCs whereas increases in cAMP results in decreased Ca2+ and relaxation of VSMCs. 
These changes in Ca2+ levels cause perturbation of the cytoskeleton leading to VSMC contraction or 
relaxation. Ca2+ bound to calmodulin in VSMCs activates myosin light chain kinase (MLCK), which 
phosphorylates the regulatory light chains of myosin by adding a phosphate group to Ser-19. The 
phosphorylation of myosin light chains causes cycling of myosin heads on actin, which culminates in VSMC 
contraction. Thus, the specific nature of downstream signaling of the A2B AR (via IP3 or cAMP) in VSMCs alters 
the final impact of A2B AR stimulation on modulation of VSMC contractility and vascular tension. Several in 
vitro studies have examined the role of the A2B AR in relaxation of VSMCs, using A2-type AR agonist-treated, 
precontracted isolated aortas using a force transducer to measure tension. One study showed that NECA, 
the nonspecific adenosine receptor agonist as well as CGS21680, the A2A AR specific agonist, elicit 
vasodilation in Prostaglandin F2α (PGF2α)-precontracted porcine arterial rings (191). When potassium 
chloride (KCl) is used to precontract the arterial rings, neither NECA nor CGS21680 (Figure 13)  treatment 
causes vasodilation. This study suggests that the A2A AR (and perhaps the A2B AR) are important for 
vasodilation of porcine arterial rings. In vivo studies have also been undertaken to interrogate the role of the 
A2B AR in controlling vascular tension and blood pressure. In one study, blood pressure was measured by tail 
cuff and by arterial catheterization in young (8–12 weeks old) WT and A2B AR KO mice at baseline as well as 
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following adenosine infusion and showed no difference between genotypes, suggesting that the A2B AR plays 
no role in blood pressure regulation in young mice (103). In a mouse model of bleomycin-induced pulmonary 
hypertension secondary to pulmonary fibrosis, A2B AR signaling was found to play a role in vascular 
remodeling and proliferation. Another study found A2B AR KO mice showed decreased systolic and mean 
arterial blood pressure with angiotensin II infusion as compared to WT mice (192). Furthermore, angiotensin 
II-induced ET-1 production in the kidneys of WT mice but not in A2B AR KO mice or mice treated with an A2B 
AR antagonist. Furthermore, the authors found increased levels of A2B AR mRNA in kidney biopsies of 
hypertensive chronic kidney disease patients. Together, these in vivo models show that the A2B AR may 
promote vascular remodeling via factors such as ET-1. As noted, there are seemingly conflicting reports on 
the role of the A2B AR in regulating vascular dilation and resistance, possibly due to differences in downstream 
signaling (Gs and/or Gq), cell type, and model system tested. In addition, results are likely influenced by the 
examined species, as well as the methods employed to measure vascular tension and resistance.  
 Renal diseases 
Several studies have indicated a critical role of A2B AR in mediating the progression of diabetic nephropathy. 
Patel et al. and Valladares et al. observed that inhibition of A2B AR activation suppressed VEGF production in 
glomeruli and further attenuated renal dysfunction in diabetic nephropathy; these data suggested a 
protective role of A2B AR antagonists in VEGF-induced diabetic nephropathy (193) (194). However, this view 
was challenged by Tak et al., who reported elevated VEGF levels in diabetic A2B AR-knockout mice (195); 
concordantly, diabetic nephropathy was highly severe in mice with global or vascular endothelial tissue-
specific A2B AR deletion, but not in mice with tubular-epithelial A2B AR deletion. Therefore, Tak et al. 
suggested that vascular A2B AR signaling is the key mediator of kidney protection during diabetic nephropathy 
(195). The methods used and the specific tissues studied by the aforementioned groups were distinct, which 
might explain their conflicting observations on the role of A2B AR during diabetic nephropathy. Moreover, the 
different time window in which A2B AR inhibition was induced pharmacologically and genetically might also 
contribute to the discrepancy in the results (196). In addition to playing a role in diabetic nephropathy, A2B 
AR has been suggested, based on studies on several mouse models, to protect against renal fibrosis. In ADA-
deficient mice, a high level of adenosine in kidney tissues resulted in proteinuria and renal fibrosis, and 
treatment with A2B AR antagonists attenuated renal dysfunction and fibrosis (197). Moreover, genetic 
deletion of A2B AR protected against renal fibrosis in both mice infused with angiotensin II and mice subjected 
to unilateral ureteral obstruction (197). Furthermore, renal biopsy samples from patients with chronic kidney 
disease (CKD) showed higher levels of A2B AR expression than did samples from patients without CKD (192). 
All of these data suggest that A2B AR could serve as a potential therapeutic target in the treatment of CKD 
(Figure 10). Acute kidney injury, a devastating kidney disease, is often caused by renal ischemia. Rigorous 
studies from different laboratories have suggested a pivotal role of A2B AR in acute kidney injury. For example, 
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Grenz et al. used genetic and pharmacological approaches to reveal a role of A2B AR in protecting against 
renal injury resulting from ischemia, although the underlying molecular mechanism was not fully clarified 
(198). Subsequently, the same group proposed two possible explanations for how A2B AR might provide renal 
protection: one, A2B AR reduces neutrophil-dependent TNF-α production and suppresses inflammation (199); 
and two, A2B AR promotes optimal post ischemic blood flow within the kidney and thereby ensures the 
maximal return of blood flow, tissue oxygenation, and removal of waste products from the ischemic kidney 
through the A2B AR -ENT1 (equilibrative nucleoside transporter) pathway (200). 
 Diabetes 
Recently, A2B AR in particular has been suggested to function as a critical regulator in diabetes mellitus (DM) 
(201) (202) (203) (196) (204) (205). In a type I DM model, the non-selective receptor agonist NECA blocked 
diabetes development, and this appeared to be mediated by A2B AR-dependent suppression of 
proinflammatory cytokine production (206). These data suggest that A2B AR represents a potential target for 
the treatment of type I diabetes (Figure 10). Conversely, some of the evidence obtained using a type II DM 
model indicated that A2B AR plays a pro-diabetic role. Figler et al. suggested that A2B AR activation increases 
insulin resistance by elevating the production of proinflammatory mediators such as IL-6 and C-reactive 
protein (207). Deletion of the A2BAR gene and selective blockade of A2B AR in mice reduced hepatic glucose 
production and enhanced glucose disposal into skeletal muscle and brown adipose tissue (207). By contrast, 
other studies suggested an anti-diabetic role of A2B AR. Johnston-Cox and colleagues showed that A2B AR plays 
an essential role in high fat diet (HFD)-induced insulin resistance in mice, and mice lacking A2B AR displayed 
diminished glucose clearance and elevated insulin resistance and inflammatory cytokine production (202). 
The underlying cellular mechanism here is mediated by A2B AR expressed in macrophages: reinstatement of 
macrophage A2B AR expression in A2B AR -null mice restored HFD-induced insulin tolerance and tissue insulin 
signaling to the level in control mice. The molecular mechanism involves A2B AR altering cAMP signaling and 
the levels of macrophage cytokine expression and secretion, and this regulates the levels of insulin receptor-
2 and downstream insulin signaling (203). Similar results were obtained by Csoka et al., who suggested that 
A2B AR plays a crucial role in sustaining glucose homeostasis and preventing insulin resistance under normal 
dietary conditions by regulating alternative macrophage activation. Insulin- and glucose-induced glucose 
clearance was impaired in A2B AR -knockout mice that were fed chow diet, and these knockout mice also 
exhibited a low level of physical activity, which might contribute to decreased insulin sensitivity in skeletal 
muscles. Csoka et al. also highlighted the complex role of A2B AR in regulating liver metabolism (208). 
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Figure 10: Schematic presentation of the role of A2B AR in various human diseases (21). 
 
 Pain  
In a 2016 study, Hu et al. (209) report that sustained elevated circulating adenosine signaling via A2B AR is 
required for chronic pain behavior and neuronal hypersensitivity in three independent animal models, 
including adenosine deaminase (ADA) -/-, sickle cell disease (SCD), and complete Freund’s adjuvant-injected 
(CFA) mice. Surprisingly, adenosine-dependent pain behavior did not involve direct and acute actions of A2B 
AR on primary nociceptors. Instead, elevated adenosine required A2B AR signaling in myeloid cells to stimulate 
sensory hyperexcitability and hypersensitivity through IL-6 and sIL-6R, and consequent trans-activation of 
gp130, which stimulates a STAT3-dependent enhancement of TRPV1 gene expression in DRG neurons. These 
findings reveal an unexpectedly important role for prolonged adenosine-A2B AR signaling in several models 
of chronic pain and show that these adenosine effects depend upon IL-6 signaling from myeloid cells to 
transactivate sensory neurons. A particularly important finding was that pain-related behavior induced by 
prolonged elevation of adenosine levels was not exerted by direct action of adenosine on sensory neurons. 
Instead, adenosine-induced pain behavior was produced by activating A2B AR in myeloid cells, possibly 
including microglial cells. Although microglia are well recognized to promote local inflammation and chronic 
pain (210) (211), emerging evidence indicates that increased peripheral inflammatory responses contribute 
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to chronic pain (212) (211). Several studies show the specific infiltration of monocyte-derived macrophages 
under pathological conditions (213), including multiple sclerosis, experimental autoimmune 
encephalomyelitis, or irradiation prior to BMT. It is possible that A2B AR positive SCD mouse bone marrow 
derived cells of the myeloid lineage may infiltrate the CNS after irradiation, differentiate into A2B AR positive 
glia, and contribute to the pain behavior observed in the A2B AR -/- recipient mice. Moreover, Hu et al. (209) 
have provided considerable genetic and pharmacological evidence that elevated circulating adenosine 
signaling via myeloid cell A2B AR (including microglial cells) contributes to chronic inflammatory pain and their 
study lead to a working model for the induction of persistent pain in which activation of  A2B AR on myeloid 
cells by prolonged exposure to adenosine in the blood causes the release of IL-6 from these cells, 
transactivation of gp130 on nociceptive sensory neurons by a sIL-6R/IL-6 complex, and a consequent pSTAT3-
mediated increase in the nociceptive function of sensory neurons that involves enhanced TRPV1 gene 
expression. These mechanistic findings suggest therapeutic approaches for treating chronic pain including 
polyethylene glycol-ADA (an FDA approved drug) and application of A2B AR specific antagonists. 
 
A3 AR: 
 Pulmonary system diseases 
Adenosine regulates respiratory system through well-known processes. Elevated levels of the nucleoside 
have been found in bronco-alveolar lavage, blood, and exhaled breath condensate of patients with asthma 
and chronic obstructive pulmonary disease (COPD). A3 ARs it is known to be involved in both pro or anti-
inflammatory responses depending on the cell type involved (214). In particular, the functional role of A3 AR 
in mast cell activation is highlighted by genetic A3 AR and mast cell KO mice where degranulation appears 
dependent on A3 AR activation, thus suggesting that adenosine exposure can result in A3 AR-dependent 
airway inflammation (215). Likewise, adenosine fails to induce histamine release from lung mast cells 
obtained from A3 AR-KO mice and mediated airway hyper responsiveness by both A3 AR-dependent and -
independent mechanisms in rodents (216). In A3 AR-KO mice the reconstitution of wild-type mast cells 
restores the airway hyper responsiveness (217). In contrast, in a bleomycin model of pulmonary 
inflammation and fibrosis, A3 ARs have provided anti-inflammatory functions, regulating production of the 
mediators involved in fibrosis (218) (219). Although A3 AR protein has not been found in human lung mast 
cells, but it is highly present in human eosinophils with anti-inflammatory functions (220) (11). As A3 ARs 
inhibit degranulation of eosinophils, it has been speculated that specific A3 AR agonists might be useful in 
eosinophil-dependent allergic disorders, such as asthma and rhinitis (221). However, adenosine deaminase 
KO mice treated with selective A3 AR antagonists have shown a marked attenuation of pulmonary 
inflammation, decreased eosinophil infiltration, and reduced airway mucus production (222). Interestingly, 
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COPD patients have shown reduced A2B AR density and an increase in A2A and A3 ARs in peripheral lung 
compared with normal lung function in smokers (223). An increase in A3 ARs found in bronco-alveolar lavage 
macrophages from COPD patients appears to be closely associated with the presence of high levels of 
proinflammatory cytokines. In contrast, A3 AR agonists have been suggested as a potential effective therapy 
for ischemia-reperfusion-induced lung injury (224). Indeed, inosine has been seen to have anti-inflammatory 
effects in allergic lung inflammation by recruiting A3 ARs (225). Accordingly, A3 AR activation was recently 
found to attenuate lung ischemia-reperfusion injury through a neutrophil-dependent mechanism, suggesting 
the use of A3 AR agonists as a novel therapeutic strategy to prevent lung ischemia-reperfusion injury and 
primary graft dysfunction after transplantation (226) (227). The role of A3 AR in the human lung has still to 
be clarified, although data in recent literature would appear to lean toward a protective effect. 
 Rheumatoid arthritis and osteoarthritis  
Knowledge of the effects of adenosine has revealed that ARs could be a useful target for rheumatoid arthritis 
(RA) therapy. Adenosine production has emerged as an important cell mechanism to regulate inflammation 
due to an increase in receptor density and/or functionality. A3 AR are upregulated in RA, psoriasis, and 
Crohn’s disease (228). Interestingly they are also overexpressed in untreated RA patients and in methotrexate 
treated RA patients, and administration of anti–TNF-α drugs normalizes their number and functionality (229). 
Furthermore, A3 AR density inversely correlates with Disease Activity Score in 28 or 44 joints, suggesting a 
direct role of the endogenous activation of these receptors in the control of RA inflammation (230). The 
overexpression of A3 AR in RA has been directly linked to the increase in NF-kB, a key player in the 
pathogenesis of arthritic diseases (231) (228). In RA patients, adenosine suppresses the elevated levels of 
proinflammatory cytokines such as TNF-α and IL-1b, and clinical evidence has shown that A3 AR agonists 
modulate an improvement in signs and symptoms of the disease (232) (233). Furthermore, A3 AR agonists 
prevent cartilage damage, osteoclast/osteophyte formation, bone destruction, and markedly reduce pannus 
and lymphocyte formation in rat models (234) (235). The anti-inflammatory effect of A3 ARs has also been 
observed in fibroblast like synoviocytes derived from the synovial fluid of RA patients and is closely associated 
with a decrease in NF-kB and TNF-α release (236). Oral treatment with CF101 (IB-MECA, Figure 17) has led to 
amelioration and a marked decrease in clinical manifestations of the disease. In a phase I study in healthy 
subjects, CF101 proved safe and well tolerated, offering linear pharmacokinetic activity (237). This was 
confirmed in a now successfully concluded phase II study in RA patients in which CF101 mediated 
improvement in signs and symptoms, thus suggesting an opportunity for its development as an antirheumatic 
agent (233). The most common form of arthritis is osteoarthritis (OA), which is the most important cause of 
disability in older adults. The current recommended treatment of OA involves weight loss, physical therapy, 
and the use of pain relievers. However, these drugs do not reverse the degenerative process in OA and show 
some adverse effects on cartilage metabolism (238). It is well known that p38 MAPKs are involved in 
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controlling such cellular responses as adenosine-mediated proinflammatory cytokine release (239). 
Accordingly, a pathway involving the reduction in p38 MAPKs, NF-kB, TNF-a, and IL-8 by A3 AR activation was 
observed in human synoviocytes (240). It was also reported that the NF-kB signaling pathway is deregulated 
by the presence of IB-MECA and is involved in OA pathogenesis. In addition, CF101 induces inflammatory cell 
apoptosis and acts as a cartilage protective agent, suggesting that it may be a suitable candidate for the 
treatment of OA (235). The safety and efficacy of CF101 has also been evaluated in a phase II clinical study 
with patients suffering from OA of the knee (241). Interestingly, a link has been found between ARs and their 
modulation by such physical agents as pulsed electromagnetic fields (PEMFs). In vitro studies on joint cells 
have suggested that exposure to PEMFs mediates a significant protection against the catabolic effect of 
proinflammatory cytokines and an anabolic action increasing matrix synthesis and cell proliferation (242). 
 Eye diseases 
A3 ARs have been widely implicated in many ocular diseases including dry eyes, glaucoma, and uveitis. In the 
past, A3 AR KO mice showed lower intracellular pressure, thus suggesting that A3 AR antagonists could play a 
role in the treatment of glaucoma (243). In addition, the use of A3 AR antagonists appears to be a specific, 
alternate approach for treating ocular hypertension in patients affected by the pseudoexfoliation syndrome 
in open angle glaucoma, which is typically associated with anterior chamber hypoxia and elevated intraocular 
pressure (IOP) (243). Accordingly, a series of nucleoside-derived antagonists have been found to lower IOP 
across species (244). Recently, it was reported that adenosine may trigger oligodendrocyte death via 
activation of A3 AR, suggesting that this mechanism contributes to optic nerve and white matter ischemic 
damage (245). CF101, a prototypical A3 AR agonists, entered a clinical phase of drug development. Studies 
from a phase II clinical trial revealed that it was well tolerated and induced a statistically significant 
improvement in patients with moderate to severe dry eye syndrome. Interestingly, in the same clinical trial, 
CF101 decreased IOP, thus demonstrating its efficacy as an IOP-lowering agent. These data, and the anti-
inflammatory characteristics of CF101, support pursuing study of this drug as a potential treatment of the 
signs and symptoms of dry eye syndrome and glaucoma (246) (247). Nowadays, CF101 undergoes a phase II, 
randomized, double-masked, placebo-controlled, parallel group study of the safety and efficacy of daily IB-
MECA administered orally in subjects with elevated intraocular pressure. CF101 has also been effective in an 
experimental model of autoimmune uveitis, supporting further exploration of this molecule for the 
treatment of uveitis (248). Oral treatment with CF101, initiated upon disease onset, improves clinical uveitis 
fundoscopy score and ameliorates the pathologic manifestations of the disease. In fact, in parallel with IOP 
phase II, CF101 undergoes also a phase II, randomized, double-masked, placebo-controlled study of the 
safety and efficacy of daily CF101  administered orally in subjects with active, sight-threatening, noninfectious 
intermediate or posterior uveitis. 
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 Pain 
The contribution of A3 AR in pain states has been evaluated in different studies. A nociceptive and 
proinflammatory response resulting in edema formation was first demonstrated after activation of A3 AR; 
this effect was mediated by both serotonin and histamine release, most likely from mast cells and subsequent 
actions on the sensory nerve terminal (249). However, recently, the treatment of chronic neuropathic pain 
was proposed as a novel potential application of A3 AR agonists (250). A3 AR agonists blocked the 
development of mechanically and chemotherapy-induced neuropathic pain in a dose-dependent fashion and 
significantly augmented the analgesic effects of currently used analgesics (251). Accordingly, in an animal 
model of surgery-induced metastasis Cl-IB-MECA significantly reduced bone cancer pain, providing the 
pharmacologic rationale for using selective A3 AR agonists as a new approach in chronic neuropathic pain 
(252). Interestingly, very recently, the first mechanistic insight into beneficial effects of A3 AR agonists against 
neuropathic pain has been explored (253) (254). In particular, it has been found that these effects were due 
to the inhibition of an astrocyte-associated neuroinflammatory. 
 
1.3.6 Adenosine receptors ligands 
 
Medicinal chemistry approaches have been applied to all four of the adenosine receptor subtypes (A1, A2A, 
A2B, and A3) to create selective agonists and antagonists for each. The most recent class of selective AR ligands 
to be reported is the class of A2B AR agonists. Selective ligands have facilitated research on therapeutic 
applications on diseases in which ARs are involved and in some cases  among the large number of AR ligands 
have been possible to find good clinical candidates. Prodrug approaches have been developed which improve 
the bioavailability of the drugs, reduce side-effects, and/or may lead to site-selective effects. The A2A AR 
agonist regadenoson (Lexiscan®), a diagnostic drug for myocardial perfusion imaging, is the first selective AR 
agonist to be approved. Other selective agonists and antagonists are or were undergoing clinical trials for a 
broad range of indications, including capadenoson and tecadenoson (A1 AR agonists) for atrial fibrillation, or 
paroxysmal supraventricular tachycardia, respectively, BVT.115959 (A2A AR agonists) for pain, preladenant 
and istradefylline (A2A AR antagonist) for the treatment of Parkinson's disease, BAY 60-6583 (A2B AR agonist) 
for angina pectoris, IB-MECA (CF101) and Cl-IB-MECA (CF102) (A3 AR agonists) for inflammatory diseases and 
cancer, respectively. 
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A1 AR agonists 
 
A scheme of important A1 AR agonists is shown in Figure 11. A1 AR agonists tend to be substituted at the N6 
position with arylalkyl (R-PIA), cycloalkyl (CPA, CCPA, INO-8875, GR79236X and Capadenoson), bicycloalkyl 
(5’-Cl-5’-deoxy-(±)-ENBA), or aryl (SPA and GW493838) substituents (255). The C2 and 5’ positions also may 
be substituted with Cl, CCPA and 5’-Cl-5’-deoxy-(±)-ENBA, respectively, or the 5’ position with cyclic moieties 
(GW493838). R-PIA was one of the first AR agonists to be widely used. It was previously defined as a 
moderately A1 AR selective agonist, but its use in that capacity is discouraged in favor of more selective 
nucleosides. A1 AR agonists CPA and CCPA are widely used pharmacological probes with CCPA being more 
selective for the A1 AR. A cautionary note is that many of the selective A1 AR agonists used routinely such as 
CPA and CCPA have considerable activity at the A3 AR. CCPA and agents that increased endogenous adenosine 
mimicked the acute antinociceptive effect of acupuncture, consistent with the hypothesis that the A1 AR 
mediates this effect (256). The agonist INO-8875 7 (also known as Trabodenoson), which is an A1 agonist in 
Phase III clinical trials for glaucoma, is also intended for optic neuropathy. A1-selective nucleoside derivative 
8 failed to show efficacy in a clinical trial for dental pain and was tested in a Phase II trial for postherpetic 
neuralgia or peripheral nerve injury before being discontinued (257). A1-selective non-nucleoside derivative 
capadenoson (BAY68-4986) is in trials for treatment of persistent atrial fibrillation and is now available as a 
research tool (143). Compound 10 is highly selective for the A1 AR and displayed analgesic activity in the 
formalin test in mice (258) (259). SPA is a peripherally-selective agonist, due to its permanently charged 
sulfonate group, that is moderately A1 AR selective (70-fold). GW493838 was tested in a clinical trial for 
peripheral neuropathic pain but discontinued (260). UNC32a displayed antinociceptive effects in mice and 
was suggested to cross the blood brain barrier and act directly through the A1 AR despite the 5’-phosphate 
group (261). Partial agonists of the A1 AR (such as the 2’-deoxy analog of 6) are effective in chronic 
neuropathic but not acute pain models and lack some of the cardiovascular side effects of full A1 AR agonists 
(262). Compound 14 is a moderately selective full A1 AR agonist that protects in some seizure models (263). 
It is well tolerated in rodents and does not produce the toxicity upon dose escalation that is typical of more 
widely used A1 AR agonists, likely from cardiovascular effects. MRS5474 was shown to induce antidepressant 
effects through an increase of homer1a in the brain (264). 
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Figure 11: Some important A1 AR agonists in literature (20) 
 
 
A1 AR antagonists 
The widely ingested alkylxanthines theophylline (1,3-dimethylxanthine) and caffeine (1,3,7-
trimethylxanthine) at physiological concentrations are weak (affinity ≈ 10 mM) nonselective antagonists at 
ARs. The main caffeine metabolite paraxanthine (1,7-dimethylxanthine) also acts as a central nervous 
stimulant and with even higher potency than caffeine at ARs and might be useful for treating hypersomnia 
associated with neurodegenerative diseases (265). 8-p-sulfophenyl derivatives SPT and DPSPX are 
moderately potent nonselective antagonists of ARs with the added benefits of water solubility and restricted 
entry to the brain. A1 AR selective antagonists are derived from non-xanthines cores, e.g. adenine derivative 
WRC-0571 and pyrrolopyrimidine SLV320. An 8- cycloalkylxanthine derivative DPCPX is the most widely used 
A1 AR selective antagonist with nM affinity, but its A1 AR selectivity is greater in rodents than in human. 
Several 8-bicycloalkylxanthine derivatives KW3902 (rolofylline) and PSB36 are even more selective for the A1 
AR. As aforementioned, rolofylline was involved in the PROTECT project, a Phase III clinical study targeting 
renal failure in chronic heart disease (18) (138). 
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Figure 12: : Some important A1 AR antagonists in literature (20) 
 
A2A AR agonists 
A2A AR agonists are often substituted at the C2 position with arylalkyl (CGS21680) or ethynyl (ATL-313) 
substituents. CGS21680 is a widely used pharmacological probe for activation of the A2A AR, but its high AR 
subtype selectivity seen in rat and mouse is reduced at human (h) ARs, and its degree of entry into the brain 
is low. A single intrathecal injection of CGS21680 or ATL-313 was reported to have a long duration of 
protection against mechanical allodynia and thermal hyperalgesia in a model of chronic constriction injury 
(CCI) in mice (266). An X-ray structure of the hA2A AR complex with agonist CGS21680 was recently reported 
(267). Another A2A AR agonist BVT.115959 (structure not disclosed) advanced to clinical trials for pain (260). 
UK-432097 is a selective A2A AR agonist that was in clinical trials for COPD, which were discontinued due to 
lack of efficacy. With its large molecular weight and many H-bonding groups, it is not orally bioavailable. 
However, these molecular features increase the stability of the A2A AR complex, such that it was possible to 
obtain an X-ray crystallographic structure without extensive stabilizing point mutations (57). This was the 
first X-ray structure of an AR complex with an agonist to be reported. Although not detected in the X-ray 
structures, the A2A AR can form in situ various functional homo- and hetero- (e.g. with the A1 AR or the D2 
dopamine receptor) di- or multimers (268) (269) (270). The A2A AR can also heterodimerize with the P2Y1R. 
 
Figure 13: Some important A2A AR agonists in literature (20) 
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A2A AR antagonist 
An 8-styrylxanthine derivative, Istradefylline (KW-6002, Kyowa Hakko), is approved for Parkinson's disease 
treatment in Japan. The related compound CSC is selective for the A2A AR, but also inhibits monoamino 
oxidase-2 (MAO-2), two activities that would be beneficial in neurodegenerative diseases. Two A2A AR-
selective antagonists, ZM-241385 and SCH-442416, are commonly used as A2A AR -selective pharmacological 
probes of nM affinity. The X-ray structure of A2A AR complex with ZM-241385 was the first antagonist-bound 
AR structure to be reported (54), and now a higher resolution structure of 1.8 Å resolution is available (271). 
To the same family as SCH-442416 belongs Preladenant (SCH-420814, Merck), which was in clinical trials for 
treatment of Parkinson's disease. A2A AR-selective antagonists Tozadenant (SYN-115, Biotie) and Vipadenant 
(BII014, V2006, Biogen) were also in clinical trials for the same condition. The A2A AR affinity of SCH-442416 
was initially reported in the subnanomolar range, but the Ki value was redetermined to be 4 nM (255). The 
A2A AR-selective adenine derivative ANR94, with a relatively low molecular weight, is effective in Parkinson's 
disease models. A2A AR-selective antagonists are also of interest in the context of checkpoint blockade for 
cancer immunotherapy, possibly by coadministration with other anticancer agents (272). 
 
 
Figure 14: Some important A2A AR antagonists in literature (20) 
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A2B AR agonists 
Because of the widespread distribution of A2B AR and the involvement of this receptor subtype in important 
(patho)-physiological processes both in peripheral tissues and in the central nervous system, many efforts 
have been carried out in order to identify potent and selective A2B AR ligands yielded with noteworthy 
therapeutic potential. However, the lack of highly selective agents has hampered efforts to better 
characterize the A2B AR subtype and consequently to fully define its therapeutic potential. 5′-(N-
ethylcarboxamido)adenosine (NECA), a nonselective agonist, is currently considered to be one of the most 
potent agonists at the A2B AR, with an EC50 of  nM (273) expressed in CHO cells and is the most frequently 
used ligand to activate this subtype. In order to identify selective and high affinity agonists for the A2B AR 
many efforts have been devoted to modify the purine ring and ribose moiety of the adenosine. Nucleoside-
based agonists are the result of modifying the endogenous ligand, adenosine, by substitution at the N6-, and 
C2-positions of the purine heterocycle and/or at the 5’-position of the ribose moiety. The various 
substitutions at these positions are designed to increase metabolic stability in biological systems, binding 
specificity and/or affinity at different adenosine receptor subtypes. In consequence, equally and more 
selective NECA derivatives, for the A2B AR were obtained. These compounds have EC50 values ranging from 
82 to 450 nM for the A2B AR and showed selectivity towards the other adenosine receptor subtypes (274). 
Recently, a new A2B AR agonist 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl)pyridin-2-ylsulfanyl]acetamide 
BAY-606583, was patented by Bayer HealthCare and was used to study the cardioprotective function of A2B 
receptors (275). This compound is very selective for the A2B AR with an EC50 value of 3–10 nM for the human 
A2B AR and EC50 values > 10 μM for the A1, A2A and A3 AR subtypes, characterized by CHO cells in a gene-
reporter assay expressing recombinant human receptors in high density (184). In order to identify selective 
and high affinity BAY-606583 has been used as a non-nucleoside agonist for selective activation of the A2B 
AR, but its potency, selectivity and efficacy are less than originally reported (276) (277). Thus, it should be 
used cautiously and in combination with appropriate antagonists. BAY-606583 is of the same chemical series 
(3,5-dicyanopyridines) as A1 AR agonist Capadenoson. 
 
 
Figure 15: Some important A2B AR agonists in literature 
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A2B AR antagonists 
 
A2B AR antagonists have recently been reviewed (278). Certain modifications of the xanthine core structure 
at the 8-position with aryl groups have been found to result in selectivity for the A2B AR. The first antagonist 
to be reported was MRS1754. Later, groups at Univ. of Bonn, Germany (PSB-1115, PSB-603), University of 
Ferrara, Italy (MRE-2029-F20), at Gilead Sciences (CVT-6883, GS6201) and at Clinical Data Inc. (ATL802) 
improved on the degree of selectivity and/or the water solubility of the xanthines as A2B AR. antagonists. For 
example, GS-6201 (CVT-6883) has a selectivity of 88-fold vs. hA1 AR, 149-fold vs. hA2A AR, and 49-fold vs. hA3 
AR. PSB-603 shows a particularly high affinity and selectivity, not only in humans, but also in rodents. PSB-
1115 exhibits high water-solubility and is therefore useful for in vivo studies, however its A2B AR affinity and 
selectivity is lower than that for other A2B AR antagonists. Besides xanthines, 2-aminopyrimidine derivatives, 
such as LAS38096, 2-aminothiazolopyrimidines, benzothiazoles (279), pyridine derivatives (280), have been 
developed as A2B AR antagonists MRS1754 were introduced by the pharmaceutical industry for possible 
application to asthma, but neither remains on a clinical path. 
 
Figure 16: A2B AR selective antagonists in literature (255) 
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A3 AR agonists 
A3 AR agonists in Figure 17 are generally adenosine derivatives substituted at the C2, N6 and 5’ positions with 
various substituents. Those groups most favorable for A3 AR selectivity include: N6 - benzyl or small alkyl; C2 
e H, Cl, alkynyl or arylethynyl. IB-MECA (also known as Piclidenoson) and Cl-IB-MECA are widely used 
pharmacological probes with Cl-IB-MECA being more selective for the A3 AR, and they are in clinical trials for 
inflammation (rheumatoid arthritis and psoriasis) and primary liver cancer, respectively (241). HEMADO has 
been used as a highly selective A3 AR radioligand of high affinity (281). The actions of A3 AR agonists IB-MECA 
and MRS5698 in chronic neuropathic pain and cerebroprotection have been described (282). They 
completely reverse or prevent allodynia and hyperalgesia in the chronic constriction injury (CCI) model but 
have no effect on acute pain.  
 
Figure 17: Some A3 AR selective agonists in literature. 
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MRS5841, MRS5698 and MRS1898 contain a conformationally constrained bicyclic ring in place of ribose with 
a North conformation (N)-methanocarba ring system, which adds to the A3 AR selectivity (283) (284) (285). 
MRS5698 is a peripherally-selective agonist that is highly A3 AR selective (250). The pharmacokinetics of 
MRS5698, administered intraperitoneally in rat, indicates a t1/2 of 1.09 h (285), consistent with its duration 
of action in vivo in the CCI pain model. MRS5698 is also orally active in the CCI model. 
 
A3 AR antagonists 
In an initial broad screen, several classes of non-xanthine antagonists were identified for the A3 AR: 1,4- 
dihydropyridines, pyridines, and flavones. The pyridine derivative MRS1523 (Figure 18) has become a useful 
tool since it shows relatively high affinity not only for the human but also for the rat A3 AR. Later it was noted 
that the potent non-selective AR antagonist CGS15943 could be modified to produce A3 AR selectivity, and 
from selective modifications was obtained MRE3008-F20, one of the most potent and selective compounds 
at hA3 AR.  
 
 
Figure 18: Some A3 AR antagonists in literature (255) 
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The urea-substituted quinazoline derivative VUF5574 also possesses high A2B AR affinity and selectivity. Some 
tricyclic xanthines (KF2677, PSB-10 and PSB-11) have been found to be very potent and selective antagonists 
at hA3 AR showing increased water-solubility due to a basic nitrogen atom in the additional imidazole ring. 
Recently described A3 AR-selective antagonists include pyrazolopyrimidinones. Many A3 AR antagonists are 
much more potent at human as compared to rat A3 AR. The principles for converting selective A3 AR agonists 
into selective A3 AR antagonists are based on either a conformationally constrained ribose-like ring or one 
that is truncated at the 4′-position (i.e., missing the ribose CH2OH group entirely). Thus, the nucleoside 
derivatives MRS5147 and its 3-iodo analogue MRS5127 are highly selective A3 AR ligands generally across 
species. MRS5127 was recently reported as a radioligand selective for the A3 AR (286). The truncated 4′-
thioadenosine derivative LJ-1251, which acts as a A3 AR antagonist across species, was shown to lower 
intraocular pressure when applied topically (287) (244). 
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2. Aim of the work 
 
The work characterizing this Ph.D. thesis is part of a wider project that the research group I have joined during 
my Ph.D. course has undertaken in recent years and is actually developing. In fact, many compounds 
belonging to different heterocyclic classes were synthesized and evaluated as AR ligands (288) (289) (290) 
(291). In particular, the studies were focused on the development of selective antagonists for hA3 and hA2A 
ARs, and also to obtain combined hA1/A2A AR ligands with antagonistic activity (292). 
As a general trend, AR ligands have been often projected through rational approaches, including molecular 
modeling studies based on the AR subtype structure they are targeting. In the past, the first approach that 
was used, usually started from the modification of the endogenous ligand, adenosine. These studies led to 
many different classes of ligands and several recurring structural features have been identified for defining 
affinity or efficacy of the compounds at the specific AR subtype (20). Antagonists are characterized by a large 
structural variability. They are generally nitrogen-containing heterocycles with a mono-, bi- or tricyclic core 
skeleton. In contrast, there is no such flexibility for the agonists. In fact, the agonist profile of AR ligands has 
been associated, for a long time, to an adenosine-like structure with the ribose moiety only slightly modified.  
However, in the last 15 years, a major breakthrough with respect to both affinity and selectivity was achieved 
with the discovery of a new class of non-adenosine like compounds, the aminopyridine-3,5-dicarbonitrile 
series. These ligands first appeared in patent literature and the preliminary data suggested the involvement 
of the  A2B AR as a target (293) (294) (295) but their intriguing characteristics emerged later. Successively, 
some research (296) reported that non-nucleoside AR agonists show less species differences than the 
adenosine-like ones and thus more versatility for pharmacological studies (255).  
 
Figure 19: Non-nucleoside A1 and A2B AR agonist Capadenoson (BAY68-4986) and BAY60-6583, respectively 
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Based on the aminopyridine-3,5-dicarbonitrile scaffold, Bayer Healthcare synthesized two interesting 
compounds belonging to this series: Capadenoson (BAY68-4986), a potent and selective A1 AR agonist, and 
BAY60-6583 (Figure 19) which showed high affinity and selectivity for A2B AR. In particular, BAY60-6583 was 
a real breakthrough: it was the first potent and selective AR agonist reported in literature with non-adenosine 
like structure. It has rapidly overcome the use of other nucleoside-like agonist in most of the pharmacological 
assays regarding A2B AR.  In particular it substituted the 5′-(N-ethylcarboxamido)adenosine (NECA, see Figure 
15) that, since its discover in 1983, has been used as A2B AR elected agonist, despite its scarce selectivity 
versus the other AR subtypes.Although BAY60-6583 has been largely studied, its real pharmacological profile 
is nowadays a matter of debate: in the patent describing BAY60-6583, Bayer Healthcare assessed its full 
agonist profile at A2B AR. However, a 2014 study of Hinz et al. (277) reported that BAY60-6583 behaves as a 
partial agonist, with a maximum effect of 56% compared with the 100% of NECA as  reference in cAMP 
accumulation assays, performed on CHO cells stably transfected with the hemagglutinin (HA)-tagged human 
A2B AR (CHO-HA-hA2B cells). In contrast, in our pharmacological assay (see Result Section below) BAY60-6583 
acts as full agonist and shows to be less potent at A2B AR than reported by Bayer Healthcare.  
Contemporarily, Bayer Healthcare carried on studies on the A1 AR agonist Capadenoson (Figure 19) which 
was one of the most interesting compound emerged as potentially useful for the treatment of angina being 
devoid of the side effect (e.g. bradycardia) proper of full agonist compounds. Since A1 AR are the most 
extensively investigated among the ARs, the effects of Capadenoson emerged as so interesting that now it is 
in clinical trial for the treatment of persistent atrial fibrillation and also available as research tool (143). More 
recently, the focus of attention has moved to the antinociceptive effect exerted by A1 AR agonist at the spinal 
cord level (144) (145) (146) (147) (148).  
Starting from these results, in 2004 Beukers et al. (297) reported a small series of four aminopyridine-3,5-
dicarbonitriles and among them LUF-5845 (Figure 20)  resulted highly active at A2B subtype though endowed 
with a scarce selectivity toward the other ARs. 
 
Figure 20 
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On this basis, our research group focused attention on the aminopyridine-3,5-dicarbonitrile series in order 
to obtain new AR ligands and to enlarge the scarcely known structure-activity relationships on this chemical 
class. In fact, few data are reported in the open literature, the majority of the known being included in patents 
(255). This kind of scaffold could allow to obtain ligands not only with a wide range of affinities but 
interestingly with different degrees of efficacy at the different ARs.  
In fact, in a master degree thesis developed in our research group (298) four interesting compounds 
belonging to this chemical class were synthesized and pharmacologically evaluated at the ARs (Figure 21): 
 
Figure 21: Lead compounds for aminopyridine-3,5-dicarbonitrile scaffold modifications 
 
Pharmacological evaluation of these compounds highlighted the good affinity of compounds A-D at A1 AR, 
being A and B A1 selective. In contrast, while derivative C binds also the A3 subtype, D emerges as totally 
unselective ligand. Together with the dicyanopyridine derivatives reported in literature (Figure 19 and 20), in 
this Ph.D. thesis we elect compounds A-C as leads, in order to evaluate how modifications at the 
dicyanopyridine core could modulate the affinity and selectivity, but also the pharmacological profile of the 
members of this chemical class at the AR subtypes. Thus, based on preliminary molecular modelling studies 
(299) (300), different substituents were introduced in diverse positions on the selected scaffold (Figure 22). 
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Figure 22: Modifications performed on the aminopyridine-3,5-dicarbonitrile scaffold 
 
Modifications were performed at both R4 and R6 positions (see Figure 22) on the dicyanopyridine core. In 
particular, while various aryl and heteroaryl substituents were introduced at R4, position R6 generally contains 
groups or atoms able to engage hydrogen-bonding interactions with the receptor site, being this latter a 
condition that seems to be mandatory for the AR receptor interaction. Moreover, it has been investigated 
substitution (R2) on the amine function with cycloalkyl, aryl and acyl moieties in order to evaluate how they 
could have modulated the pharmacological profile of the target compounds on the diverse AR subtypes. 
Further modifications regard the sulfanyl linker of the leads which has been substituted with an oxygen atom 
or a secondary amino group. 
Two major sets of amino-3,5-dicyanopyridines were synthesized: DCP1 series that contains compounds 
preferentially binding the A1 AR (Table 3) and the DCP2B series including compounds designed in order to 
target the A2B subtype (Table 4). For DCP1 series, SAR investigations were performed at the R2, R4 and R6 
positions and also at level of the side chain linker.On the basis of compounds A-C pharmacological data 
(Figure 21), major modifications were performed at R6 position of the dicyanopyridine core while maintaining 
the 2-furanyl moiety at R4 or inserting other heteroaryl groups.  
 
Cyclopropyl, cyclopentyl, 4-(I)Ph, 
benzyl, COCH3 
CH2OH, CN, CONH2, CONHCH3, 
CONHCH2OH, CONHOH, 
COOCH3, COPh, COOCH2Ph,       
3-(COOCH3)Ph, 3-(COOH)Ph,     
3-(CONH2)Ph, 3-(CH2OH)Ph,     
3-(CN)Ph, 2-(5-COOCH3)furyl,  
2-imidazole, 2-imidazoline,      
2-benzoimidazole, 3-pyrazole, 
5-(1,2,4)triazole,                          
1-(1,2,4)triazole, 5-tetrazole ,  
2-Py, 3-Py, 4-(2-Ph)thiazole,     
4-(2-NH2)thiazole 
CH3, 3-furyl, 2-thienyl, 3-thienyl, 
3-pyridyl, 4-pyridyl, benzyl, Ph, 
4-(Cl)Ph, 4-(F)Ph, 4-(CH3)Ph,     
4-(SCH3)Ph, 4-(OCH2C3H5)Ph,    
4-(OCH2C4H7)Ph,                           
4-(OCH2CH(CH3)2)Ph,                    
4-(OCH2CH3)Ph,                                
4-(OCH2CH=CH2)Ph,                               
4-(OCH2C(CH3)=CH2)Ph,                     
4-(OH)Ph,                                         
4-(NHCOCH3)Ph 
X = S, NH, O 
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DCP1 series  
 
n° X R2 R4 R6 n° X R2 R4 R6 
1 S H 2-furyl 3-(COOCH3)C6H4 14 S H 2-furyl 2-pyridyl 
2 S H 2-furyl 3-(CONH2)C6H4 15 S H 2-furyl 
2-phenylthiazol-
4-yl 
3 S H 2-furyl 3-(COOH)C6H4 16 S H 2-furyl 
2-aminothiazol-
4-yl 
4 S H 2-furyl 3-(CH2OH)C6H4 17 NH H 2-furyl CH2CH2OH 
5 S H 2-furyl 3-(CN)C6H4 18 NH H 2-thienyl CH2CH2OH 
6 S H 2-furyl 
methyl 5-furan-2-
carboxylate 
19 NH H C6H5 CH2CH2OH 
7 S H 3-furyl 3-(COOCH3)C6H4 20 O H 2-furyl CH2CH2OH 
8 S H 2-thienyl 3-(COOCH3)C6H4 21 S cyclopropyl 2-furyl CH2CH2OH 
9 S H 3-pyridyl 3-(COOCH3)C6H4 22 S cyclopentyl 2-furyl CH2CH2OH 
10 S H 2-furyl CN 23 S 4-I-C6H4 2-furyl CH2CH2OH 
11 S H 2-furyl COOCH2C6H5 24 S CH2C6H5 2-furyl CH2CH2OH 
12 S H 2-furyl COC6H5 25 S COCH3 2-furyl CH2CH2OH 
13 S H 2-furyl 3-pyridyl  
 
Table 3: Synthesized compounds belonging to the DCP1 series 
 
Thus, substituents bearing H-bond acceptor and donor groups were introduced at R6 (compounds 1-16). 
Firstly, aryl homologation of the R6 of the leads A-C were performed (compounds 1-9) togheter with other 
variegated modifications (10-14). Also nitrogen-containing heterocycles were inserted at R6 (derivatives 13-
16) in order to imitate the lead Capadenoson (Figure 19). Then, the influence of the nature of the linker X 
(compounds 17-20) or of the presence of R2 substituents on the amine function (21-25) was evaluated. R2 
groups were selected on the basis of the SAR of adenosine-like agonists which preferentially bind the A1 
subtype. Such modifications were performed on the lead A or on strictly correlated analogues. As for the 
DCP2B series is concerned, major modifications were performed at R4 and R6 positions in order to target the 
A2B subtype.  
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DCP2B series  
 
n° X R4 R6 n° X R4 R6 
26 S 3-furyl imidazol-2-yl 47 S 4-(OCH2C3H5)-C6H4 CONHCH3 
27 S 3-thienyl imidazol-2-yl 48 S 4-(OCH2C3H5)-C6H4 CONHCH2OH 
28 S 3-pyridyl imidazol-2-yl 49 S 4-(OCH2C3H5)-C6H4 CONHOH 
29 S 4-pyridyl imidazol-2-yl 50 S 4-(OCH2C3H5)-C6H4 COOCH3 
30 S CH2C6H5 imidazol-2-yl 51 S 4-(OCH2C3H5)-C6H4 3-(COOCH3)C6H4 
31 S 4-Cl-C6H5 imidazol-2-yl 52 S 4-(OCH2C3H5)-C6H4 3-(CONH2)C6H4 
32 S 4-F-C6H5 imidazol-2-yl 53 S 4-(OCH2C4H7)-C6H4 imidazol-2-yl 
33 S 4-CH3-C6H5 imidazol-2-yl 54 S 4-(OCH2C4H7)-C6H4 CONH2 
34 S 4-SCH3-C6H5 imidazol-2-yl 55 S 4-(OCH2CH(CH3)2)-C6H4 imidazol-2-yl 
35 S CH3 imidazol-2-yl 56 S 4-(OCH2CH(CH3)2)-C6H4 CONH2 
36 NH C6H5 imidazol-2-yl 57 S 4-(OCH2CH3)-C6H4 imidazol-2-yl 
37 S 
4-(OCH2C3H5)-
C6H4 
imidazol-2-yl 58 S 4-(OCH2CH3)-C6H4 CONH2 
38 S 
4-(OCH2C3H5)-
C6H4 
imidazol-5-yl 59 S 4-(OCH2CH3)-C6H4 CONHCH3 
39 S 
4-(OCH2C3H5)-
C6H4 
4,5-dihydro-1H-imidazol-2-
yl 
60 S 4-(OCH2CH3)-C6H4 pyrazol-3-yl 
40 S 
4-(OCH2C3H5)-
C6H4 
benzoimidazol-2-yl 61 S 4-(OCH2CH=CH2)-C6H4 imidazol-2-yl 
41 S 
4-(OCH2C3H5)-
C6H4 
pyrazol-3-yl 62 S 4-(OCH2CH=CH2)-C6H4 CONH2 
42 S 
4-(OCH2C3H5)-
C6H4 
1,2,4-triazol-1-yl 63 S 4-(OCH2CH=CH2)-C6H4 pyrazol-3-yl 
43 S 
4-(OCH2C3H5)-
C6H4 
1,2,4-triazol-5-yl 64 S 
4-(OCH2C(CH3)=CH2)- 
C6H4 
imidazol-2-yl 
44 S 
4-(OCH2C3H5)-
C6H4 
tetrazol-5-yl 65 S 
4-(OCH2C(CH3)=CH2)- 
C6H4 
CONH2 
45 S 
4-(OCH2C3H5)-
C6H4 
2-aminothiazol-4-yl 66 S 4-(NHCOCH3)-C6H4 imidazol-2-yl 
46 S 
4-(OCH2C3H5)-
C6H4 
3-pyridyl 67 S 4-(NHCOCH3)-C6H4 CONH2 
 
Table 4: Synthesized compounds belonging to the DCP2B series 
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While keeping the imidazol-2yl moiety at R6 as it in compound D (Figure 21), different substituents were 
introduced at R4 position (26-37, Table 4). Firstly, various heteroaryls, poorly investigated in literature, were 
evaluated together with diverse para-substituted phenyl moieties and also benzyl and methyl groups.  
In parallel, position R6 was modified while maintaining the para-(cyclopropyloxymethyl)phenyl substituent 
at R4 that is typical of BAY60-6583 (Figure 19). Following the imidazole moiety idea (see the lead compound 
D, Figure 21), preferentially five-membered nitrogen-containing heterocycles bearing H-bond donor and 
acceptor groups were introduced at R6 (compounds 38-46, Table 4). Also different carboxyamide bioisosters 
(47-50) and their aryl homologues (51-52) were evaluated by maintaining the possibility of hydrogen bonding 
interaction at this level. Moreover, by in progress selecting the best substituents at R6 in term of hA2B AR 
affinity and selectivity, different para-oxysubstituted phenyl groups were introduced at R4 (compounds 53-
65). The O-(cyclo)alkyl and alkenyl substituents were chosen in order to maintain similar electronic and steric 
hindrance of the O-cyclopropyl moiety of BAY60-6583. In addition, the para-acetamido substituent 
(compounds 66-67, Table 4) as containing both H-bond donor and acceptor groups was evaluated.  
Moreover, the 3,6-diamino-5-cyano-4-phenyl-thieno[2,3-b]pyridine-2-carboxamide scaffold will be evaluate 
and obtained by an intramolecular cyclization of the 6-amino-3,5-dicyanopyridines (proved to be AR ligands) 
bearing a sulfanyl-acetamido substituent at position-2 of the pyridine core. Preliminary investigation was 
performed on BAY60-6583 (Figure 23) in order to evaluate how molecular stiffening could influence the 
affinity and /or the pharmacological profile of these compounds at the ARs.  
 
Figure 23: Bicyclic compound derived from cyclization of BAY60-6583 
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In addition to probe a new set of compounds as AR ligands, the information obtained could be useful for SAR 
studies and molecular modeling rationalization.  
Finally, another objective of this work was the synthesis of a small set of compounds, the 7-amino-2-
phenylpyrazolo[1,5-c]pyrimidine-4-carbonitriles 70-73 (Figure 24) through a procedure that can be 
considered brand new for the most part. These compounds can be considered as ensued from a molecular 
complication of the amino-3,5-dicyanopyridine scaffold by condensation with a pyrazole core. The 
modification was planned in order to maintain the most important hydrophobic and hydrogen-bonding 
interactions potentially engaged by the original pattern.  
Most of the effort was directed to finalize the procedure to obtain 2-arylpyrazolo[1,5-c]pyrimidines suitably 
substituted at position 5 in analogy to the lead DCP1 and DCP2B amino-3,5-dicyanopyridines. However, in 
the preliminary exploration of different synthetic approches yielding the target compounds, a set of 7-amino-
substituted derivatives 70-73 were synthesized and evaluated for their affinity at ARs. The latter, due to their 
structure and to the 5-amino-functionalization can be considered as potential A2A AR antagonists if compared 
for example to the well known ZM-241385 (Figure 24) even if they are lacking the essential 2-furyl moiety. 
 
 
Figure 24: Newly synthesized 7-Amino-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitriles and lead compounds 
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In addition to identify a new scaffold for the development of new AR ligands, this molecular complication 
approach was undertaken to evaluate the effect of this modification on the pharmacological profile of the 
new bicyclic derivatives, in particular at A2B AR subtype. 
To summarize, the main aim of this Ph.D. research was the investigation of the aminopyridine-3,5-
dicarbonitrile chemical class in order to obtain potent and selective AR ligands. The study was an exploration 
of the potentiality of this scaffold to produce AR ligands with different affinities and pharmacological profiles 
with an eye to the A2B and A1 subtypes. Preliminary studies were carried out on 7-amino-2-
phenylpyrazolo[1,5-c]pyrimidine-4-carbonitriles (70-73) to establish whether this heterocyclic scaffold 
suitably decorated could lead to the discover of new AR ligands. 
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3. Chemistry 
 
3.1 Aminopyridine-3,5-dicarbonitriles 
 
In order to achieve the desired aminopyridine-3,5-dicarbonitrile derivatives a short synthetic pathway was 
developed, following literature and patent advices (293) (294) (295). Most of the aminopyridine-3,5-
dicarbonitrile compounds were synthesized applying the same procedures with only some exceptions. In fact, 
some compounds were synthesized with small deviation from the usual synthetic pathway for a matter of 
scarce yield or reactivity. 
 
3.1.1 Chemistry of DCP1 
 
For what may concern the aminopyridine-3,5-dicarbonitrile derivatives targeting A1 AR, the synthesis of 
compounds 1-16, B starts from the one-pot cyclization of the suitable commercial aldehyde to give 
sulfanylphenyl compounds 74-77 (scheme 1). In order to achieve these latter, the condensation reaction  was 
performed by using tetrabutylammonium fluoride (TBAF), producing higher yields with respect to other 
methods reported in literature (293) (297). Intermediates 74-77 were converted into the sulfanyl derivatives 
78-81 with sodium sulfide, which were used in order to obtain compounds 1-16, A by reacting with the 
suitable halides in mild alkaline conditions using sodium hydrogencarbonate as base. This reaction afforded 
final compounds in good yields. 
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Compound R4 R6 
A 2-furyl CH2OH 
1 2-furyl 3-(COOCH3)C6H4 
2 2-furyl 3-(CONH2)C6H4 
3 2-furyl 3-(COOH)C6H4 
4 2-furyl 3-(CH2OH)C6H4 
5 2-furyl 3-(CN)C6H4 
6 2-furyl methyl 5-furan-2-carboxylate 
7 3-furyl 3-(COOCH3)C6H4 
8 2-thienyl 3-(COOCH3)C6H4 
9 3-pyridyl 3-(COOCH3)C6H4 
10 2-furyl CN 
11 2-furyl COOCH2C6H5 
12 2-furyl COC6H5 
13 2-furyl 3-pyridyl 
14 2-furyl 2-pyridyl 
15 2-furyl 2-phenylthiazol-4-yl 
16 2-furyl 2-aminothiazol-4-yl 
 
Scheme 1 
 
In order to modify the sulfanyl bridge with an amine linker, compounds 17 and 18 were synthesized starting 
from intermediates 74 and 76, respectively, taking advantage of the good property of sulfanylphenyl group 
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as leaving group in a nucleophile substitution. The reaction was easily performed at 100°C in N,N-
dimethylformamide (DMF) using 2-aminoethanol as nucleophile (scheme 2). 
 
 
Scheme 2 
 
Compound 19, bearing a phenyl group at position R4, was obtained through the synthesis of the chlorine 
intermediate 82 (scheme 3), prepared in a one-pot reaction (301) involving triethylorthobenzoate, 
malononitrile and hydrochloric acid and then used as starting material for coupling with commercial 2-
aminoethanol to afford compound 19. 
 
Scheme 3 
 
Pursuing the modifications at the sulfanyl linker, compound 20, bearing a 6-oxyethanol chain was 
synthesized. One-pot cyclization of commercial 2-furaldehyde and malononitrile in the presence of NaOCH3, 
afforded in low yields intermediate 83 (scheme 4) which was converted into the corresponding hydroxy 
analogue 84 by treatment with concentrated hydrochloric acid and glacial acetic acid at 100°C (302). Then, 
84 was used as starting material for the coupling reaction with 2-bromoethanol, performed in microwave 
reactor, affording final compound 20. 
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Scheme 4 
 
Replacement of the primary amine function of the lead compound B with suitable substituted amino groups 
(21-24) was performed starting from B which undergoes Sandmeyer reaction using isoamylnitrite as 
nitrosonium-donor molecule and CuCl2 (scheme 5) (303). This reaction afforded compound 85 in good yields. 
Thus, the 2-chlorine atom of 85 was replaced with the suitable substituted amine yielding final compounds 
21-24 in high yields. 
 
 
Scheme 5 
 
Finally, derivative 25, bearing an acetyl moiety at the amino group, was synthesized starting from the reaction 
of the derivative 74 with acetic anhydride in the presence of pyridine, affording the intermediate 86 (scheme 
6) (304). Then, the latter was converted into the corresponding sulfanyl derivative 87 by reacting with sodium 
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sulfide. Then, compound 87 was used as starting material for the coupling reaction with 2-bromoethanol 
affording compound 25. 
 
Scheme 6 
 
 
 
3.1.2 Chemistry of DCP2B 
 
Concerning the synthesis of the aminopyridine-3,5-dicarbonitrile derivatives targeting the A2B AR, it is pretty 
similar to the general procedure showed before for the preparation of compound 1-16, B (scheme 1). The 
synthesis of compounds 26-34 starts from the one-pot cyclization of the suitable commercial aldehyde to 
give sulfanylphenyl intermediates 75, 77, 88-94 (scheme 7). This reaction has been performed by using 
diverse cyclization alkaline adjuvant able to work in a phase-transfer system. The synthetic pathway reported 
in scheme 7 involves the use of sodium sulfide for the achievement of the sulfanyl intermediates (79, 81, 95-
101) and the coupling reaction with the 2-bromomethylimidazole 102 (scheme 10) in the presence of sodium 
hydrogencarbonate for obtaining the final compounds 26-34 (scheme 7). 
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Scheme 7 
 
For what may concern the sulfanyl intermediate 104, the precursor of final compound 35, a different 
approach was used: acetaldehyde highlighted a scarce reactivity in the one-pot reaction showed before, so 
it was necessary to synthesize the intermediate 103 by reaction of trimethylorthobenzoate with 
malononitrile (305) (Scheme 8). This intermediate allowed an easier cyclization to the sulfanyl compound 
104 by direct reaction with thiocyanoacetamide. Treatment of the latter with bromomethyl-2-imidazole 
hydrobromide 102 (scheme 10) in the presence of sodium hydrogencarbonate afforded the final derivative 
35. 
 
Scheme 8 
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Introduction of an amine function replacing the sulfanyl linker typical of most of the final compounds was 
performed by using the chloro-intermediate 82 obtained in scheme 3. The latter was used as starting material 
for coupling with commercial (1H-imidazol-2-yl)methanamine to afford compound 36 (scheme 9).  
 
 
Scheme 9 
 
 
Due to the unavailability of commercial 2-bromomethyl-1H-imidazole hydrobromide 102, this product was 
synthesized (297) (scheme 10) starting from imidazole-2-carboxyaldehyde, which was reduced to the 
corresponding alcohol 105 using sodium borohydride in absolute ethanol at room temperature for 2h. The 
latter was transformed into the bromomethyl derivative 102 by treatment with a 33% hydrobromic acid 
solution in acetic acid at 100°C. 
 
 
Scheme 10 
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In order to achieve (para-O-phenyl)-substituted aldehydes 106-111, 4-hydroxybenzaldehyde was alkylated 
at the para-OH function with the suitable alkyl halide in refluxing acetone in the presence of potassium 
carbonate (scheme 11) (306). 
 
 
Scheme 11 
 
O-susbtituted aldehydes 106-111 following a one-pot reaction with thiophenol, malononitrile and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in aqueous ethanol (307) afforded the sulfanylphenyl intermediates 
112-117 (scheme 12). Initially, compound 112 was synthesized by using Al2O3 as base, which was then 
replaced by DBU, leading to a general procedure with an easier work-up and higher yield. Thus, intermediates 
112-117 were transformed into the sulfanyl analogues 118-123 with sodium sulfide in the conditions 
aforementioned, and then used as nucleophile in the coupling reaction with suitable halides yielding 
derivatives 37-65.  
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n° R R6 R6CH2X n° R R6 R6CH2X 
37 cyclopropylmethyl imidazol-2-yl 102 52 cyclopropylmethyl 3-(CONH2)C6H4 c.a. 
38 cyclopropylmethyl imidazol-5-yl c.a. 53 cyclobutylmethyl imidazol-2-yl 102 
39 cyclopropylmethyl 
4,5-dihydro-1H-
imidazol-2-yl 
135 54 cyclobutylmethyl CONH2 c.a. 
40 cyclopropylmethyl benzoimidazol-2yl c.a. 55 CH2CH(CH3)2 imidazol-2-yl 102 
41 cyclopropylmethyl pyrazol-3-yl 124 56 CH2CH(CH3)2 CONH2 c.a. 
42 cyclopropylmethyl 1,2,4-triazol-1-yl c.a. 57 CH2CH3 imidazol-2-yl 102 
43 cyclopropylmethyl 1,2,4-triazol-5-yl 128 58 CH2CH3 CONH2 c.a. 
44 cyclopropylmethyl tetrazol-5-yl c.a. 59 CH2CH3 CONHCH3 c.a. 
45 cyclopropylmethyl 2-aminothiazol-4-yl 130 60 CH2CH3 pyrazol-3-yl 124 
46 cyclopropylmethyl 3-pyridyl c.a. 61 CH2CH=CH2 imidazol-2-yl 102 
47 cyclopropylmethyl CONHCH3 c.a. 62 CH2CH=CH2 CONH2 c.a. 
48 cyclopropylmethyl CONHCH2OH c.a. 63 CH2CH=CH2 pyrazol-3-yl 124 
49 cyclopropylmethyl CONHOH 134 64 CH2C(CH3)=CH2 imidazol-2-yl 102 
50 cyclopropylmethyl COOCH3 c.a. 65 CH2C(CH3)=CH2 CONH2 c.a. 
51 cyclopropylmethyl 3-(COOCH3)C6H4 c.a. c.a. = commercially available 
Scheme 12 
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As previously assumed, some of the halides used to achieve final products are not commercially available, so 
it has been necessary to synthesize them. The 3-(chloromethyl)-1H-pyrazole 124 was synthesized starting 
from commercial 3-methylpyrazole, which, in the first step, was oxidized with aqueous potassium 
permanganate to afford the 3-carboxylic acid 125 (scheme 13). Thus, the latter was transformed into the 
corresponding ethyl ester 126 using thionyl chloride in absolute ethanol, in a reaction in which was involved 
the formation of the acyl chloride, immediately reacting with ethanol and yielding compound 126. This 
procedure was the preferred one since the direct reduction of the carboxylic acid 125 did not give compound 
127 in good yields. In contrast, reduction of 126 with lithium aluminum hydride in anhydrous THF afforded 
the target 127 in good yields, which was converted into the corresponding chloromethyl derivative 124 by 
reacting with thionyl chloride in anhydrous dichloromethane (308).  
 
 
Scheme 13 
 
Moreover, 3-chloromethyl(1H-1,2,4-triazole) hydrochloride 128 was synthesized starting from commercial 
ethyl 1H-1,2,4-triazole-3-carboxylate, which was previously converted into the corresponding alcohol 129 
(scheme 14) using lithium aluminum hydride in anhydrous THF. This intermediate was finally transformed 
into 128 through a reaction in which thionyl chloride has been used as chlorinating agent (309). 
 
Scheme 14 
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Furthermore, 4-(chloromethyl)thiazol-2-amine 130 and 4-(chloromethyl)-2-phenylthiazole 131 were 
synthesized in a similar way, starting from thiourea and thiobenzamide, respectively, by using 1,3-
dichloroacetone in dry acetone (scheme 15) (310). 
 
 
Scheme 15 
 
The 3-(chloromethyl)benzamide (311) 132, was synthesized starting from commercial 3-
(chloromethyl)benzoic acid going through 3-(chloromethyl)benzoyl chloride obtained with oxalyl chloride in 
DCM using DMF as catalyst (scheme 16). The acyl chloride was not isolated, but it has been immediately used 
for the next step by reacting with anhydrous ammonia in dioxane to afford the desired compound 132. 
 
 
Scheme 16 
 
The synthesis of benzyl 2-chloroacetate 133 (312) starts from commercial chloroacetic acid which was 
reacted with benzyl alcohol in the presence of p-toluenesulfonic acid (scheme 17). Furthermore, 2-chloro-N-
hydroxyacetamide 134 was synthesized (313) from ethyl chloroacetoacetate in a 50% aqueous solution of 
hydroxylamine. 
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Scheme 17 
 
The 2-(chloromethyl)-4,5-dihydro-1H-imidazole 135 was produced (314) by cyclization of the iminoester 
hydrochloride 136 which was synthesized (315) (scheme 18) from commercial chloroacetonitrile in a 
saturated hydrochloric acid solution in absolute ethanol and dry diethyl ether while hydrochloric acid is 
bubbling. After isolation, the intermediate 136 was cyclized using ethylenediamine in absolute ethanol. 
 
 
Scheme 18 
 
In order to obtain compounds 66 and 67 which bear a 4-(para-acetamidophenyl) moiety on the 
aminopyridine-3,5-dicarbonitrile core, it was not possible to achieve intermediate 137 in a one-pot reaction, 
due to the scarce reactivity of 4-acetamidobenzaldehyde. Thus, the aldehyde was reacted with malononitrile 
in a straightforward Knoevenagel condensation (scheme 19) (293) in the presence of piperidine as catalyst in 
ethanol to give intermediate 138 which was isolated to be used in the cyclization reaction involving 
thiophenol and DBU to yield 137. 
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Scheme 19 
 
Then, the sulfanylphenyl derivative 137 was converted into the sulfanyl intermediate 139 using sodium 
sulfide as previously shown. The latter was used to synthesize the final compounds 66 and 67 by reacting 
with 2-bromomethyl-1H-imidazole hydrobromide 102 or commercially available 2-chloroacetamide, 
respectively, in the presence of sodium hydrogencarbonate as base. 
In order to shorten the procedure leading to the para-oxyphenyl-substituted compounds 37-65, a further 
pathway had been evaluated starting from commercial 4-hydroxybenzaldhyde (scheme 20). The latter was 
reacted with thiophenol, malononitrile and DBU in aqueous ethanol to afford the sulfanylphenyl 
intermediate 140 that was converted into the corresponding sulfanyl intermediate 141 then coupled with 2-
chloroacetamide to yield compound 142. Here, the O-alkylation with potassium carbonate was expected to 
produce compound 54, but a competitive reaction afforded a diverse compound (69). In fact, due to the long 
time reaction and the basicity of the medium, the nitrile group in position 3 of the aminopyridine core 
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undergoes condensation with the active methylene group on the sulfanylacetamide chain affording the 
bicyclic compound 69. This collateral product was characterized through 1H NMR, 13C NMR and IR 
spectroscopy confirming our hypothesis. 
 
 
Scheme 20 
 
 
 
 
 
Chemistry 
74 
  
Consequentially, cyclization of BAY60-6583 was performed forcing reaction condition (316) which involved 
potassium hydroxide in absolute ethanol as alkaline reactant to obtain compound 68 (scheme 21). 
 
 
Scheme 21 
 
 
3.2 Chemistry of 7-amino-2-phenylpyrazolo[1,5-c]pyrimidine-4-
carbonitriles 
 
The 7-amino-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile derivatives 70-73 were prepared following a 
new and unique synthetic pathway (scheme 22). The synthesis included a one-pot condensation of ethyl 
cyanoacetate with carbon disulfide in DMF dry, followed by methylation of sulfide groups with methyliodide, 
to afford intermediate 143. This latter was cyclized (317) with acetophenone in the presence of potassium 
hydroxide in dry dimethylsulfoxide (DMSO) yielding the oxo-pyranone 144 in good yields which was used as 
starting material for the production of the pyrazole 145 by reacting with hydrazine monohydrate in pyridine 
(318). Furthermore, the pyrazole NH of compound 145 was acylated with a Boc protecting group in order to 
avoid parasite reactions on the free nitrogen atom. The reaction was performed by using tert-butyl anhydride 
in dry acetonitrile in the presence of triethylamine (TEA), obtaining compound 146. Condensation of the 
latter with carbon disulfide using sodium hydride in dry DMSO and following methylation with methyl iodide 
in a one-pot reaction allowed to obtain intermediate 147, which was then deprotected by using 
trifluoroacetic acid in DCM to yield compound 148. Cyclization of the latter in N-methylpyrrolidin-1-one 
(NMP) by reacting with a strong excess of cyanamide in the prescence of 4-toluenesulfonic acid afforded 
compound 149.  
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Scheme 9 
 
The reaction was performed in microwave reactor at 160°C for 1h. Consequentially, methylsulfanyl function 
of compound 149 was oxidize to the methylsulfonyl group with 3-chloroperoxybenzoic acid (m-CPBA) in DCM 
affording compound 150. The latter was used as starting material for the reaction with the suitable primary 
amine in the presence of N,N-diisopropylethylamine (DIPEA) to obtain the desired final compounds 70-73 in 
high yields.
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4. Results and discussions 
 
All the synthesized compounds were evaluated by the group of Prof. Katia Varani at the Medical Science 
Department – Pharmacology section of the University of Ferrara, for their affinity at human (h) A1, hA2A and 
hA3 AR (expressed as Ki values obtained in binding experiments) displacing the suitable radioligand for each 
AR subtype ([3H]DPCPX for A1 AR, [3H]ZM241385 for A2A AR and [125I]AB-MECA for A3 AR, respectively) stably 
expressed on chinese hamster ovary (CHO) cells. The potency at the hA2B AR (expressed as EC50 values in 
cAMP functional assay) was assessed in hA2BCHO cells stimulated by 200 nM NECA, at 1µM concentration of 
the examined compounds. Ki values are means ± SEM of four separate assays each performed in duplicate 
while EC50 values are expressed as means ± SEM of four separate cAMP experiments. Some selected 
derivatives (A, C, 1, 2, 4, 5, 9, 14, 15, 26, 36) were tested to assess their agonistic or antagonistic properities 
at hA1 and hA2A ARs. Thus their capability to modulate cAMP production was evaluated on hA1 and hA2A CHO 
cells. 
4.1 DCP1 series 
 
Based on the preliminary results obtained for compound A-C (Figure 21), modifications on dicyanopyridine 
scaffold were performed at position R6 (Table 5). Firstly, replacement of the methyl carboxylate function of 
B with a nitrile group yielded compound 10 which results equipotent at the hA1 AR as the leads A-C. Aryl 
homologation on methyl ester function of B led to compound 1, which binds at the hA2A subtype but loses 
selectivity for the hA1 AR with respect to the lead B. In functional assays 1 shows an inverse agonist profile 
at the hA1 AR, while it acts as antagonist at the hA2A AR (Table 6). In order to enlarge information on this kind 
of residues at position R6, the methyl ester of 1 was transformed into the carboxamido (2) (as aryl homologue 
of the lead C), carboxylic acid (3), methyl alcohol (4) and nitrile (5) analogues which maintain on the whole 
the same trend of AR affinity with respect to compound 1. In contrast, compound 2, 3 and 5 show some 
affinity for hA3 AR but in the high nanomolar range thus maintaining a good selectivity. In fact, the carboxylic 
acid 3 shows more than 100 fold hA1 selectivity versus hA2A and hA3 receptors, thus higher than the parents 
1, 2, 4, 5. It is important to highlight that compounds 2, 4 and 5, such as 1, act as inverse agonist at hA1 AR 
while 2 and 4 behave as hA2A AR antagonists. An interesting result was obtained performing an isosteric 
replacement of the phenyl ring of compound 1 with a furane moiety obtaining the methyl 5-furan-2-
carboxylate derivative 6 which is endowed with good affinity and high selectivity at the hA1 AR. Meanwhile, 
modifications at R4 were performed replacing the 2-furyl moiety of 1 with a 3-furyl (7), 2-thienyl (8) and 3-
pyridyl (9) substituent in order to understand if a diverse heterocycle could modulate the affinity and the 
pharmacological profile of the target compounds. While compound 7 bearing the 3-furyl substituent at R4 
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maintains the same trend of affinity of the reference 1, derivatives 8 and 9 acquire a higher selectivity versus 
the hA2A AR with respect to 1.  
 
 
hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R4 R6 
[3H]DPCPX 
Ki (nM) or 
I% at 1Ma 
[3H]ZM241385 
Ki (nM) or 
I% at 1Ma 
EC50 (nM)b 
 (efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1Ma 
A 2-furyl CH2OH 
57 ± 4 
(inverse agonist) 
27% >1000 (7%) 29% 
B 2-furyl COOCH3 108 ± 9 17% >1000 (4%) 25% 
C 2-furyl CONH2 175 ± 12 21% >1000 (17%) 177 ± 15 
1 2-furyl 3-(COOCH3)C6H4 
7.22 ± 0.63 
(inverse agonist) 
68±3 
(antagonist) 
>1000 (7%) 26% 
2 2-furyl 3-(CONH2)C6H4 
1.32±0.11 
(inverse agonist) 
67±6 
(antagonist) 
>1000 (6%) 326±31 
3 2-furyl 3-(COOH)C6H4 4.12±0.38 581±54 >1000 (1%) 611±58 
4 2-furyl 3-(CH2OH)C6H4 
0.98±0.09 
(inverse agonist) 
31±3 
(antagonist) 
>1000 (4%) 25% 
5 2-furyl 3-(CN)C6H4 
1.02±0.11 
(inverse agonist) 
93±9 >1000 (7%) 668±64 
6 2-furyl 
methyl 5-furan-2-
carboxylate 
82 ± 8 1% >1000 (7%) 11% 
7 3-furyl 3-(COOCH3)C6H4 2.11±0.19 96±8 >1000 (7%) 1% 
8 2-thienyl 3-(COOCH3)C6H4 2.72± 0.21 693 ± 68 
982±95 
(62%) 
15% 
9 3-pyridyl 3-(COOCH3)C6H4 
1.18± 0.11 
(inverse agonist) 
636±57 >1000 (15%) 8% 
10 2-furyl CN 93 ± 8 887 ± 84 >1000 (1%) 582 ± 56 
11 2-furyl COOCH2C6H5 86±7 8% >1000 (10%) 1% 
12 2-furyl COC6H5 23 ± 2 224±21 >1000 (1%) 26% 
13 2-furyl 3-pyridyl 1.42±0.15 24±3 >1000 (1%) 948 ± 82 
14 2-furyl 2-pyridyl 
2.71±0.21 
(inverse agonist) 
108±9 >1000 (9%) 134±12 
15 2-furyl 2-phenylthiazol-4-yl 
3.85±0.32 
(partial agonist) 
523±49 
947±92 
(29%) 
438±41 
16 2-furyl 2-aminothiazol-4-yl 1.27 ± 0.11 22 ± 2 >1000 (9%) 193 ± 17 
aKi values are means ± SEM of four separate assays each performed in duplicate. Percentage of inhibition (I%) are determined at 1µM concentration 
of the tested compounds.  bcAMP experiments in hA2BCHO cells stimulated by 200 nM NECA, at 1µM concentration of the examined compounds. EC50 
values are expressed as means ± SEM of four separate cAMP experiments.  
Table 5 
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This data let us to hypothesize that the furan ring is important for the anchoring of these derivatives at the 
hA2A subtype. Further modifications were performed at R6 keeping the 2-furyl moiety at position R4. Thus, 
compound 11 and 12 were synthesized, spacing the phenyl residue at R6 from the dicyanopyridine core with 
respect to compounds 1-6. While compound 12 maintains the same profile of derivatives 1-5 binding at both 
hA1 and hA2A AR, the benzyl ester 11 showed a good affinity for hA1 AR and high selectivity suggesting the 
possibility to modulate A1 selectivity with respect to A2A AR by performing this modification on the 
sulfanylmethyl function. 
Furthermore, in order to evaluate the presence of diverse heteroaryl moieties at position R6 for the binding 
at ARs, 3-pyridyl (13) and 2-pyridyl (14) derivatives were produced which maintain hA1 and hA2A affinity in 
the low and in the high nanomolar range, respectively. For compound 14 which behaves as inverse agonist 
(Table 5 and 6) also the binding at hA3 subtype increseas. What is noteworthy is that preliminary functional 
data indicate that compound 13 seems to behave as a weak agonist at the hA2A AR opening the possibility to 
consider this compound as a lead to design new A2A agonists belonging to this series. Pursuing modifications 
at position R6, 2-phenylthiazol-4-yl (15) and 2-aminothiazol-4-yl (16) derivatives were synthesized. These 
compounds showed high affinity for hA1 AR, and compound 15, acting as a partial agonist, a good selectivity 
versus the other ARs. At this moment, no data are available about the functional profile of the aminotiazole 
compound 16, that could have been of help for understanding the potential role of a thiazolyl moiety at R6 
for shifting the profile of these derivatives from inverse agonist to agonist (compare to 15). 
 cAMP assay 
 
hA1  
EC50 (nM) 
hA2ACHO cells 
EC50 (nM) 
hA2ACHO cells 
IC50 (nM) 
A 128 ± 11 - - 
1 1.43 ± 0.11 < 20% 
313 ± 29 
(10 µM: 67%) 
2 2.84 ± 0.27 < 20% 
58 ± 5 
(10 µM: 49%) 
4 0.98 ± 0.09 < 20% 
22 ± 2 
(10 µM: 99%) 
5 4.82 ± 0.39 - - 
9 6.26 ± 0.58 - - 
14 34 ± 3 - - 
15 4.12 ± 0.37 - - 
Table 6: Functional assays at A1 and A2A ARs of selected compounds  
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Moreover, replacement of the sulfanyl linker of the lead compound A with an amino group (17) or an oxygen 
atom (20) results to be detrimental for affinity at hA1 AR (Table 7), thus confirming the importance of the 
sulfur atom as linker in this position. While keeping the aminoethanol function of 17, replacement of the 2-
furyl moiety with 2-thienyl (18) or phenyl (19) substituent enhanced affinity at the A1 AR with respect to 17.  
 
 
hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R4 X 
[3H]DPCPX 
Ki(nM)  or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
 (efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
A 2-furyl S 57 ± 4 27% >1000 (7%) 29% 
17 2-furyl NH 20% 18% >1000 (1%) 17% 
18 2-thienyl NH 324 ± 28 33% >1000 (1%) 29% 
19 C6H5 NH 943 ± 87 1% >1000(1%) 1% 
20 2-furyl O 632 ± 53 25% >1000 (11%) 3% 
 
Table 7 
 
Substitution of the primary amine function with R2 groups (Table 8) was useful to evaluate the role of this 
position for the binding at the others ARs. In particular, this information is important to evaluate the mode 
of binding of these compounds at the A1 subtype with respect to the adenosine-like ligands. Cycloalkyl groups 
such as cyclopropyl (21) and cyclopentyl (22) and also other moieties (compounds 23-25) have been 
introduced at R2 on the basis of advice coming from the SARs on the adenosine-like A1 AR agonists reported 
in literature. While compound 21 binds the hA1 AR as the lead A, compound 22 bearing the usual cyclopentyl 
substituent for selective A1 ligands was inactive at this subtype. Unexpectedly, also the aryl-substituted 
compound 23 showed any affinity at the ARs, although some nucleosidic A1 AR agonists bear this moiety. 
Nevertheless, this behavior can confirm the diverse binding mode of these non-nucleoside ligands with 
respect to the nucleoside ones. Compound 24 bearing a NH-benzylamino substituent is endowed with high 
affinity and good selectivity for the hA1 AR that are comparable to those of derivative 21. Probably, an 
increased length chain of this residue could be useful for the anchoring at the active site of the A1 AR. 
Replacement of the amine function of A with an acetammido group (compound 25) enhances hA3 AR affinity 
suggesting that an acyl moiety could be useful for shifting the binding of the aminopyridine-3,5-dicarbonitrile 
derivatives toward the hA3 AR, as extensively demonstrated for other AR ligands in literature. 
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hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R2 
[3H]DPCPX  
Ki (nM) or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
 (efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
A H 57 ± 4 27% >1000 (7%) 29% 
21 cyclopropyl 89±7 30% >1000 (4%) 30% 
22 cyclopentyl 742 ± 68 8% >1000 (1%) 780±72 
23 4-I-C6H5 10% 1% >1000 (1%) 8% 
24 benzyl 65±6 461±42 >1000 (3%) 14% 
25 COCH3 243±21 11% >1000 (3%) 211±18 
 
Table 8 
 
4.2 DCP2B series 
 
All the derivatives designed as A2B AR ligands (Table 9) behave generally as partial agonists (Table 10) with 
the only exception of derivatives 66, 67 which show a full agonist profile. 
Previously reported compound D bearing a 2-imidazolyl moiety at position R6 shows high affinity at all the AR 
subtypes, and in particular high activity at the hA2B AR behaving as a partial agonist. The trend is similar to 
that of the analogue LUF-5845, reported in literature (296). In order to explore the potentiality of the 
imidazolyl moiety at position R6 for activity at A2B AR, the 2-furyl substituent at R4 of D was replaced especially 
by other heteroaryl and 4-substituted-aryl residues, obtaining a set of compounds showed in Table 9. All 
these derivatives are endowed with a partial agonist profile at the hA2B AR. 
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hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° X R4 
[3H]DPCPX 
Ki(nM)  or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
(efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
D S 2-furyl 12 ± 2 
26 ± 2  
(partial agonist) 
1.7 ± 0.2 
(52%) 
65 ± 5 
26 S 3-furyl 0.77±0.09 
37±3  
(antagonist) 
2.32±0.21 
(42%) 
274±23 
27 S 3-thienyl 1.01±0.09 55±6 
3.15±0.29 
(47%) 
221±20 
28 S 3-pyridyl 5.26±0.48 463±38 
63±5 
(58%) 
19% 
29 S 4-pyridyl 8.85±0.82 81±7 
12.5±1.3 
(36%) 
26% 
30 S CH2C6H5 31% 8% 
260±24 
(44%) 
1% 
31 S 4-Cl-C6H4 30±4 865±68 
109±12 
(32%) 
850±62 
32 S 4-F-C6H4 0.78±0.08 139±12 
18±2 
(76%) 
410±38 
33 S 4-CH3-C6H4 5.32±0.42 47±4 
78±6 
(78%) 
212±19 
34 S 4-SCH3-C6H4 8.32±0.78 227±21 
35.7±3.4 
(30%) 
388±29 
35 S CH3 74±8 331±32 1% 510±53 
36 NH C6H5 140 ± 12 
115±10  
(antagonist) 
1% 19% 
37 S 4-(OCH2C3H5)-C6H4 235±24 764±72 
9.52±0.91 
(70%) 
474±45 
LUF-5845 (296) S 4-(OCH3)-C6H4 7 214 9 24 
BAY60-6583 31% 2% 31 ± 3 8% 
 
Table 9 
 
 
Results and discussion 
82 
  
 
 
 
 
 
 
Table 10: Functional assays on A1 and A2A ARs for selected compounds 
 
Substitution at R4 with different heterocyclic residues such as 3-furyl (26), 3-thienyl (27), 3-pyridyl (28) and 
4-pyridyl (29) maintains the activity at the A2B AR, but also scarce selectivity. Various para-substituted phenyl 
groups were also introduced at this position: 4-Cl (31), 4-F (32), 4-CH3 (33) and 4-SCH3 (34) residues positively 
influence affinity and activity at A1 and A2B AR, even if in minor extent for the 4-chloro-substituent, and have 
different effects on selectivity versus the other AR subtypes. However, para-substitution with a 
cyclopropylmethyloxy, which is typical of BAY60-6583, makes compound 37 as a very potent and selective 
hA2B agonist. In fact, 37 results 3-fold more active than BAY60-6583 at the hA2B AR, and shows also very good 
selectivity versus the other AR subtypes (25 times vs hA1, 80 times vs hA2A, and 50 times vs hA3). Furthermore, 
it acts as partial agonist. Indeed, substitution at R4 of a benzyl moiety (30) produces a very good selectivity 
for hA2B but also a decrease of potency is observed. Thus, it remains to be demonstrated whether a 
compromise between length and dimension of the appended R4 substituent could exist, in order to target 
selectively the A2B subtype. Moreover, a methyl group at position R4 was introduced yielding compound 35 
that is totally inactive at the hA2B AR but shows nanomolar affinity for the hA1 subtype. Replacement of the 
sulfanyl linker with an amine function (36) as performed on DCP1 series is extremely detrimental for hA2B AR 
activity, while some affinity for hA1 and hA2A AR is maintained. 
Thus, keeping the 4-cyclopropylmethyloxyphenyl moiety at R4, the imidazolyl at R6 was replaced with diverse 
H-bond donor/acceptor-group containing heterocycles to yield a subset of compounds showed in Table 11. 
All these derivatives show a partial agonist profile at hA2B AR. 
 
 
  cAMP assay  
 hA1 EC50 (nM) 
hA2ACHO cells 
EC50 (nM) 
hA2ACHO cells 
IC50 (nM) 
D - 
19 ± 2 (39%) 
Partial Agonists 
- 
26 0.77 ± 0.09 < 20% 
138 ± 12 
(10 µM: 64%) 
36 - < 20% 
814 ± 72 
(10 µM: 93%) 
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hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R6 
[3H]DPCPX 
Ki(nM)  or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
(efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
37 imidazol-2-yl 235±24 764±72 
9.52±0.91 
(70%) 
474±45 
38 imidazol-5-yl 483 ± 33 14% 
139 ± 11 
(50%) 
6% 
39 4,5-dihydro-1H-imidazol-2-yl 1% 7% 7% 1% 
40 benzoimidazol-2-yl 21% 6% 12% 1% 
41 pyrazol-3-yl 552±54 2% 
84±6 
(48%) 
6% 
42 1,2,4-triazol-1-yl 12% 1% 1% 1% 
43 1,2,4-triazol-5-yl 338±31 1% 51±4 1% 
44 tetrazol-5-yl 3% 1% 25% 1% 
45 2-aminothiazol-4-yl 140±12 1% 17% 1% 
46 3-pyridyl 67±7 424±37 1% 19% 
47 CONHCH3 14% 1% 
94±8 
(63%) 
3% 
48 CONHCH2OH 10% 1% 
182±14 
(57%) 
8% 
49 CONHOH 536 ± 49 1% 20% 31% 
50 COOCH3 23% 1% 1% 1% 
51 3-(COOCH3)C6H4 66±5 1% 
347±31 
(27%) 
4% 
52 3-(CONH2)C6H4 83±7 25% 
12.7±1.1  
(69%) 
1% 
BAY60-6583 CONH2 31% 2% 31 ± 3 8% 
 
Table 11 
 
Firstly, the isomer of compound 37, which bears an imidazol-5-yl moiety (38), was produced. The latter 
results less active than its isomer at the hA2B AR, but but also at hA2A and hA3 ARs. Unexpectedly, replacement 
of the 2-imidazolyl group of 37 with an imidazoline (39) was detrimental for hA2B activity. The same is 
observed for the 2-benzoimidazole moiety (compound 40). In this case, the inactivity at A2B receptor could 
be ascribed to the excessive steric hindrance of this moiety at this level. Compound 41, bearing a 3-pyrazolyl  
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group shows a good affinity and selectivity at hA2B AR which are comparable with those of the 1,2,4-triazol-
5-yl group (43). These data, together with those of the 1,2,4-triazol-1-yl compound (42), which is totally 
inactive at all the ARs, suggest how important is the presence at R6 of H-bond acceptor/donor functions. 
Compound 42 drastically loses activity at A2B AR due probably to the loss of NH function on the appended 
triazole moiety useful for a profitable interaction with the binding site. Tetrazolyl-substitution in compound 
44 results detrimental for affinity at all ARs, probably due to the excessive acidity of the NH tetrazole moiety. 
Moreover, confirming data on the DCP1 series, 2-aminothiazol-4-yl (45) and 3-pyridyl (46) moieties shift the 
affinity toward the hA1 AR, to the detriment of hA2B AR. N-methylacetamido compound 47 and its analogous 
N-hydroxymethylacetamido 48 result to be highly selective and active at hA2B AR, while hydroxamic acid 49 
loses its potency, probably due to the acidity of its R6 residue, scarcely tolerated by A2B AR. Hence, a methyl 
carboxylate function results detrimental (compound 50) for hA2B affinity. Also its aryl homologue 51 has low 
activity at hA2B AR confirming how both H-bond acceptor and donor functions at this position are essential 
for receptor-ligand interaction. In fact, 3-benzamido-substituted compound 52 is highly active at hA2B AR 
while maintains good affinity for hA1 subtype.  
At the end, further substitutions were performed in para position of the phenyl moiety at R4, while keeping 
few selected substituents (imidazol-2-yl, pyrazol-3-yl, carboxyamido and N-methylcarboxyamido) at position 
R6, thus, a subset of compounds were generated whose pharmacological data are expressed in Table 12. It 
has to be outlined that all the aminodicyanopyridine reported until now behave as partial agonist at the hA2B 
AR with the only exception of compounds 66 and 67 that show a full agonist profile at this subtype. 
Preliminary data show that 4-cyclobutylmethyloxy substitution results detrimental for activity at all the ARs 
(compound 53), this result being quite unexpected. Furthermore, the 4-isobutyloxy derivatives 55, 56 show 
divergent results. In fact, compound 55, bearing a imidazol-2-yl moiety at R6 is endowed of modest activity 
at the hA2B AR, while the carboxamido derivative 56 is completely inactive at this subtype. The 4-ethyloxy 
substituted compounds 57-60 are endowed from high (57,58) to modest (59,60) activity at A2B AR but scarce 
selectivity. 
Balanced A1/A2B AR activity is proper of the 4-allyloxy-substituted compound 61, which bears the imidazol-2-
yl moiety at R6. However, despite the same 4-allyloxy group on R4 position, substitution with both 
carboxyamido (62) and pyrazol-3-yl (63) moieties resulted detrimental for hA2B AR activity although 
compound 63 binds with high activity and selectivity the hA1 AR. Also the 4-methylallyloxy substituent 
(derivatives 64) shifts the affinity toward the hA1 AR. In some case, the replacement of the para-
cyclopropylmethyloxy-phenyl group at position R4 typical of the A2B agonist BAY60-6583 with other para-
cycloalkyl- or para-cycloalkenyl-methyloxyphenyl substituents do not produce a high decrease of hA2B activity 
but preferentially an increase of affinity at the other ARs, thus reducing the selectivity. Finally, para-
acetamidophenyl-substituted derivatives 66, 67, bearing respectively a imidazol-2-yl and a carboxyamido 
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moiety at R6, are endowed of high activity at hA2B AR despite a scarce selectivity versus the others AR 
subtypes. However, as already outlined, compounds 66 and 67 are the only two amino-3,5-dicyanopyridines 
in the whole series having a full agonist profile. 
 
 
 
hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP 
assay 
hA3 
CHO cells 
n° R4 R6 
[3H]DPCPX 
Ki (nM)  or 
(I% at 
1M) 
[3H]ZM241385 
Ki (nM) or 
(I% at 1M) 
EC50 (nM) 
(efficacy 
%) 
[125I]ABMECA 
Ki (nM) or 
(I% at 1M) 
37 4-(OCH2C3H5)-C6H4 imidazol-2-yl 235±24 764±72 
9.52±0.91 
(70%) 
474±45 
53 4-(OCH2C4H7)-C6H4 imidazol-2-yl 25% 4% 12% 574 ± 46 
54 4-(OCH2C4H7)-C6H4 CONH2     
55 4-(OCH2CH(CH3)2)-C6H4 imidazol-2-yl 26% 1% 227±21 1% 
56 4-(OCH2CH(CH3)2)-C6H4 CONH2 603 ± 52 307 ± 27 1% 9% 
57 4-(OCH2CH3)-C6H4 imidazol-2-yl 8.21±0.73 221±19 
11.7±1.2 
(62%) 
85±6 
58 4-(OCH2CH3)-C6H4 CONH2 345±27 1% 
38±3 
(66%) 
20% 
59 4-(OCH2CH3)-C6H4 CONHCH3 104 ± 8 8% 
211 ± 17 
(48%) 
834 ± 74 
60 4-(OCH2CH3)-C6H4 pyrazol-3-yl 21 ± 2 4% 
332 ± 28 
(34%) 
18% 
61 4-(OCH2CH=CH2)-C6H4 imidazol-2-yl 16±2 17% 
27±3 
(56%) 
8% 
62 4-(OCH2CH=CH2)-C6H4 pyrazol-3-yl 44 ±4 8% 7% 13% 
63 4-(OCH2CH=CH2)-C6H4 CONH2 323 ± 25 18% 11% 444 ± 39 
64 4-(OCH2C(CH3)=CH2)- C6H4 imidazol-2-yl 77 ± 6 1% 14% 8% 
65 4-(OCH2C(CH3)=CH2)- C6H4 CONH2     
66 NHCOCH3 imidazol-2-yl 83 ± 7 38 ± 3 
12 ± 1 
(100%) 
48 ± 4 
67 NHCOCH3 CONH2 17% 572±51 
164±12 
(92%) 
742±67 
BAY60-6583 31% 2% 31 ± 3 8% 
 
Table 12 
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This “result” can be considered as a real breakthrough due to the actually limited number of non-adenosine 
hA2B AR full agonists reported in literature, as this information can be used to generate in the near future a 
new series of non-nucleosidic derivatives with this pharmacological profile. However, it has to be clarified 
the role of the N-acetamido function at para position of the 4-phenyl substituent of derivative 66, 67 in 
determininig the A2B pharmacological profile of these compounds. 
The two bicyclic compounds originated by intramolecular cyclization of both BAY60-6583 and the analogue 
54, i.e. derivatives 68 and 69, respectively, bind none of the ARs (Table 13), suggesting that this kind of 
molecular complication, making the structure more rigid, is detrimental for activity at ARs and in particular 
at A2B subtype. However, molecular docking at the ARs are on going to obtain some suggestion about the 
potentiality of this scaffold to be correctly modified and decorated to obtain AR ligands.  
 
                  
 
 
 
hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R4 
[3H]DPCPX  
Ki (nM) or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
 (efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
BAY60-6583 cyclopropyl 31% 2% 31 ± 3 8% 
68 cyclopropyl 19% 3% >1000 (1%) 13% 
54 cyclobutyl 25% 4% >1000 (12%) 574 ± 46 
69 cyclobutyl 14% 1% >1000 (1%) 11% 
 
Table 13 
 
In order to evaluate how a molecular complication of aminopyridine-3,5-dicarbonitriles could modulate the 
affinity and the pharmacological profile of these derivatives at the ARs, a small set of 7-aminopyrazolo[1,5-
c]pyrimidine-4-carbonitriles was synthesized (Table 14). The substituents firstly introduced at position-2 
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(phenyl group) and -5 (substituted amines) of the scaffold have been selected to make easier the 
development of a synthetic procedure, new for the most part, that was as much as possible generalizable. 
Then an investigation in this regard was undertaken and it is still on-going.  
The 5-amino substituents are characteristic of hA2A AR antagonists, of which ZM-241385 (see Table 14) is one 
of the most popular reported in literature, due to its high affinity and selectivity at this subtype. Evident is 
the structure similarity of the pyrazolopyrimidine scaffold of 70-73 to that of ZM-241385 and to those of 
many other A2A AR antagonists reported in the literature (255).  
In fact, as expected, introduction of a phenyl moiety at position 2 of the bicylic scaffold is not the best choice 
to obtain A2A AR antagonists. Compounds 70-73 preferentially bind the hA1 AR due to the lack of the 2-furyl 
moiety, generally mandatory for potent and selective hA2A AR antagonists. Interestingly, compound 71 shows 
a balanced A1/A3 AR affinity.  
Despite the small set of synthesized compounds, preliminary information suggest that this new scaffold, 
suitably decorated, could be a good starting point for the design of new AR ligands. 
 
 
 
hA1 
CHO cells 
hA2A 
CHO cells 
hA2B 
cAMP assay 
hA3 
CHO cells 
n° R5 
[3H]DPCPX 
Ki (nM) or 
I% at 1M 
[3H]ZM241385 
Ki (nM) or 
I% at 1M 
EC50 (nM) 
(efficacy %) 
[125I]ABMECA 
Ki (nM) or 
I% at 1M 
70 C6H5 193±16 3% >1000 (1%) 9% 
71 3-OCH3-C6H4 116±9 7% >1000 (1%) 12% 
72 2-furyl 64±5 3% >1000 (2%) 110±11 
73 CH2C6H5 68±5 1% >1000 (1%) 1% 
ZM-241385 (255) 774 1.6 75* 743 
*Ki from binding experiments 
Table 14 
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5. Molecular modeling studies 
 
In order to rationalize the results obtained from pharmacological assays, the synthesized compounds were 
subjected to a molecular modeling investigation. Docking simulations were performed at both hA1 and hA2B 
AR by Prof. Diego Dal Ben at the School of Pharmacy, Medicinal Chemistry Unit of the University of Camerino. 
Although docking studies are still ongoing some results have emerged. In particular, the newly synthesized 
amino-3,5-dicyanopyridine derivatives were docked into the binding site of homology models of both hA1 
and hA2B AR built by using the crystal structure of the hA2A receptor as a template.  
Molecular modeling studies aimed at analyzing the interaction between AR binding sites and non-nucleoside 
agonists have been reported in literature (319) (320) (321) (299) (300) (322) (323). While the binding mode 
of nucleoside agonists has been depicted from experimental results obtained through X-ray crystallography, 
the interaction between these receptors and agonists based on simplified scaffolds (i.e. pyridine or 
pyrimidine) has been only simulated by molecular docking approaches. In addition, while for the A2A AR 
several crystal structures in the activated or inactivated state have been solved and reported, in the case of 
the A1 and A2B ARs subtypes the protein architecture has been obtained through homology modeling 
techniques and then used as target for docking studies. 
 
Figure 25 
 
The binding modes obtained in this study for the AR non-nucleoside agonists may be grouped in four families, 
according to modeling results reported in literature. One of the first non-nucleosidic AR ligand which was 
evaluated in this study was LUF-5833 (Figure 25) (323). This compound behaves as an agonist at all the AR 
subtypes with different degees of efficacies and belongs to the amino-3,5-dicyanopyridine series developed 
in this thesis. In Figure 26 are shown the four binding modes obtained at the hA2A receptor model for this 
compound. This set of conformations comprises the potential binding modes suggested not only at the A2A 
receptor but also at the A1 and A2B ARs. 
In fact, the first binding mode (Figure 26-A) presents the compounds oriented in a way similar to the one 
previously described for analogue agonists at the ARs (319) (321) (300) (322) (323), where the 5-cyano group 
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and the 6-amine of the pyridine derivatives giving a polar interaction with the amide function of Asn2536.55. 
The phenyl group in 4-position is located in proximity of residues of TM3,6,7 and the 2-thio substituent points 
toward the extracellular environment getting close to residues of TM1,2,7. This binding mode was compared 
with the one of the AR endogenous ligand adenosine, with the nitrogen atom of the 5-cyano group and the 
6-amine of pyridines being located in correspondence of the N7 atom and the N6 amine of adenosine. This 
binding mode is one of the most populated ones by the A1 ligands developed in this project, as well as binding 
mode 3. 
 
Figure 26: Binding poses of LUF-5833 as example for non-nucleoside AR agonists at A2A AR 
 
The binding mode 2 (Figure 26-B) is a 180° rotated version of binding mode 1 (321) (323). This arrangement 
makes the exocyclic amine and the proximal cyano group being located close to TM7 residues, while the 3-
cyano group gets in proximity of Asn2536.55. The 4-phenyl ring gets located at the entrance of the binding 
cavity, while the sulfanyl substituent is close to TM 3,5,6 residues. The binding mode 3 (Figure 26-C) makes 
the exocyclic amine and the proximal cyano group being located close to TM7 residues and the 3-cyano group 
in proximity of Asn2536.55. The phenyl group in 4-position is located in proximity of TM 3,6,7 residues while 
the sulfanyl substituent points toward the extracellular environment. As such as binding mode 1, the number 
3 is one of the most populated for the A1 ligands of this project. The binding mode 4 (Figure 26-D) presents 
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the N1 atom and the exocyclic amino group giving polar interaction with the Asn2536.55 amide function and 
the 3-cyano group close to TM7 residues. The sulfanyl substituent gets in proximity of TM 3,5,6 residues. In 
the case of derivatives presenting small and polar groups within this substituent, polar interactions with TM3 
and TM6 residues are observable. Even this binding mode was previously described in literature for non-
nucleoside agonists of ARs, in particular A2BAR (320) (299) (322). 
A classical strategy to improve the A1 AR affinity for nucleoside compounds has been the introduction of 
cycloalkyl groups at the N6 amine function of adenosine derivatives. Comparing the binding mode 1 and 3 at 
the A1 AR taking the A1 selective agonist 15 as template (Figure 27), it may be noticed as the introduction of 
alkyl or aromatic groups at the exocyclic amine function may be well admitted for binding mode 1 (Figure 27-
A) as these substituents would get located at the extracellular environment. The docking of the 6-
cyclopentylamino-substituted derivative 22 and of the other analogues 21,23-25 are on going. In fact, the 
results of binding studies show that the introduction of cycloalkyl groups or aromatic groups at this amine 
function leads to a decrease of A1 AR affinity, conversely to what observed for nucleoside derivatives. It may 
be concluded that the non-nucleoside derivatives follow a different binding strategy than the nucleoside 
ones. In fact, the binding mode 3 does not provide sufficient free space within the binding cavity to allow the 
introduction of these substituents at the 6-amine for a matter of steric hindrance, thus suggesting that 
binding mode 3 could present higher reliability than the binding mode 1, even if further modelling studies 
and a deepen knowledge in SAR at the aminopyridine-3,5-dicarbonitrile scaffold could be necessary to get a 
final depiction. 
 
 
Figure 27: Binding mode 1 (A) and 3 (B) for compound 15 at A1 AR 
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Concerning docking at A2B AR, as preliminary step, the study starts from the rebuilding of homology models 
of the human A2B AR by using as templates the crystal structures of the human A2A AR that is the member of 
AR family presenting also the highest sequence conservation with the A2B AR. The binding mode of ligands is 
then simulated by molecular docking tools, followed by energy minimization and post-docking analysis. In 
this study, it is not possible to depict any correlation between binding scores or interaction energies and 
activity data, as the potencies of the compounds have been measured as EC50 with functional studies and not 
as Ki affinity with radioligand binding assays. Furthermore, the study provides an interpretation of the 
interaction features for both series of ligands at the A2B AR but do not consider the interaction with the other 
AR subtypes. To simulate the binding mode of nucleoside and non-nucleoside agonists at A2B AR and to 
compare the key ligand-target interaction features of the two structural families of compounds, a molecular 
docking analysis was performed at homology models of the human A2B AR developed by using two recently 
published crystal structures of the agonist-bound A2A AR as templates (pdb code: 2YDO; 3.0-Å resolution and 
pdb code: 3QAK; 2.7-Å resolution, in complex with Ado and UK-432097 (see Figure 5), respectively). The final 
A2B AR models contain a disulfide bridge given by two cysteine residues belonging to TM3 and extracellular 
loop (EL) 2 domains (Cys783.25 - where 3.25 indicates the residue position within helix and Cys171, 
respectively), in agreement with recent mutagenesis studies (324) and as observed in the case of recently 
reported modelling analyses on this AR subtype (320).  
 
 
Figure 28: NECA docked in the crystal structure of the A2A AR 
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The binding sites of the two developed A2B AR models are very similar considering both receptor residues 
orientation and pocket volumes. Slight differences are still observable, due to diverse arrangements of some 
residues detectable even at the two A2A AR crystal structures templates. In order to evaluate differences 
regarding docking at A2B AR between adenosine-like agonist and the aminopyridine-3,5-dicarbonitriles, both 
NECA (Figure 15) and compound D were docked. While NECA was docked in the crystal structure of the hA2A 
AR (Figure 28), docking study of compound D was performed at hA2B AR homology model (Figure 29). 
 
 
 
Figure 29: Docking of compound D at A2B AR. 
 
For summarizing, the exocyclic amino group of compound D mimics the same function in NECA, while the 
cyano at position-3 of the pyridine scaffold could be essential in keeping the 4-furyl substituents and the 2-
sulfanylacetamide function in a non-coplanar conformation. This behavior seems to be mandatory for the 
agonist profile at the A2B AR of these derivatives.  
In fact, considering the non-nucleoside pyridine derivatives, the lowest score and most populated family of 
docking conformations shows the pyridine ring located in rough correspondence to the adenine scaffold of 
nucleoside agonists and forming a π-stacking interaction with Phe173 in the EL2 and this conformation seems 
to be stabilized by the non-coplanarity of the pyridine ring and the substituent at position 2, where H-bond 
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acceptor and donor group help in reaching a stable conformation. In detail, the interaction of the scaffold 
with the A2B AR binding site is given as H-bonding between the N1 atom and the exocyclic amino group of 
pyridines and the amine and carbonyl groups of Asn2546.55 amide function, respectively. This double polar 
interaction is clearly present only for some derivatives, due to the nature of the 4-substituent that slightly 
modifies in some cases the orientation of the scaffold. Analogously to the nucleoside agonists, the exocyclic 
amino group of pyridines gives a H-bond interaction with Glu174 in the case of the 2YDO-based A2B AR model, 
while in the case of the 3QAK-based model the side chain of the same residue in some cases is not close 
enough to the ligand amino group and hence not able to provide a clear H-bonding. The 
sulfanylmethylimidazole group of compound 37 (Figure 30) and the sulfanylacetamide function of compound 
D (Figure 29) at 2-position are inserted between TM3, TM5, and TM6 residues. In the case of compound 37, 
the H-bond donor function of imidazole is oriented towards the oxygen atom of Thr893.36, while the 
acceptor feature points towards the polar hydrogen of His2516.52. The 4’-N-ethyl-carboxyamide function of 
the nucleoside derivative NECA (Figure 28) is in a nearly identical position to the analogue sulfanylacetamide 
group of compound D (Figure 29), suggesting the importance of the presence of a combination of H-bond 
acceptor and donor features located in this region. The 3-cyano group is inserted in a sub-cavity between 
Val853.32, Leu863.33, Thr893.36, Ser2797.42, and His2807.43. No clear interaction with binding site is given 
by this group, even though the presence of some space between this function and the polar groups of 
Ser2797.42 and His2807.43 could allow the presence of a water molecule providing a sort of “bridge 
interaction” between ligand and binding site residues, as observed, for example, in the case of a crystal 
structure of A2A AR in complex with ZM241385 (54). The substituted aromatic group at the 4-position is 
located in a sub-cavity given by TM1, TM2, TM3, and TM7 residues, in close proximity to Tyr101.35, 
Ala642.61, Ile672.64, Ser682.65, and Ile2767.39. Further residues in proximity of this group are Val853.32 
and Phe173.  
 
 
 
 
 
 
Molecular modeling studies 
94 
  
 
 
 
 
Figure 30: Docking of compound 37 at A2B AR: the first binding mode (A) was observed and reported in literature mainly for a series of A1 
receptor agonists (300), while the second (B) was already observed also at the A2B receptor (299). 
A 
B 
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The interaction is mainly hydrophobic, and the presence of a hydrophobic group in para –position of the 
phenyl ring (BAY60-6583, Figure 31 and compound 37, Figure 30) suggests the presence of a large 
hydrophobic feature located within TM1, TM2, and TM7 domains, similar to the e 2-position of nucleosides 
agonists. This group seems critical in particular for pyridine derivatives. Finally, the 5-cyano group points 
towards the extracellular environment and is located in proximity to the couple of residues Glu174-Lys269. 
 
Figure 31: Docking of BAY60-6583 at A2B AR 
 
Concerning in particular docking at A2B AR for compound 37 (Figure 30) receptor interaction is given in 
particular through Asn254 (TM6) and Phe173 (EL2), even if further contacts with residues belonging to TM2, 
TM6, and TM7 that probably play a role for receptor activation are observable (300) (299). 
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6. Evaluation of the antinociceptive effect and stability 
studies  
 
6.1 Evaluation of the antinociceptive effect 
 
Experimental evidence (325) supports the use of caffeine and of other A1/A2A antagonists as well A1 AR 
agonists in the reduction of hyperalgesia or in antinociception. With this in mind, and to clarify these 
paradoxical data, the pain reliever effect of compound 1 (dual A1 inverse agonist/A2A antagonist), derivative 
3 (carboxylic acid analogue of 1, as possible methabolite) and 15, which behaves as partial A1 AR agonist 
(Figure 32), were evaluated in a rat model of chemotherapy-dependent neuropathy induced by oxaliplatin. 
Anticancer therapy based on the repeated administration of oxaliplatin is limited by the development of a 
neuropathic syndrome difficult to treat. Oxaliplatin neurotoxicity is based on complex nervous mechanisms, 
the comprehension of the role of single neurotransmitters and the knowledge of the signal flow among cells 
is matter of importance to improve therapeutic chances. Neuropathic pain evolves from the physiological 
role of nociceptive pain to pathological aspects depending on the complex response of the nervous system 
to a lesion or disease of its somatosensory component. Electrical, molecular and cellular activity participate 
in sensitizing nervous circuits of periphery, dorsal horn as well as anterior cingulate gyrus, prefrontal cortex, 
amygdala, and periaqueductal gray leading to pain-mediating signals (326). The maladaptive plasticity of the 
central nervous system (CNS) assumes increasing evidence in the pathophysiology of chemotherapy-induced 
neuropathies (327) (328), a peculiar iatrogenic damage of the nervous tissue that results in therapy dose 
reduction or discontinuation and negatively influences quality of life on cancer survivors (329). Oxaliplatin is 
effective in various solid tumors (330) (331). Colorectal cancer is the main target, introduced for the 
management of the advanced stages oxaliplatin is currently the regimen of choice for the adjuvant treatment 
of patients with curative resection of node-positive colon cancer (332) (333). The dose-limiting toxicity of this 
compound is the development of peripheral neuropathy (334) related to the total cumulative dose and to 
the treatment doseintensity (335). Although acute symptoms typically resolve within a week, cumulative 
oxaliplatin causes chronic neuropathy in approximately 50% of patients receiving doses higher than 1000 
mg/m2. Signs and symptoms of chronic neuropathy include pain, paresthesia, hypoesthesia, dysesthesia, and 
changes in proprioception that persist between cycles (336). The pathophysiology of oxaliplatin neurotoxicity 
involves multiple aspects. Molecular damages to peripheral nerves and dorsal root ganglia (327) result in 
decreased cellular metabolism and axoplasmatic transport (337). Despite the oxaliplatin limited ability to 
cross the blood brain barrier (338) (339), the CNS appears strongly involved since oxidative damage (338), 
peroxisome derangement and intracellular signaling alteration have been shown at spinal and supraspinal 
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level (327) (339). In the spinal dorsal horn of oxaliplatin-treated mice, Renn and co-workers (328) observed 
an increased activity of wide dynamic range neurons.  
On the other hand, oxaliplatin induces a significant glial cell density increase differently according to cell type, 
anatomical region and treatment time-points revealing a prominent role of astrocytes (327). In recent years, 
there have been further significant developments that enhance an understanding of the role of adenosine in 
nociception. Thus, novel methods useful for taking advantage of A1 AR antinociceptive effect have been 
developed (144), and the role of adenosine A2A in nociception has been further elaborated (160). 
Furthermore, a contribution of endogenous adenosine and AR modulation to the actions of several 
pharmacological agents, as well as non-pharmacological procedures, used to manage pain has been 
described. As previously assumed (see Introduction) A1 AR and A2A AR, as well as A2B AR are fully involved in 
neuropathic pain modulation.  
                                                 
 
Figure 32: Compound tested in the oxaliplatin-induced allodynia assay 
 
Pro-nociceptive effects mediated by A2B AR activation were discovered only in the last 10 years. And recently, 
the focus of attention has moved to the antinociceptive effect exerted by A1 AR agonists at the spinal cord 
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level thus hypothesizing a therapeutic potential for the treatment of neuropathic pain (258). Also A2A AR 
seems to be involved in pain response. However, the finding regarding the A2A AR signaling in pain have been 
controversial, with studies supporting both pro- and anti-nociceptive roles. Moreover, it is still controversial 
the role in antinociception mediated by one of the most known non selective AR antagonists, caffeine. In 
fact, with respect to pain, caffeine (100 mg) is an adjuvant analgesic in humans when given in combination 
with common analgesics (acetylsalicylic acid, acetaminophen/paracetamol, ibuprofen). Furthermore, a few 
is known about the effect of caffeine (340) in neuropathic pain. Recent reports, assess a role of the potential 
of caffeine in this disease to its antagonistic properties at A1 and A2A ARs. The hyperalgesic effect mediated 
by A1 AR blockade may be compensated for by an antinociceptive effect of antagonism at A2A subtype. Thus, 
it is particularly important to deepen the role of the balanced A1/A2A antagonism of caffeine in nociception.  
This oxaliplatin-induced allodynia assay was performed by the group of Prof. Carla Ghelardini at the 
NEUROFARBA Department – Pharmacology and Toxicology section, of the University of Florence.  
 
 Cold plate (s) 
Treatment Before treatment After treatment 
 15 min 30 min 45 min 60 min 
vehicle + vehicle 18.4 ± 0.2 18.6 ± 1.2 19.0 ± 0.4 22.6 ± 0.6 21.4 ± 0.6 
oxaliplatin + vehicle 10.9 ± 1.2* 11.7 ± 0.6* 12.0 ± 1.0* 12.5 ± 0.9* 13.4 ± 1.6* 
oxaliplatin + 1  
(0.03 mg Kg-1 p.o.) 
11.3 ± 0.3* 12.8 ± 0.6 13.2 ± 0.6 13.0 ± 0.5 14.2 ± 0.6 
oxaliplatin + 1  
(0.1 mg Kg-1 p.o.) 
10.3 ± 0.4* 14.5 ± 0.6^ 16.8 ± 0.3^^ 18.0 ± 0.6^^ 14.2 ± 0.3 
oxaliplatin + 1  
(0.3 mg Kg-1 p.o.) 
10.3 ± 0.3* 17.0 ± 0.7^^ 19.2 ± 0.5^^ 17.7 ± 0.6^^ 15.0 ± 0.6 
oxaliplatin + 3  
(0.1 mg Kg-1 p.o.) 
10.6 ± 0.5* 12.8 ± 1.2 14.0 ± 0.8 11.0 ± 1.1 11.1 ± 0.8 
oxaliplatin + 3  
(0.3 mg Kg-1 p.o.) 
11.0 ± 0.4* 14.2 ± 1.5 20.8 ± 1.2^^ 14.0 ± 0.6 11.9 ± 0.7 
oxaliplatin + 15  
(0.3 mg Kg-1 p.o.) 
11.5 ± 0.5* 12.2 ± 0.5 12.2 ± 1.0 12.7 ± 0.6 12.0 ± 1.2 
oxaliplatin + 15 
(1.0 mg Kg-1 p.o.) 
10.6 ± 0.2* 16.6 ± 1.1^ 12.0 ± 1.6 12.1 ± 0.5 11.7 ± 0.6 
 
Table 15: Oxaliplatin (2.4 mg kg-1, i.p.)  was dissolved in glucose 5% and administered daily for 2 weeks. After 14 days from the first injection of 
oxaliplatin, P301 (suspended in 1% carboxymethylcellulose) was per os (p.o.) administered. Control animals were treated with vehicles. Pain-
related behavior (i.e. lifting and licking of the hind paw) were observed and the time (seconds) of the first sign was recorded. *P<0.01 vs vehicle 
+ vehicle treated animals; ^P<0.05 and ^^P<0.01 vs oxaliplatin + vehicle treated mice. Each value represents the mean of 10 mice 
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After repeated treatment with oxaliplatin (2.4 mg kg-1 daily intraperitoneally for 2 weeks), animals developed 
a characteristic thermal allodynia to cold stimuli evaluable by the cold plate test (licking latency 10.9 ± 1.2 s 
in comparison to 18.4 ± 0.2 s of control animals). While the partial agonist 15 showed only a modest effect 
30min after treatment (Table 15), a single treatment with 1 per os was able to dose-dependently decreased 
oxaliplatin-induced pain. Starting from 0.1 mg kg-1 the compound significantly reduced the cold 
hypersensitivity for 45 min after administration. The 1 high dose tested (0.3 mg kg-1) was able to fully revert 
allodynia peaking 30 min after treatment. The behavior of this two compound in this pharmacological assay 
can be seen as paradoxal: activation of A1 AR is known to exert an antinociceptive effect in a large variety of 
pain models in literature while A1 AR blocking can be associated to pro-nociceptive action. In contrast, the 
expected pain reliever effect of compound 15, the A1 AR partial agonist, was not evidenced in this model. 
Moreover, the A1 inverse agonist/A2A antagonist 1 exerts antinociceptive effect that appears to be modulated 
by A2A AR that could outweigh the pro-nociceptive effect mediated by the A1 subtype. Also the carboxylic 
acid 3 (Figure 25) was evaluated in this model in order to clarify if the data on antinociceptive actions of 
compound 1 could be related to its metabolic hydrolysis to 3. In this model, 3, whose pharmacological profile 
was not yet evaluated, shows to be less active than the corresponding methyl ester 1 in this oxaliplatin-
induced allodynia assay at 0.1 mg/Kg p.o. and 0.3 mg/Kg p.o., despite a higher peak of effect at 30 minutes 
after somministration. These results do not help the understanding of the pathophysiological role of A1 and 
A2A ARs in neuropathic pain. Thus, in the future others A1 AR agonists, dual A1/A2A AR antagonist or inverse 
agonist, and A1 AR inverse agonist already obtained, will be tested in this model. In order to evaluate the 
potential role of the carboxylic acid 3 as methabolite of the carboxylic ester 1 in the antinociceptive action of 
this latter, stability studies on human and rat plasma were performed. 
6.2 Stability studies 
 
The stability study on compound 1 was performed by the group of Dr. Gianluca Bartolucci at the 
NEUROFARBA Department – Pharmaceutical Science section, of the University of Florence. The degradation 
profiles were obtained by using LC-MS/MS analysis monitoring the variation of the analyte 1 concentration, 
by using BAY60-6583 as internal standard, at different incubation times. Comparison of results obtained in a 
phosphate buffer solution (PBS) and plasma permits to distinguish between chemical stability and 
bioavailability of the analyte. Both Ketoprofene ethyl ester and Enalapril degradation experiments were 
carried out to check the hydrolytic activity of human or rat plasma batch employed, respectively. In order to 
summarize all experimental data, the half-life (T1/2) of compound 1 was reported in Table 16. 
In the graphs are shown the degradation profiles of 1 in human plasma and PBS (figure 33) and in rat plasma 
(Figure 34) using Ketoprofen ethyl ester and Enalapril as control enzyme activity of the human and rat plasma, 
respectively. 
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The data obtained in this study confirm the stability of 1 during of the whole oxaliplatin-induced neuropathy 
assay in rats showing a high hydrolyzing time in these conditions.  
 
Compound 
 
Human Plasma T 1/2 
(min) 
Rat Plasma T 1/2 
(min) 
KEE 93 - 
Enalapril - 60 
1 >240 170 
 
Table 16 
 
Degradation profiles of 1 indicate a similar trend in rat and human plasma, leading to validate the 
pharmacological model here used. 
 
 
 
Figure 33 
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Figure 34
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7. Studies on oligodendrocytes precursor cells 
 
Current available multiple sclerosis (MS) therapies target immune modulation with some efficacy, however, 
concomitantly with adverse side effects (341). Oligodendrocytes are the only myelin-producing cells in the 
CNS (342). Damaged oligodendrocytes no longer generate myelin and remyelination requires generation of 
new mature oligodendrocytes from the differentiation of oligodendrocyte progenitor cells (OPCs) (Figure 35) 
(343). These cellular resources are especially active after demyelinating episodes in early phases of MS. 
Indeed, OPCs actively proliferate, migrate to and repopulate the lesioned areas. Ultimately, efficient 
remyelination is accomplished when new oligodendrocytes reinvest nude neuronal axons, restoring the 
normal properties of impulse conduction. As the disease progresses, this fundamental process fails. Multiple 
causes seem to contribute to such transient decline, including the failure of OPCs to differentiate and enwrap 
the vulnerable neuronal axons. For example, the observation that OPCs are present in MS lesions but fail to 
differentiate into mature oligodendrocytes (344) suggests that the remyelination process is blocked at a 
premyelinating stage in demyelinating lesions. There are no effective remyelination therapies for MS 
patients. Thus, OPCs are a viable treatment target for MS clinical therapy (345) (346). 
Purinergic signaling (exerted by adenosine and ATP) has recently emerged as a most pervasive mechanism 
for intercellular communication in the nervous system, affecting communication between many types of 
neurons and all types of glial cells (347). Not only neurons but also glial cells in fact release and respond to 
purinergic molecules, under both physiological and pathological conditions (348). Concerning 
oligodendrocytes, it has been demonstrated that purines exert multiple effects including increased motility, 
proliferation and differentiation of cultured OPCs (349). Among purines, adenosine is a neuromodulator of 
the CNS. It is known that OPCs express all these receptors, as detected by RT-PCR in cultured OPCs, including 
A2B AR (350). To date, a functional role has been attributed only to A1 and A2A AR (349). It has recently clarified 
the role of A2A AR on oligodendrogenesis, demonstrating that their selective activation decreases outward 
rectifying, sustained, inward K+ currents and inhibits in vitro OPC differentiation towards mature, 
myelinating, oligodendrocytes, without affecting cell division (351). Conversely, adenosine, through the 
activation of A1 AR, seems to be a primary activity-dependent signal inhibiting the proliferation and 
promoting differentiation of premyelinating progenitors into myelinating oligodendrocytes (350) and 
stimulating OPC migration (352). The functional role of the A2B AR in oligodendrocytes has not yet been 
clarified because, as already assumed in this thesis, A2B AR is the least studied and still remains the most 
enigmatic AR subtype. However, there is a growing interest in A2B AR in recent years, as it has been shown to 
play a role in inflammation and cancer and is even considered a promising new pharmacotherapeutic target 
(320). Of particular note is that in the brain during different pathological conditions, such cerebral ischemia, 
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extracellular adenosine is elevated to levels sufficient for A2B AR (349). White matter damage is a clinically 
important aspect of several central nervous system diseases, including stroke. Cerebral white matter 
primarily consists of axonal bundles unsheathed with myelin secreted by mature oligodendrocytes, which 
play an important role in neurotransmission between different areas of gray matter. During the acute phase 
of stroke, damage to oligodendrocytes leads to white matter dysfunction through the loss of myelin. For 
effective remyelination to take place, OPCs play critical roles by proliferating and differentiating into mature 
oligodendrocytes, which help to decrease the burden of axonal injury. Although it was demonstrated that 
the selective A2A AR antagonism prevented myelin disorganization induced 24 h after occlusion of medial 
cerebral artery (MCAo) in rat (353), the role of A2B AR both on ischemia-induced neuronal and glial damage 
was not investigated during cerebral ischemia. 
The aim of this study was to clarify the oligodendrogenetic potential of A2B AR, in particular to investigate, in 
cultured OPCs at different times of maturation (from t0 to t10, Figure 35), whether A2B AR modulates ionic 
currents and cell proliferation and maturation by using selective A2B AR agonists (commercially available and 
newly synthetized), alone or in combination with A2B AR selective antagonists. All these experiments were 
carried out in cultured rat oligodendrocytes by using patch clamp recordings and immunocytochemical 
analysis (Figure I) and performed by Dr. Anna Maria Pugliese, belonging to the Prof. Felicita Pedata group at 
the NEUROFARBA Department – Pharmacology and Toxicology section, of the University of Florence.  
 
 
 
Figure 35: Immunocytochemical analysis of OPCs at different times of maturation and ouward K+ current variation during maturation 
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To examine the effects of A2B AR stimulation on the in vitro oligodendrocyte progression towards mature 
phenotypes, an immunocytochemical labeling of OPC cultures was performed. OPC were allowed to 
differentiate for different days in differentiation medium (DM) (t6 and t10) in order to characterize the time 
course of the expression of specific markers of cell differentiation. In parallel experiments, OPC cultures will 
be differentiated in the presence of different concentrations of the A2B AR agonists 37 and BAY 60-6583 
(Tocris, Italy) (Figure 15) alone or in combination with the A2B AR antagonist PSB-603 (Figure 16) in order to 
verify whether A2B AR receptor activation could influence OPC differentiation. 
Preliminary experiments demonstrated that selective stimulation of A2B AR in cultured OPCs reduces the 
amplitude of outward currents, as recorded in patch clamp experiments (Figure 36). The selective stimulation 
was guaranteed by silenciating A1, A2A and A3 ARs in coltures. These currents were abolished when K+ was 
replaced by equimolar Cs+ concentration into the intracellular pipette solution indicating that ramp-evoked 
outward currents are K+ currents. Compound 37, applied at the concentrations of 50 nM, reduces the 
amplitude of outward currents elicited by a ramp voltage protocol (Figure 36 A and B). Similar effect to that 
produced by 37 was recorded in the presence of BAY 60-6583 which was applied at concentrations of 1 and 
10 µM. Thus, applying A2B AR antagonist PSB-603 the effect of both agonists was reverted, confirming the 
involvement of A2B AR (Figure 37 A and B). 
 
 
Figure 36: (A) Outward currents elicited by 37 in a ramp voltage protocol; (B) net outward K+ current sensitive to 37 
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Figure 37: (A) outward currents elicited by 37 in the presence of PSB-603 1µM in a ramp voltage protocol; (B) net outward K+ current sensitive to 
37 in the presence of PSB-603 1µM 
 
Thus, in this assay was demonstrated that A2B AR is involved in OPC maturation. In particular, activation of 
A2B AR inhibits OPC differentiation in oligodendrocytes by blocking outward K+ currents, essential for the 
differentiation process. Furthermore, compound 37 exert its effect at lower concentrations than BAY60-
6583, the reference agonist reported in literature. Finally, two other compounds acting as full agonist, 66 and 
67, will be tested in this in vitro model, despite their scarce selectivity at A2B AR, since in this assay the other 
AR subtypes will be silenced.  
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8. Conclusions and perspectives 
 
The research reported in this Ph.D. thesis, though it has to be deepened, furthers our understanding about 
the ARs. New AR ligands were developed preferentially belonging to the aminopyridine-3,5-dicarbonitrile 
series whose structure-activity relationships have been till now poorly investigated. In fact, most of the 
compounds reported in the literature are included in patent documents. In this work, many derivatives were 
synthesized and biologically evaluated in binding and functional assays in order to assess affinity and 
selectivity towards a specific AR subtype, but also to evaluate their pharmacological profile. The data 
obtained confirmed the peculiarity of this series whose derivatives are not only characterized by a wide range 
of affinities but interestingly endowed with different degree of efficacies at the different ARs.  
Based also on molecular modelling studies two set of compounds, named DCP1 and DCP2B were designed 
preferentially targeting the A1 and A2B AR, respectively.  
 Most of the compounds belonging to the DCP1 set (compounds 1-25, Tables 5, 7-8) are endowed 
with high affinity and good selectivity at the hA1 AR. Some selected derivatives showed also an 
inverse agonist profile with the only exception of compound 15 which emerged as partial agonist 
bearing a peculiar 2-phenylthiazole group at R6. Thus, further modification at the level of the thiazole 
moiety will be planned in order to evaluate the importance of this substituent for obtaining hA1 AR 
agonists.   
Moreover, when evaluated in an oxaliplatin-induced neuropathic pain model in mice, compound 1 
(dual A1 inverse agonist/A2A antagonist) resulted to revert allodynia at very low doses after oral 
administration (Table 15). This effect is similar to that exerted by both caffeine and other A1/A2A 
antagonists as well as A1 AR agonists in reverting hyperalgesia and in antinociception.  
Stability studies in mouse and human plasma on 1 (Figure 33, 34) confirmed no significant chemical 
modification of the compound for the whole duration of the assay. Thus, to clarify this paradoxical 
data, other molecules belonging to this set, endowed with similar degree of affinities and efficacies 
with respect to 1, will be tested in this in vivo assay, also to evaluate their potentiality for neuropathic 
pain treatment. 
The results obtained on the DCP1 set, especially in the in vivo assay, suggested that the amino-3,5-
dicyanopyridine scaffold could be of interest for obtaining non-nucleoside AR agonists as to prevent two 
serious problems hampering the development of classical adenosine-like agonists: the low oral bioavailability 
and the short half-life due to the presence of the typical ribose (or ribose-mimicking) moiety.   
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 DCP2B set is composed of compounds preferentially targeting the hA2B receptor (26-67, Tables 9-
12). Most of them showed to behave as partial agonist, with the best results concerning activity and 
selectivity of compound 37, which is three fold more potent than the reference agonist BAY60-6583. 
This result can be considered a real breakthrough since BAY60-6583 is absolutely the sole potent and 
selective hA2B AR agonist reported in literature.  
Moreover, it is noteworthy that derivatives 66 and 67, showing high activity at the hA2BAR but scarce 
selectivity, emerged as the only two amino-3,5-dicyanopyridines reported till now which are 
endowed with a full agonist profile. With this in mind, a study to clarify the structural requirements 
which are important in determining the A2B pharmacological profile of these compounds is currently 
on going. 
Thus, identification of new selective hA2B agonists could be of help in deepening the medicinal 
chemistry and the pharmacology related to this still unknown AR subtype. In fact, compound 37 was 
used as pharmacological tool in an oligodendrocyte precursor cell (OPC) differentiation assay in order 
to clarify whether the A2B receptor represents a promising target to modulate endogenous 
remyelinization process in multiple sclerosis patients. Compound 37 inhibits OPC differentiation into 
oligodendrocytes at lower concentration than those used for BAY60-6583 demonstrating the role of 
A2B AR in this important physiological process (Figure 36, 37).  
Moreover, docking studies were performed on selected DCP1 and DCP2B derivatives at A1 and A2B homology 
receptor models, respectively, showing the best binding poses for compounds 15 (Figure 27) and 37 (Figure 
30) and the most important residues involved in the binding at these two AR subtypes. It seems to clarify the 
role of R4 and R6 substituents, containing atoms or groups able to engage hydrogen-bonding interactions with 
the receptors, in modulating affinity and efficacy of the amino-3,5-diyanopyridine derivatives.  
Moreover, since some affinity was also achieved at the hA2A and hA3 AR with some of the compounds detailed 
in this thesis, it may be possible that this heterocycle core could be also manipulated to enhance affinity and 
selectivity for these subtypes. In fact, neither A2A nor A3 agonists belonging to the amino-3,5-dicyanopyridine 
series has been ever designed. 
 Preliminary studies on the newly synthesized 7-amino-2-phenylpyrazolo[1,5-c]pyrimidine-4-
carbonitrile system, derived from molecular complications of the amino-3,5-dicyanopyridine core, 
were reported. Biological results on a small set of compounds (70-73, Table 14), that bind with good 
affinity the hA1 AR, indicated that this scaffold suitably decorated could generate new AR ligands. No 
functional data are currently available, thus preventing any conclusion about the influence of this 
structural modification on the pharmacological profile of the new compounds. Introduction of 
suitable substituents on the bicyclic ring in order to modulate affinity and selectivity at the AR 
subtypes is on going.
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9. Experimental section 
 
The microwave-assisted syntheses were performed using an Initiator EXP Microwave Biotage instrument 
(frequency of irradiation: 2.45 GHz). Silica gel plates (Merck silica gel 60 F254, 250 μm) were used for 
analytical chromatography; while, preparative silica gel plates (Merck silica gel 60 F254, 2 mm) and silica gel 
60 (Merck, 70-230 mesh) were employed for preparative thin layer (TLC) and column chromatography. All 
melting points were determined on a Gallenkamp melting point apparatus. All final compounds revealed a 
purity not less than 95%. The IR spectra were recorded with a Perkin-Elmer Spectrum RX I spectrometer or 
Shimadzu IR-prestige 21 in Nujol mulls and are expressed in cm−1. The 1H NMR spectra were obtained with a 
Bruker Avance 400 MHz instrument. The chemical shifts are reported in δ (ppm) and are relative to the 
central peak of the solvent. The following abbreviations are used: s = singlet, d = doublet, t = triplet, m = 
multiplet, br = broad, and Ar = aromatic protons. The following abbreviation are used for solvents and 
reactive products: ACN = Acetonitrile, DMF = Dimethylformamide, TEA = Triethylamine, NMP = N-Methyl-2-
pyrrolidone, EtOAc = Ethyl acetate, CHCl3 = Chloroform, DCM = Dichloromethane, Et2O = Diethyl ether,  EtOH 
= Ethanol, HCl = Hydrochloric acid, MeOH = Methanol, D2O = Deuterium oxide, AcOH = Acetic acid, Py = 
Pyridine, DIPEA = NN-Diisopropylethylamine, DMSO = Dimethyl sulfoxide, CDCl3 = Deuterated chloroform, 
THF = Tetrahydrofuran, rt = room temperature, eq = equatorial protons, ax = axial protons, exc D2O = protons 
exchanging with deuterium oxide. 
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General procedure for the synthesis of 74-77, 88-94, 112-117 and 140 
 
 
 
Procedures 
Method A: To a stirred solution of the suitable aldehyde (10.00 mmol), 1,8-diazabicycloundec-7-ene (5% mol) 
and malononitrile (20.00 mmol) in 10% EtOHaq (20ml), thiophenol (10.00 mmol) was added after 20 min. 
Thus, the reaction mixture was stirred at 55°C for 3 to 18 h. The suspension was then cooled at rt and a solid 
precipitated which was collected by filtration, washed with Et2O (5-10 ml) and then dried in oven at 60°C 
overnight. 
Method B: To a solution in water (50 ml) of the suitable aldehyde (10.00 mmol) and malononitrile (20.00 
mmol), tetrabutylammonium fluoride (10% mol) is added. After 20 minutes, thiophenol (10.00 mmol) is 
added and the mixture is allowed to stir at 80°C for 2 hours. After completing of the reaction the mixture is 
allowed to cool at rt and the water is removed. The residue obtained is dissolved in AcOEt and dried over 
anhydrous sodium sulfate. The solution is then filtered, the solvent removed under vacuum and the residue 
obtained is triturated with a mixture Et2O : EtOH (10:1) and filtered in order to obtain the pure product. 
Method C: A suspension of Al2O3 (10% p/v) in water (2 ml) was added to a solution of the suitable aldehyde 
(10.00 mmol) and malononitrile (20.00 mmol) in water (18 ml), and the mixture was allowed to stir at rt for 
10 min. After addition of thiophenol (10.00 mmol) the suspension was heated at reflux for 6 h and then 
cooled at rt. The water was removed under reduced pressure and the residue was triturated with a mixture 
of Et2O/EtOH (5:1). The solid obtained was filtered and extracted with hot EtOAc (4 x 100 ml). The dried 
organic phases (Na2SO4) were evaporated in order to obtain the pure compound. 
Compound R Compound R 
74 2-furyl 93 4-CH3-(C6H4) 
75 3-furyl 94 4-SCH3-(C6H4) 
76 2-thienyl 112 4-(OCH2C3H5)-(C6H4) 
77 3-pyridyl 113 4-(OCH2C4H7)-(C6H4) 
88 3-thienyl 114 4-(OCH2CH(CH3)2)-(C6H4) 
89 4-pyridyl 115 4-(OCH2CH3)-(C6H4) 
90 CH2C6H5 116 4-(OCH2CH=CH2)-(C6H4) 
91 4-Cl-(C6H4) 117 4-(OCH2C(CH3)=CH2)- (C6H4) 
92 4-F-(C6H4) 140 4-OH-(C6H4) 
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Examples: 
2-Amino-4-(furan-2-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (74) 
Method B; Yield: 18%; mp: 191-193°C (lit. 178-180°C) (MeOH); 1H NMR (400 MHz, 
DMSO-d6): 8.13 (s, 1H, Fur), 7.79 (br s, 2H, NH2, exc. D2O), 7.60 (d, 2H, Ar), 7.50 
(m, 3H, Ar+Fur), 7.43 (t, 1H, Ar), 6.86 (s, 1H, Fur). IR (cm-1): 3303, 3212, 2215. 
 
2-Amino-4-(furan-3-yl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (75) 
Method B; Yield: 22%; mp: 204-206°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 
8.22-8.29 (m, 1H, Fur), 7.93-7.94 (m, 1H, Fur ), 7.81 (br s, 2H, NH2, exc D2O), 
7.59- 7.60 (m, 2H, Ar), 7.50-7.51 (m, 3H, Ar), 6.90-6.91 (m, 1H, Fur). IR (cm-1): 
3328, 3218, 2220. 
 
2-Amino-6-(phenylthio)-4-(thiophen-2-yl)pyridine-3,5-dicarbonitrile (76) 
Method B; Yield: 32%; mp: 216-217°C (lit. 208-210°C) (MeOH); 1H NMR (400 MHz, 
DMSO-d6): 7.97 (d, 1H, Th, J = 4 Hz), 7.86 (br s, 2H, NH2, exc D2O), 7.58- 7.61 (m, 
3H, Ar + Th), 7.50-7.51 (m, 3H, Ar), 7.30 (dd, 1H, Th, J1= 3.7 Hz, J2 = 4.8 Hz); IR 
(cm-1): 3352, 3216, 2210. 
 
2'-Amino-6'-(phenylthio)-[3,4'-bipyridine]-3',5'-dicarbonitrile (77) 
Method C; Yield: 31%; mp: >300°C (EtOH/DMF); 1H NMR (400 MHz, DMSO-d6): 
8.77 (m, 1H, Py), 8.05 (d, 1H Py, J= 8.08 Hz), 7.85 (br s, 2H, NH2, exc D2O), 7.60- 
7.65 (m, 4H, Ar +1H Py), 7.50-7.52 (m, 3H, 2H Ar + 1H Py), IR (cm-1): 3374, 3307, 
2212, 2221. 
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2-Amino-6-(phenylthio)-4-(thiophen-3-yl)pyridine-3,5-dicarbonitrile (88) 
Method B; Yield: 14%; mp: 236-238°C (lit. 235-236°C) (MeOH); 1H NMR (400 
MHz, DMSO-d6): 8.06-8.07 (m, 1H, Th), 7.78-7.80 (m, 3H, NH2 + Th, 2H exc D2O), 
7.59- 7.61 (m, 2H, Ar), 7.49-7.51 (m, 3H, Ar), 7.40 (d, 1H, Th, J= 4.9 Hz), IR (cm-
1): 3333, 3217, 2210. 
 
2-Amino-6-(phenylthio)-[4,4'-bipyridine]-3,5-dicarbonitrile (89) 
Method C; Yield: 32%; mp: 204-206°C (lit. 208-209°C) (EtOH); 1H NMR (400 
MHz, DMSO-d6): 8.26 (m, 1H, Fur), 7.93 (m, 1H, Fur), 7.81 (br s, 2H, NH2, exc 
D2O), 7.60 (m, 2H, Ar), 6.91 (m, 1H, Fur), 7.51 (m, 3H, Ar); IR (cm-1): 3328, 3218, 
2220. 
 
2-Amino-4-benzyl-6-(phenylthio)pyridine-3,5-dicarbonitrile (90) 
Method C; Yield: 35%; mp: 247-249°C (MeOH); 1H NMR (400 MHz, DMSO-
d6): 7.81 (br s, 2H, NH2 exc D2O), 7.58 (m, 2H, Ar), 7.5 (m, 3H, Ar), 7.37 (m, 
2H, Ar), 7.28 (m, 3H, Ar), 4.12 (s, 2H, CH2); IR (cm-1): 3329, 3225, 2198. 
 
 
2-Amino-4-(4-chlorophenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (91) (354) 
Method C; Yield: 37%; mp: 236-237°C (EtOH); 1H NMR (400 MHz, DMSO-
d6): 7.75 (br s, 2H, NH2, exc D2O), 7.49-7.65 (m, 6H, Ar), 7.40-7.44 (m, 3H, 
Ar) 
 
 
2-Amino-4-(4-fluorophenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (92) (355) 
Method C; Yield: 36%; mp: 220-222°C (lit. 221-223°C); 1H NMR (400 MHz, 
DMSO-d6): 7.85 (s, 2H, NH2, exc D2O), 7.63 (m, 4H, Ar), 7.54 – 7.48 (m, 3H, 
Ar), 7.44 (t, J = 8.8 Hz, 2H, Ar) 
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2-Amino-6-(phenylthio)-4-(p-tolyl)pyridine-3,5-dicarbonitrile (93) (355) 
Method C; Yield: 32%; mp: 220-221°C (lit. 208-211°C); 1H NMR (400 MHz, 
DMSO-d6): 7.87 (br s, 2H, NH2, exc D2O), 7.55-7.65 (m, 3H, Ar), 7.37-7.48 
(m, 6H, Ar), 2.41 (s, 3H, CH3) 
 
 
2-Amino-4-(4-(methylthio)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (94) (354) 
Method C; Yield: 28%; mp: 244-246°C (lit.254-256°C); 1H NMR (400 
MHz, DMSO-d6): 7.81 (br s, 2H, NH2, exc D2O), 7.64 – 7.57 (m, 2H, Ar), 
7.50 (m, 5H, Ar), 7.43 (m, 2H, Ar), 2.56 (s, 2H) 
 
 
2-Amino-4-(4-(cyclopropylmethoxy)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (112) 
Method A and C; Yield: 33%; mp: 261-263°C (EtOH); 1H NMR (400 MHz, 
DMSO-d6):  7.70 (br s, 2H, NH2 exc D2O), 7.60-7.62 (m, 2H, Ar), 7.48-7.51 
(m, 5H, Ar), 7.10 (d, 2H, Ar, J = 8.1 Hz), 3.92 (d, 2H, CH2, J = 7.8 Hz), 1.25-
1.28 (m, 1H, CH), 0.58-0.62 (m, 2H, 2CH eq), 0.36-0.38 (m, 2H, 2CH ax); 
IR (cm-1): 3330, 3220, 2224 
 
2-Amino-4-(4-(cyclobutylmethoxy)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (113) 
Method A; Yield: 18%; mp: 180-182°C (MeOH); 1H NMR (400 MHz, 
DMSO-d6): 7.76 (br s, 2H, NH2 exc D2O), 7.61-7.60 (m, 2H, Ar), 7.51-
7.49 (m, 3H, Ar), 7.12 (d, 2H, Ar, J = 8.60 Hz), 4.05 (d, 2H, OCH2, J = 6.5 
Hz), 2.77-2.75 (m, 1H, CH), 2.11-2.09 (m, 2H, CH2), 1.93-1.89 (m, 4H, 
2CH2); IR (cm-1): 3348, 3280, 2216 
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2-Amino-4-(4-isobutoxyphenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (114) 
Method A; Yield: 26%; mp: 180-182°C (MeOH); 1H NMR (400 MHz, 
DMSO-d6): 7.74 (s, 2H, NH2, exc D2O), 7.61-7.59 (m, 2H, Ar), 7.50-7.49 
(m, 5H, Ar), 7.11 (d, 2H, Ar, J= 8.76 Hz), 3.84 (d, 2H, OCH2, J= 6.4 Hz), 
2.09-2.02 (m, 1H, CH), 1.02 (s, 3H, CH3,), 1.00 (s, 3H, CH3,); IR (cm-1): 
3302, 3232, 2214 
 
 
2-Amino-4-(4-ethoxyphenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (115) 
Method A; Yield: 37%; mp: 252-254°C (2-propanol); 1H NMR (400 MHz, 
DMSO-d6): 7.6 (s, 2H, NH2, exc D2O), 7.62-7.60 (m, 2H, Ar), 7.58-7.48 (m, 
5H, Ar), 7.11 (d, 2H, Ar, J= 8.8 Hz), 4.13 (q, 2H, OCH2, J= 6.8 Hz), 1.37 (t, 
3H, CH3, J= 7.2 Hz); IR (cm-1): 3344, 3215, 2216 
 
 
4-(4-(Allyloxy)phenyl)-2-amino-6-(phenylthio)pyridine-3,5-dicarbonitrile (116) 
Method A; Yield: 28%; mp: 234-236°C (EtOAc/CHx); 1H NMR (400 MHz, 
DMSO-d6): 7.77 (s, 2H, NH2, exc D2O), 7.61-7.60 (m, 2H, Ar), 7,59-7.58 (m, 
3H, Ar), 7.51 (d, 2H, Ar, J= 8.8 Hz), 7.14 (d, 2H, Ar, J= 8.8), 6.13-6.03 (m, 
1H, CH), 5.45 (d, 1H, CHallyl), 5.30 (d, 1H, CHallyl), 4.67 (d, 2H, OCH2, J= 5.6 
Hz); IR (cm-1): 3358, 3215, 2214, 1624 
 
2-Amino-4-(4-((2-methylallyl)oxy)phenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (117) 
Method A; Yield: 25%; mp: 198-200°C (EtOH); 1H NMR (400 MHz, 
DMSO-d6): 7.76 (s, 2H, NH2, exc D2O), 7.60-7.61 (m, 2H, Ar), 7.60-7.59 
(m, 3H, Ar), 7.55 (d, 2H, Ar, J= 8.4 Hz), 7.14 (d, 2H, Ar, J= 8.4 Hz), 5.11 
(d, 1H, CH), 5.00 (d, 1H, CH), 4.58 (s, 2H, CH2), 1.81 (s, 3H, CH3); IR (cm-
1): 3481, 3369, 2212 
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2-Amino-4-(4-hydroxyphenyl)-6-(phenylthio)pyridine-3,5-dicarbonitrile (140) (297) 
Method A; Yield: 29%; mp: > 300°C (MeOH); 1H NMR (400 MHz, DMSO-
d6): 10.08 (br s, 1H, OH, exc D2O), 7.72 (br s, 2H, NH2, exc D2O), 7.60-7.41 
(m, 5H, Ar), 7.40 (d, 2H, Ar, J= 8.4 Hz), 6.92 (d, 2H, Ar, J= 8.4 Hz); IR (cm-1): 
3491, 3368, 2216  
 
Synthesis of N-(4-(2,2-dicyanovinyl)phenyl)acetamide (138) (356) 
 
Malononitrile (17.3 mmol) and piperidine (2 gtt) were added to a solution of 4-acetamidobenzaldehyde (17.3 
mmol) in EtOH (20 ml). The mixture was heated at 80°C for 2h until reaction completion, then cooled to rt 
affording an orange solid which was filtered and washed with Et2O (5 ml) and petroleum ether (2 ml). Yield: 
63%; mp: 234-236°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 10.51 (s, 1H, NH, exc D2O), 8.37 (s, 1H, CH), 7.94 
(d, 2H, Ar, J= 8.4 Hz), 7.80 (d, 2H, Ar, J= 8.8 Hz), 2.11 (s, 3H, CH3); IR (cm-1): 2224; 1693 
 
Synthesis of N-(4-(2-amino-3,5-dicyano-6-(phenylthio)pyridin-4-yl)phenyl)acetamide (137) (356) 
 
 
A solution of compound 138 (5.4 mmol), malononitrile (5.4 mmol), thiophenol (5.4 mmol) and TEA (0.54 
mmol) in EtOH (30 ml) was heated at 100°C for 2h. Then, cooling at rt afforded a yellow solid which was 
filtered and washed with Et2O (5 ml). Yield: 44%; mp: >300°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 10.24 (s, 
1H, NH, exc D2O), 7.76 (s, 2H, NH2, exc D2O), 7.74 (m, 2H, Ar), 7.61-7.60 (m, 5H, Ar,), 7.50 (d, 2H, Ar, J= 8 Hz), 
2.10 (s, 3H, CH3); IR (cm-1): 3481; 3344; 3298; 2212; 1681 
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General procedure for the synthesis of 78-81, 95-101, 118-123, 139 and 141 
 
 
 
 
Procedure: 
To a stirred solution of compounds 74-77, 88-94, 112-117, 137 and 140 (10 mmol) in dry DMF (1 ml) 
maintained at rt and under nitrogen atmosphere, an excess of sodium sulfite (33 mmol) was added. The 
reaction mixture was then heated at 80°C for 2 h. When the reaction was completed, 1N HCl (25 ml) was 
added followed by addition of 6N HCl to obtain a huge precipitate which is filtered and washed with water 
(20 ml) and Et2O (5 ml). 
 
Examples 
2-Amino-4-(furan-2-yl)-6-mercaptopyridine-3,5-dicarbonitrile (78) (357) 
Yield: 96%; mp: 260-261°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.94 (br s, 1H, SH, 
exc D2O), 8.12 (d, 1H, Fur, J= 1.4 Hz), 7.85 (br s, 2H, NH2, exc D2O), 7.43 (d, 1H, J= 3.6 
Hz, Fur), 6.84 (dd, J = 3.6, 1.7 Hz, 1H, Fur); IR (cm-1): 3306, 3196, 2214. 
 
Compound R Compound R 
78 2-furyl 101 4-SCH3-(C6H4) 
79 3-furyl 118 4-(OCH2C3H5)-(C6H4) 
80 2-thienyl 119 4-(OCH2C4H7)-(C6H4) 
81 3-pyridyl 120 4-(OCH2CH(CH3)2)-(C6H4) 
95 3-thienyl 121 4-(OCH2CH3)-(C6H4) 
96 4-pyridyl 122 4-(OCH2CH=CH2)-(C6H4) 
97 CH2C6H5 123 4-(OCH2C(CH3)=CH2)- (C6H4) 
98 4-Cl-(C6H4) 139 4-NHCOCH3 
99 4-F-(C6H4) 141 4-OH-(C6H4) 
100 4-CH3-(C6H4)  
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2-Amino-4-(furan-3-yl)-6-mercaptopyridine-3,5-dicarbonitrile (79) 
Yield: 92%; mp: 260-262°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.97 (br s, 1H, SH, 
exc D2O), 8.25-8.27 (m, 1H, Fur), 8.00 (br s, 2H, NH2, exc D2O), 7.90 (t, J= 1.6 Hz, 1H, 
Fur), 6.84- 6.85 (m, 1H, Fur); IR (cm-1): 3307, 3192, 2216. 
 
 
2-Amino-6-mercapto-4-(thiophen-2-yl)pyridine-3,5-dicarbonitrile (80) (358) 
Yield: 90%; mp: 270-272°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 13.01 (br s, 1H, SH, 
exc D2O), 7.80 (br s, 2H, NH2, exc D2O), 7.95 (d, J= 5 Hz, 1H, CH thiophene), 7.55 (d, J= 
3.6 Hz, 1H, CH thiophene), 7.26 (t, J= 4.2 Hz, 1H, CH thiophene); IR (cm-1): 3317, 3206,  
2216. 
 
2'-Amino-6'-mercapto-[3,4'-bipyridine]-3',5'-dicarbonitrile (81) (359) 
Yield: 86%; mp: >300°C (EtOH/DMF); 1H NMR (400 MHz, DMSO-d6): 13.20 (br s, 1H, 
SH, exc D2O), 8.76-8.79 (m, 2H, Py), 8.27 (br s, 2H, NH2, exc D2O), 8.06 (d, J= 7.84 Hz, 
1H, Py), 7.66 (t, J = 6.60 Hz, 1H, Py); IR (cm-1): 3319, 3124,  2212. 
 
 
2-Amino-6-mercapto-4-(thiophen-3-yl)pyridine-3,5-dicarbonitrile (95) 
Yield: 89%; mp: 237-239°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.98 (br s, 1H, SH, 
exc D2O), 8.03-8.04 (m, 1H, CH thiophene), 7.85 (br s, 2H, NH2, exc D2O), 7.74-7.76 (m, 
1H, CH thiophene), 7.34-7.36 (m, 1H, CH thiophene); IR (cm-1): 3315, 3204, 2208. 
 
 
2-Amino-6-mercapto-[4,4'-bipyridine]-3,5-dicarbonitrile (96) 
Yield: 89%; mp: >300°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 13.2 (br s, 1H, SH, exc 
D2O), 8.8 (d, J = 1,2 Hz, 2H, Py), 7.56 (d, J = 1,2 Hz, 2H, Py); IR (cm-1): 3310, 3193, 2225. 
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2-Amino-4-benzyl-6-mercaptopyridine-3,5-dicarbonitrile (97) 
Yield: 80%; mp: 231-233°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.96 (br s, 1H, SH 
exc D2O), 7.82 (br s, 2H, NH2 exc D2O), 7.36 (m, 2H, Ar), 7.28 (m, 3H, Ar), 4.02 (s, 2H, 
CH2); IR (cm-1): 3319, 3280, 2229. 
 
 
2-Amino-4-(4-chlorophenyl)-6-mercaptopyridine-3,5-dicarbonitrile (98) (354) 
Yield: 80%; mp: 202-204°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 13.12 (br s, 1H, 
SH, exc D2O), 8.01 (br s, 2H, NH2, exc D2O), 7.65 (d, J = 8 Hz, 2H, Ar), 7.58 (d, J = 8 
Hz, 2H, Ar), IR (cm-1): 3320, 3192, 2220. 
 
 
2-Amino-4-(4-fluorophenyl)-6-mercaptopyridine-3,5-dicarbonitrile (99) (355) 
Yield: 86%; mp: 234-236°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 13.03 (br s, 1H, 
SH, exc D2O), 8.01 (br s, 2H, NH2, exc D2O), 7.6 (m, 2H, Ar), 7.38 (m, 2H, Ar); IR (cm-
1): 3319, 3182, 2224 
 
 
2-Amino-6-mercapto-4-(p-tolyl)pyridine-3,5-dicarbonitrile (100) (355) 
Yield: 83%; mp: 228-230°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 13.03 (br s, 1H, 
SH, exc D2O), 7.97 (br s, 2H, NH2, exc D2O), 7.39 (q, 4H, Ar, J = 8.2 Hz), 2.40 (s, 3H, 
CH3); IR (cm-1): 3322, 3190, 2215 
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2-Amino-6-mercapto-4-(4-(methylthio)phenyl)pyridine-3,5-dicarbonitrile (101) (354) 
Yield: 82%; mp: 188-190°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 13.1 (br s, 1H, 
SH, exc D2O), 7.45 (d, 2H, Ar, J = 8 Hz), 7.4 (d, 2H, Ar J = 8 Hz), 2.51 (s, 3H, CH3); 
IR (cm-1): 3311, 3195, 2222 
 
 
2-Amino-4-(4-(cyclopropylmethoxy)phenyl)-6-mercaptopyridine-3,5-dicarbonitrile (118) (293) 
Yield: 80%; mp: 168-170°C (EtOAc); 1H NMR (400 MHz, DMSO-d6): 12.9 (br s, 
1H, SH, exc D2O), 7.8 (br s, 2H, NH2, exc D2O), 7.45 (d, 2H, Ar, J = 8 Hz), 7.08 (d, 
2H, Ar, J = 8 Hz), 3.91 (d, 2H, CH2, J = 7.8 Hz), 1.23-1.27 (m, 1H, CH), 0.57-0.62 
(m, 2H, 2CH eq), 0.33-0.37 (m, 2H, 2CH ax); IR (cm-1): 3309, 3190, 2219  
 
 
2-Amino-4-(4-(cyclobutylmethoxy)phenyl)-6-mercaptopyridine-3,5-dicarbonitrile (119) 
Yield: 84%; mp: 256-259°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.95 (s, 
1H, SH, exc D2O), 7.08 (s, 2H, NH2, exc D2O), 7.46 (d, 2H, Ar, J= 8 Hz), 7.09 (d, 
2H, Ar, J= 8.4 Hz), 4.04 (d, 2H, OCH2, J= 6 Hz), 2.87-2.73 (m, 1H, CH), 2.10-1.92 
(m, 2H, CH2), 1.9-1.89 (m, 4H, 2CH2); IR (cm-1): 3474, 3335, 2214 
 
 
2-Amino-4-(4-isobutoxyphenyl)-6-mercaptopyridine-3,5-dicarbonitrile (120) 
Yield: 86%; 1H NMR (400 MHz, DMSO-d6): 13.02 (s, 1H, SH, exc D2O), 7.77 (s, 
2H, NH2, exc D2O), 7.45 (d, 2H, Ar, J= 8.8 Hz), 7.09 (d, 2H, Ar, J= 8.4 Hz), 3.83 
(d, 2H, CH2, J= 6.4 Hz), 2.06-2.03 (m, 1H, CH), 1.02 (s, 3H, CH3,), 0.99 (s, 3H, 
CH3,) 
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2-Amino-4-(4-ethoxyphenyl)-6-mercaptopyridine-3,5-dicarbonitrile (121) 
Yield: 76%; mp: 290-292°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.99 (s, 1H, 
SH, exc D2O), 8.11 (s, 2H, NH2, exc D2O), 7.54 (d, 2H, Ar, J= 8.8 Hz), 7.14 (d, 2H, Ar, 
J= 8.8 Hz), 4.14 (q, 2H, CH2, J= 6.8 Hz), 1.38 (t, 3H, CH3, J= 6.8 Hz); IR (cm-1): 3336, 
3117, 2212 
 
 
4-(4-(Allyloxy)phenyl)-2-amino-6-mercaptopyridine-3,5-dicarbonitrile (122) 
Yield: 84%; mp: 208-211°C (EtOAc); 1H NMR (400 MHz, DMSO-d6): 12.98 (s, 1H, 
SH, exc D2O); 7.90 (s, 2H, NH2, exc D2O); 7.47 (d, 2H, Ar, J= 8.6 Hz); 7.12 (d, J= 8.6 
Hz, 2H, Ar); 6.11-6.04 (m, 1H, CH allyl); 5.47-5.43 (dd, Jgem= 1.2 Hz, Jtrans= 17.2 Hz, 
1H, CH), 5.30 (d, J= 10.4 Hz, 1H, CH), 4.66 (d, J= 5.6 Hz, 2H, OCH2); IR (cm-1): 3476, 
3319, 3209, 2212 
 
 
2-Amino-6-mercapto-4-(4-((2-methylallyl)oxy)phenyl)pyridine-3,5-dicarbonitrile (123) 
Yield: 72%; (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.98 (s, 1H, SH, exc D2O), 
8.12-8.10 (s, l, 2H, NH2, exc D2O), 7.53 (d, 2H, Ar, J= 7.4 Hz), 7.08 (d, 2H, Ar, J= 
8.8), 5.09 (s, 1H, CH), 4.90 (s, 1H, CH), 4.58 (s, 2H, OCH2), 1.80 (s, 3H, CH3) 
 
 
 
N-(4-(2-amino-3,5-dicyano-6-mercaptopyridin-4-yl)phenyl)acetamide (139) (356) 
Yield: 40%; mp: 275-277°C (d)(EtOH/EtOAc); 1H NMR (400 MHz, DMSO-d6): 
12.94 (s, 1H, SH, exc D2O), 10.37 (s, 1H, NH, exc D2O), 8.19 (s, 2H, NH2, exc 
D2O), 7.73 (d, 2H, Ar, J= 8.0 Hz), 7.44 (d, 2H, Ar, J= 8.0 Hz), 2.08 (s, 3H, CH3); 
IR (cm-1): 3317, 3215, 2214, 1539 
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2-Amino-4-(4-hydroxyphenyl)-6-mercaptopyridine-3,5-dicarbonitrile (141) (297): 
Yield: 69%; mp: >300°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 12.94 (br s, 1H, 
SH, exc D2O), 10.09 (br s, 1H, OH, exc D2O), 7-96-7.89 (br s, NH2, exc D2O), 7.38 (d, 
2H, Ar, J= 8.8 Hz), 6.90 (d, 2H, Ar, J= 8.4) 
 
 
General procedure for the synthesis of p-alkyloxybenzaldehydes (106-111) 
 
Procedures: 
Method A: To a solution of 4-hydroxybenzaldehyde (12.3 mmol) in dried acetone (20 ml), potassium 
carbonate (18.5 mmol) was added, followed by the suitable alkyl halide (18.5 mmol). The mixture was heated 
at reflux until starting material disappears (6-48h) monitored by TLC. Then, the mixture was cooled to rt and 
the insoluble material was filtered and washed with acetone (3 x 20 ml). The resulting filtrates were collected 
and evaporated under vacuum, affording the desired compounds as viscous oils. 
Method B: To a mixture of 4-hydroxybenzaldehyde (8.2 mmol), cyclopropyl methanol (9.02 mmol) and 
triphenylphosphine (10.66 mmol) in THF dry maintained at 0°C, diethyl azodicarboxylate (DEAD, 10.66 mmol) 
was carefully added within 10/15 min, keeping temperature under 0°C. The mixture was kept at 0°C for 
further 10 min, then warmed to rt and stirred for 24h. The reaction mixture was then evaporated carefully 
until affording a raw semisolid which was purified by silica gel flash chromatography using DCM 9 : MeOH 1 
as eluent affording compounds as a viscous oil. 
Method C: Potassium carbonate (18.5 mmol), the suitable alkyl halide (18.5 mmol) and potassium iodide 
(0.123 mmol) were sequentially added to a solution of 4-hydroxybenzaldehyde (12.3 mmol) in DMF dry (15 
ml). The mixture was refluxed until reaction completion (TLC monitoring). The mixture was then cooled to rt 
and water (50 ml) was added. The resulting suspension was extracted with AcOEt (4 x 30 ml) and the organic 
phases were collected, dried (Na2SO4), and the solvent removed under vacuum, affording compounds as a 
viscous oil. 
 
 
Experimental section 
121 
  
Examples 
4-(Cyclopropylmethoxy)benzaldehyde (106) (360) 
Method A and B; Yield: 77%; 1H NMR (400 MHz, DMSO-d6): 9.86 (s, 1H, CHO), 7.85 (d, 
2H, Ar, J=8.1 Hz), 7.10 (d, 2H, Ar, J=7.7 Hz), 3.93 (d, 2H, CH2, J=7.8 Hz), 1.22-1.28 (m, 
1H, CH), 0.56-0.61 (m, 2H, 2CH eq), 0.33-0.36 (m, 2H, CH ax) 
 
4-(Cyclobutylmethoxy)benzaldehyde (107) (361) 
Method A; Yield: 67%; 1H NMR (400 MHz, DMSO-d6): 9.86 (s, 1H, CHO), 7.85 (d, 2H, 
Ar, J= 8.8 Hz), 7.11 (d, 2H, Ar, J= 8.4 Hz), 4.06 (d, 2H, OCH2, J= 6.8 Hz), 2.77-2.71 (m, 
1H, CH), 2.08-2.07 (m, 2H, CH2), 1.90-1.82 (m, 4H, 2CH2) 
 
4-Isobutoxybenzaldehyde (108) (362) 
Method C; Yield: 66%; 1H NMR (400 MHz, DMSO-d6): 9.86 (s, 1H, CHO), 7.85 (d, 2H, 
Ar, J= 8.8 Hz), 7.10 (d, 2H, Ar, J=8.8 Hz), 3.84 (d, 2H, OCH2, J= 6.4 Hz), 2.06-1.98 (m, 1H, 
CH), 1.00 (s, 3H, CH3,), 0.96 (s, 3H, CH3,) 
 
4-Ethoxybenzaldehyde (109) (363) 
Method A; Yield: 83%; 1H NMR (400 MHz, DMSO-d6):  9.86 (s, 1H, CHO), 7.85 (d, 2H, Ar, 
J= 8.4 Hz), 7.10 (d, 2H, Ar, J=8.8 Hz), 4.13 (q, 2H, OCH2, J= 6.8 Hz), 1.35 (t, 3H, CH3, J= 7.2 
Hz) 
 
4-(Allyloxy)benzaldehyde (110) (364) 
Method A; Yield: 97%; 1H NMR (400 MHz, DMSO-d6): 9.87 (s, 1H, CHO), 7.87 (d, 2H, 
Ar, J= 8.6 Hz), 7.15 (d, 2H, Ar, J= 8.7 Hz), 6.10-6.02 (m, 1H, CHallyl), 5.45-5.40 (dd, 1H, 
CH2, Jgem= 1.6 Hz, Jcis=18 Hz), 5.31-5.24 (dd, 1H, CH2, Jgem= 10.4 Hz, Jtrans= 22 Hz), 4.70 
(d, 2H, OCH2, J= 5.2 Hz) 
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4-((2-Methylallyl)oxy)benzaldehyde (111) (365) 
Method A; Yield: 85%; 1H NMR (400 MHz, DMSO-d6): 9.87 (s, 1H, CHO), 7.86 (d, 2H, 
Ar, J= 8.4 Hz), 7.13 (d, 2H, Ar, J= 8.4 Hz), 5.09 (d, 1H, CH, J= 0.8 Hz), 4.98 (d, 1H, CH, 
J= 1.2 Hz), 4.57 (s, 2H, CH2), 1.77 (s, 3H, CH3) 
 
Synthesis of 2-(1-ethoxyethylidene)malononitrile (103) (366) 
 
A suspension of malononitrile (0.45 mmol) and triethylorthoacetate (0.5 mmol) was refluxed for 2 h. At 
reaction completion, the liquid phase was removed by distillation at reduced pressure, affording a solid which 
was recovered with Et2O (5 ml), filtered and recrystallized from EtOH. Yield: 82%; mp: 145-147°C (EtOH); 1H 
NMR (400 MHz, DMSO-d6): 4.41 (q, 2H, CH2, J = 4 Hz), 2.42 (s, 3H, CH3), 1.31 (t, 3H, CH3, J = 4 Hz); IR (cm-1): 
2245, 2238. 
 
Synthesis of 2-amino-6-mercapto-4-methylpyridine-3,5-dicarbonitrile (104) (367) 
 
Thiocyanoacetamide (22.3 mmol) was portiowise added to a solution of compound 102 (23.00 mmol) and 
NaOCH3 (24.79 mmol) in MeOH (25 ml). The reaction mixture was refluxed for 4 h, then, the solvent was 
removed under vacuum and the resulting yellow solid was recovered with Et2O and filtered. Yield: 62%; mp: 
226-228°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.94 (br s, 1H, SH, exc D2O), 7.10 (br s, 2H, NH2, exc D2O), 
2.30 (s, 3H, CH3); IR (cm-1): 3338, 3253, 2248. 
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Synthesis of (1H-imidazol-2-yl)methanol (105) (297) 
 
Imidazole-2-carboxyaldehyde (20.8 mmol) was added to a suspension of sodium borohydride (41.6 mmol) in 
absolute EtOH (30 ml) under nitrogen atmosphere which was then stirred at rt for 2h. After reaction 
completion, the excess of sodium borohydride was quenched with a 20% aqueous sodium hydroxide solution 
and the resulting suspension was filtered. The filtrate was extracted with EtOAc (5 x 15 ml) and the collected 
organic phases were dried (Na2SO4), and evaporated under reduced pressure to yield a white solid that was 
used for the next step without any further purification. Yield: 46%; 1H NMR (400 MHz, DMSO-d6): 11.89 (s, 
1H, NH, exc D2O), 6.90 (s, 2H, 2CH), (s, 1H, OH, exc D2O), 4.44 (s, 2H, CH2). 
 
Synthesis of 2-(bromomethyl)-1H-imidazole hydrobromide (102) (297) 
 
 
A solution of 104 (3.1 mmol) in 33% HBr in acetic acid (8 ml) was heated at 100°C for 4h. Then, the solvent 
was removed by distillation at reduced pressure and the red-brown residue was triturated with petroleum 
ether (10 ml), filtrate and quickly used for the next step without any further purification. Yield: 70%; 1H NMR 
(400 MHz, DMSO-d6): 14.00 (s, 1H, NH, exc D2O), 7.71 (s, 2H, 2CH), 4.84 (s, 2H, CH2). 
 
Synthesis of 1H-pyrazole-3-carboxylic acid (125) (308) 
 
Potassium permanganate (128.7 mmol) was added in small portions to a solution of 3-methyl-1H-pyrazole 
(58.5 mmol) in water (225 ml), and the mixture was heated at reflux for 4 h. After cooling to rt, the suspension 
was filtered and the filtrate was concentrated under vacuum to small volume. 6M HCl (80 ml) was added and 
the mixture was kept cool for 1h to afford a white solid which was collected by filtration and dried at 60°C. 
Yield: 62%; mp: 193-195°C (Et2O); 1H NMR (400 MHz, DMSO-d6): 13.01 (br s, 1H, COOH, exc D2O), 7.72 (s, 1H, 
CH), 6.68 (s, 1H, CH). 
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Synthesis of ethyl 1H-pyrazole-3-carboxylate (126) (368) 
 
Thionyl chloride (20.6 mmol) was added to a solution of compound 125 (18.7 mmol) in absolute EtOH (20 
ml). Then the mixture was refluxed until starting material disappeared (TLC monitoring). The excess of liquid 
reactant was removed under reduced pressure, and water (25 ml) was added affording a white solid which 
was collected by filtration and used for the next step without any further purification. Yield: 76%; 1H NMR 
(400 MHz, DMSO-d6): 13.48 (s, 1H, NH, exc D2O), 7.81 (s, 1H, CH), 6.76 (s, 1H, CH), 4.27 (q, J = 7.1 Hz, 2H, CH2), 
1.29 (t, J = 7.1 Hz, 3H, CH3). 
 
Synthesis of (1H-pyrazol-3-yl)methanol (127) (308) 
 
Lithium aluminum hydride (35.7 mmol) was portiowise added to a suspension of compound 126 (17.8 mmol) 
in anhydrous THF (40 ml), maintained in a ice bath keeping temperature under 5°C. The mixture was allowed 
to warm at rt, stirred for 2 h and then, while keeping in an ice bath, MeOH (1 ml) was carefully added, 
followed by a solution of aqueous MeOH (4:1). The resulting solid was filterd and the filtrate was extracted 
with EtOAc (3 x 25 ml). The collected organic phases were washed with brine (25 ml), dried (Na2SO4) and 
filtered. Evaporation of solvent afforded a yellow oil which was used without any further purification for the 
next step. Yield: 66%; 1H NMR (400 MHz, DMSO-d6): 12.58 (s, 1H, NH, exc D2O), 7.51 (s, 1H, CH), 6.15 (s, 1H, 
CH), 5.07 (s, 1H, OH, exc D2O), 4.44 (s, 7H, CH2). 
 
Synthesis of 3-(chloromethyl)-1H-pyrazole (124) (308) 
 
An excess of thionyl chloride (15.1 mmol) was added to a suspension of compound 127 (10.1 mmol) in 
anhydrous DCM (20 ml), and the mixture was refluxed for 3 h. Then, removal of liquid component under 
reduced pressure afforded a yellowish solid which is dried in desiccator at rt. Yield: 86%; 1H NMR (400 MHz, 
DMSO-d6): 7.66 (s, 1H, CH), 6.32 (s, 1H, CH), 4.72 (s, 2H, CH2). 
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Synthesis of (1H-1,2,4-triazol-3-yl)methanol hydrochloride (129) (309) 
 
A solution of methyl 1H-1,2,4-triazole-3-carboxylate (7.87 mmol) in anhydrous THF (25 ml) was slowly added 
to a suspension of lithium aluminum hydride (19.76 mmol) in anhydrous THF (10 ml) and the mixture was 
refluxed for 12 h. At reaction completion MeOH (1 ml) was carefully added followed by 50 % aqueous MeOH 
(5 ml) affording a solid that was filtered and washed with MeOH (20 ml). The filtrate was then evaporated 
and the resulting residue was triturated with absolute EtOH (40 ml) and conc. HCl (1 ml). The mixture was 
concentrated under vacuum and the resulting semisolid was worked up with a mixture of MeOH and Et2O 
(1:1, 10 ml), filtered and dried in desiccator at rt. Yield: 72%; mp: 138-140°C; 1H NMR (400 MHz, DMSO-d6): 
13.85 (br s, 1H, NH, exc D2O), 8.90 (s, 1H, CH), 5.69 (t, 1H, OH, exc D2O), 4.70 (s, 2H, CH2). 
 
Synthesis of 3-(chloromethyl)-1H-1,2,4-triazole (128) (309) 
 
A solution of compound 129 (2.21 mmol) in thionyl chloride (10 ml) was refluxed for 6 h. Then, the excess of 
chlorinating agent was removed under vacuum affording a residue that was triturated with a mixture 
Et2O/EtOH (5:1, 10 ml), filtered and washed with petroleum ether (5 ml). Yield: 40%; mp: 102-104°C; 1H NMR 
(400 MHz, DMSO-d6): 14.03 (br s, NH, exc D2O), 8.54 (s, 1H, CH), 4.77 (s, 2H, CH2). 
 
Synthesis of 4-(chloromethyl)thiazol-2-amine (130) (310) 
 
To a solution of 1,3-dichloroacetone (26.8 mmol) in anhydrous acetone (100 ml), thiourea (26.27 mmol) was 
added in small portions. The mixture was allowed to stir at rt for 12 h. The resulting white solid was filtered, 
washed with acetone (30 ml) and Et2O (10 ml), suspended in EtOH (100 ml) and stirred for 3 h at rt. The solid 
was then removed by filtration and the filtrate was evaporated affording a white solid. Yield: 37%; mp: 117-
119°C (Acetone); 1H NMR (400 MHz, DMSO-d6): 9.13 (br s, 2H, NH2), 6.96 (s, 1H, CH), 4.67 (s, 2H, CH2). 
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Synthesis of 4-(chloromethyl)-2-phenylthiazole (131) (369) 
 
1,3-Dichloroacetone (18.22 mmol) was added to a solution of thiobenzamide (3.64 mmol) in dry acetone (45 
ml) and the mixture was refluxed for 8 h. After cooling at rt, the white crystalline precipitated was filtered 
and washed with fresh acetone (10 ml). The solid obtained was then dissolved in sulfuric acid (1.2 ml) and 
the resulting solution was stirred for 30 min at rt. Then 20 ml of iced-water was carefully added affording 
white crystals, that were quickly filtered and stored at 4°C. Yield: 65%; mp: 53-55°C; 1H NMR (400 MHz, 
CDCl3): 8.05 – 7.89 (m, 2H, Ar), 7.55 – 7.39 (m, 3H, Ar), 7.33 (s, 1H, CH), 4.77 (s, 2H, CH2). 
 
Synthesis of 3-(chloromethyl)benzamide (132) (311) 
 
Oxalyl chloride (14.90 mmol) and dry DMF (2 gtt) were added to a solution of 3-(chloromethyl)benzoic acid 
(6.00 mmol) in anhydrous DCM (30 ml). The reaction mixture was allowed to stir at rt overnight. The solvent 
was removed under vacuum and the oily residue was immediately dissolved in a saturated ammonia solution 
in dioxane (100 ml). The reaction mixture was stirred at rt overnight and the resulting white crystals were 
collected by filtration and washed with Et2O (2 ml). Yield: 60%; mp: 130-131°C (Et2O); 1H NMR (400 MHz, 
DMSO-d6): 8.0 (br s, 1H, NH, exc D2O), 7.95 (s, 1H, Ar), 7.83-7.85 (m, 1H, Ar), 7.58-7.60 (m, 1H, Ar), 7.45-749 
(m, 1H, Ar), 7.41 (br s, 1H, NH, exc D2O), 4.81 (s, 2H, CH2); IR (cm-1): 3350; 3182; 1651. 
 
Synthesis of benzyl 2-chloroacetate (133) (370) 
 
Benzylalcohol (46.24 mmol) and p-toluenesulfonic acid (0.63 mmol) were added to a solution of chloroacetic 
acid (55.35 mmol) in toluene (25 ml). After heating at 140°C for 2 h, the reaction mixture was cooled to rt   
and washed with a 5% sodium hydrogencarbonate (2 x 25 ml) and water (25 ml). The collected organic phases 
were dried (Na2SO4) and evaporated affording a yellowish oil that was used without any further purification 
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for the next step. Yield: 78%; 1H NMR (400 MHz, CDCl3): 7.59 – 7.30 (m, 5H, Ar), 5.25 (s, 2H, OCH2), 4.12 (s, 
2H, CH2Cl) 
 
Synthesis of 2-chloro-N-hydroxyacetamide (134) (371) 
 
50 % Aqueous solution of hydroxylamine (12.00 mmol) was added to ethyl chloroacetate (12.00 mmol) in a 
50 ml round bottomed flask and stirred for 5 minutes at rt. Then, the mixture was cooled at 4°C for 15 min, 
re-warmed to rt and stirred for 3 h. The precipitate was collected by filtration and used for the next step 
without any further purification. Yield: 53%; 1H NMR (400 MHz, DMSO): 7.41 (br s, 2H, OH + NH, exc D2O), 
3.94 (s, 2H, CH2). 
 
Synthesis of ethyl 2-chloroacetimidate hydrochloride (136) (372) 
 
Anhydrous HCl was bubbled for 1 h at 0°C in a solution of chloroacetonitrile (66.22 mmol) in absolute EtOH 
(5 ml) and Et2O anhydrous (30 ml), then the reaction mixture was allowed to stir at rt overnight under 
nitrogen atmosphere. Concentration of the solution under vacuum afforded white crystals that were 
collected by filtration and used for the following step without any further purification. Yield: 86%; 1H NMR 
(400 MHz, DMSO): 12.4 (br s, 1H, NH, exc D2O), 4.38 (s, 2H, CH2), 4.17 (q, 2H, J = 7.1 Hz, CH2), 1.22 (t, 3H, J = 
7.1 Hz, CH3). 
 
Synthesis of 2-(chloromethyl)-4,5-dihydro-1H-imidazole (135) (373) 
 
Ethyl 2-chloroacetimidate hydrochloride 136 (9.49 mmol) was added in small portions to a solution of 
ethylenediamine (14.24 mmol) in absolute EtOH (25 ml) maintained at 0°C. The mixture was stirred at 0°C 
for 1h, then a solution of anhydrous HCl (82.3 mmol) in absolute EtOH (25 ml) was carefully added in small 
portions, keeping temperature to 0°C. The mixture was stirred at 0°C for 1 h and then was warmed at rt and 
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stirred overnight. Concentration at small volume of the mixture afforded a white solid which was filtered and 
washed with EtOH (5 ml) and Et2O (5 ml). Yield: 82%; 1H NMR (400 MHz, DMSO): 10.90-10.59 (br s, 2H, NH2+, 
exc D2O), 4.67 (s, 2H, CH2), 3.89 (s, 4H, 2CH2).  
 
General procedure for the synthesis of final compounds A, 1-16, 26-35, 37-67 and 142  
 
 
Sodium hydrogencarbonate (2.00 mmol) and the suitable alomethyl-derivative (1.00 mmol) were added to a 
solution of the mercapto compound 78-81, 95-101, 104, 118-123, 139 and 141 (1.00 mmol) in DMF dry (1 
ml). The reaction mixture was stirred at rt until disappearance of the starting material (TLC monitoring). At 
reaction completion, water was added (25 ml) to precipitate a solid which was collected by filtration and 
triturated with Et2O (5 ml). The crude product was then recrystallized or purified by column chromatography 
or preparative TLC using DCM 9 : MeOH 1, EtOAc 5 : CHx 5 : MeOH 1, CHx 7 : EtOAc 3 or EtOAc 1 : CHx 1 as 
eluents. 
 
Examples 
2-Amino-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile (A) (298) 
yield: 63%; mp: 171-173°C (EtOAc/CHx); 1H NMR (400 MHz, DMSO-d6): 8.11-
8.12 (m, 1H, Fur), 7.99 (br s, 2H, NH2, exc D2O), 7.39 (d, 1H, Fur, J = 3.6 Hz), 6.83 
(dd, 1H, Fur, J1 = 1.72, J2 = 3.6 Hz), 4.99 (t, 1H, OH, exc D2O, J = 5.4 Hz), 3.65 (q, 
2H, CH2, J = 12 Hz), 3.33 (t, 2H, CH2 , J = 6.3 Hz); IR (cm-1): 3320, 3219, 2212. 
 
Methyl 3-(((6-amino-3,5-dicyano-4-(furan-2-yl)pyridin-2-yl)thio)methyl)benzoate (1) 
yield: 62%; mp: 208-210°C (MeOH/2-methoxyethanol); 1H NMR 
(400 MHz, DMSO-d6): 8.09-8.08 (m, 1H, Fur), 8.00 (sl, 2H, NH2, exc 
D2O), 7.83-7.85 (m, 3H, Ar), 7.47 (t, 1H, Ar, J = 7.72 Hz), 7.38 (d, 1H, 
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Fur, J = 3.64 Hz), 6.83 (dd, 1H, fur, J1 = 1.72 Hz, J2 = 3.64 Hz), 4.58 (s, 2H, CH2), 3.86 (s, 3H, CH3); IR (cm-1): 2214, 
1728. 
 
3-(((6-Amino-3,5-dicyano-4-(furan-2-yl)pyridin-2-yl)thio)methyl)benzamide (2) 
Yield: 43%; mp: 249-251°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.10 
(d, J = 1.1 Hz, 1H, Fur), 8.07 (br s, 2H, NH2, exc D2O) 7.98 (s, 1H, Ar), 
7.96 (br s, 1H, NH amide, exc D2O), 7.76 (d, J = 7.8 Hz, 1H, Ar), 7.68 (d, 
J = 7.7 Hz, 1H, Ar), 7.49 – 7.29 (m, 3H, Ar, NH amide, Fur, overlapping, 
partially exc D2O), 6.83 (dd, J = 3.6, 1.8 Hz, 1H, Fur), 4.53 (s, 2H, CH2). IR (cm-1): 3424, 3360, 3331, 3213, 2210, 
1643 
 
3-(((6-Amino-3,5-dicyano-4-(furan-2-yl)pyridin-2-yl)thio)methyl)benzoic acid (3) 
Yield: 35%; mp: 255-257°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
13.01 (s, 1H, COOH, exc D2O), 8.10 (d, J = 1.0 Hz, 1H, Fur), 8.05 (s, 1H, 
Ar), 8.13 (br s, 2H, NH2, exc D2O), 7.86 – 7.76 (m, 2H, Ar), 7.44 (t, J = 
7.7 Hz, 1H, Ar), 7.39 (d, J = 3.6 Hz, 1H, Fur), 6.83 (dd, J = 3.6, 1.7 Hz, 
1H, Fur), 4.58 (s, 2H, CH2). IR (cm-1): 3329, 3327, 2214, 1541 
 
2-Amino-4-(furan-2-yl)-6-((3-(hydroxymethyl)benzyl)thio)pyridine-3,5-dicarbonitrile (4) 
Yield: 43%; mp: 193-195°C (EtOAc); 1H NMR (400 MHz, DMSO-d6): 8.24 
(s, 1H, Fur), 8.10 (br s, 2H, NH2, exc D2O), 7.90 (t, J = 1.6 Hz, 1H, Fur), 
7.42 (s, 1H, Ar), 7.37 (d, J = 7.5 Hz, 1H, Ar), 7.27 (t, J = 7.5 Hz, 1H, Ar), 
7.21 (d, J = 7.5 Hz, 1H, Ar), 6.87 (s, 1H, Fur), 5.19 (t, J = 5.7 Hz, 1H, OH, 
exc D2O), 4.55 – 4.43 (m, 4H, 2CH2 partially overlapping). IR (cm-1): 3398, 3314, 3215, 2214 
 
2-Amino-6-((3-cyanobenzyl)thio)-4-(furan-2-yl)pyridine-3,5-dicarbonitrile (5) 
Yield: 68%; mp: 193-195°C (EtOH); 1H NMR (400 MHz, DMSO): 8.23 (s, 
1H, Fur), 8.15 (br s, 2H, NH2, exc D2O), 8.08 (s, 1H, Fur), 7.90 (dd, J = 3.6, 
1.8 Hz, 1H, Ar), 7.88 (d, J = 8.0 Hz, 1H, Ar), 7.72 (d, J = 7.7 Hz, 1H, Ar), 7.53 
Experimental section 
130 
  
(t, J = 7.8 Hz, 1H, Ar), 6.86 (s, 1H, Fur), 4.50 (s, 2H, CH2). IR (cm-1): 3410, 3321, 3228, 2227, 2212 
 
Methyl 5-(((6-amino-3,5-dicyano-4-(furan-2-yl)pyridin-2-yl)thio)methyl)furan-2-carboxylate (6) 
Yield: 64%; mp: 260-262°C (Acetone); 1H NMR (400 MHz, DMSO-d6): 
8.25 (s, 1H, Fur), 7.91 (s, 1H, Fur), 7.25 (d, J = 3.5 Hz, 1H, SCH2Fur), 
6.88 (s, 1H, Fur), 6.79 (d, J = 3.4 Hz, 1H, SCH2Fur), 4.62 (s, 2H, CH2), 
3.80 (s, 3H, CH3). IR (cm-1): 3402, 3334, 3240, 2222, 2210 
 
Methyl 3-(((6-amino-3,5-dicyano-4-(furan-3-yl)pyridin-2-yl)thio)methyl)benzoate (7) 
Yield: 61%; mp: 229-231°C (MeOH/2-methoxyethanol); 1H NMR 
(400 MHz, DMSO-d6): 8.24 (s, 1H, Fur), 8.09 (s, 1H, Fur), 8.34 – 7.77 
(br s, 2H, NH2, exc D2O), 7.90 (t, J = 1.7 Hz, 1H, Ar), 7.85 (s, 1H, Ar), 
7.83 (s, 1H, Ar), 7.47 (t, J = 7.7 Hz, 1H, Ar), 6.87 (d, J = 1.8 Hz, 1H, 
Fur), 4.58 (s, 2H, CH2), 3.86 (s, 3H, CH3). IR (cm-1): 3373, 3113, 2210, 1527 
 
Methyl 3-(((6-amino-3,5-dicyano-4-(thiophen-2-yl)pyridin-2-yl)thio)methyl)benzoate (8) 
Yield: 76%; mp: 199-201°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
8.10 (s, 1H, Ar), 7.94 (d, J = 5.0 Hz, 1H, CH thiophene), 8.55 – 7.72 
(m, 2H, NH2, exc D2O), 7.86 (s, 1H, Ar), 7.84 (s, 1H, Ar), 7.56 (d, J = 
2.7 Hz, 1H, CH thiophene), 7.47 (t, J = 7.7 Hz, 1H, Ar), 7.27 (dd, J = 
4.9, 3.8 Hz, 1H, CH thiophene), 4.59 (s, 2H, CH2), 3.86 (s, 3H, CH3). IR (cm-1): 3462, 3329, 3217, 2210, 1547 
 
Methyl 3-(((6'-amino-3',5'-dicyano-[3,4'-bipyridin]-2'-yl)thio)methyl)benzoate (9) 
Yield: 21%; mp: 222-224°C (2-methoxyethanol/EtOH); 1H NMR 
(400 MHz, DMSO-d6): 8.83 – 8.67 (m, 2H, Ar), 8.23 (br s, 2H, NH2, 
exc D2O), 8.11 (s, 1H, Ar), 8.03 (d, J = 7.9 Hz, 1H, Ar), 7.86 (t, J = 7.8 
Hz, 2H, Ar), 7.61 (dd, J = 7.7, 4.9 Hz, 1H, Ar), 7.48 (t, J = 7.7 Hz, 1H, 
Ar), 4.61 (s, 2H, CH2), 3.86 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): 166.44, 159.88, 155.82, 151.73, 149.01, 
139.08, 136.86, 134.89, 130.65, 130.36, 129.29, 128.51, 124.01, 115.48, 93.84, 86.77, 52.65, 33.05; IR (cm-1): 
3373, 3314, 3152, 2210, 1728 
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2-Amino-6-((cyanomethyl)thio)-4-(furan-2-yl)pyridine-3,5-dicarbonitrile (10) 
Yield: 43%; mp: 297-299°C (2-methoxyethanol); 1H NMR (400 MHz, DMSO-d6): 
8.16 (br s, 2H, NH2, exc D2O), 8.17 – 8.11 (m, 1H, Fur), 7.51 – 7.39 (m, 1H, Fur), 
6.86 (dd, J = 3.7, 1.8 Hz, 1H, Fur), 4.33 (s, 2H, CH2). IR (cm-1): 3404, 3319, 3228, 
3313, 2257, 2208 
 
Benzyl 2-((6-amino-3,5-dicyano-4-(furan-2-yl)pyridin-2-yl)thio)acetate (11) 
Yield: 30%; mp: 222-224°C (EtOAc/EtOH); 1H NMR (400 MHz, DMSO-
d6): 8.12 (s, 1H, Fur), 7.99 (s, 2H, NH2, exc D2O), 7.42 (d, J = 3.6 Hz, 1H, 
Fur), 7.41 – 7.20 (m, 5H, Ar), 6.85 (dd, J = 3.6, 1.7 Hz, 1H, Fur), 5.19 (s, 
2H, CH2Bn), 4.28 (s, 2H, SCH2); 13C NMR (100 MHz, DMSO-d6): 168.41, 
166.98, 160.51, 145.44, 144.25, 136.24, 128.85, 128.54, 128.31, 116.99, 116.08, 116.01, 113.35, 89.77, 82.38, 
67.10, 32.44; IR (cm-1): 3441, 3314, 3209, 2214, 1732 
 
2-Amino-4-(furan-2-yl)-6-((2-oxo-2-phenylethyl)thio)pyridine-3,5-dicarbonitrile (12) 
Yield: 47%; mp: 251-253°C (EtOAc); 1H NMR (400 MHz, DMSO-d6): 8.28 (d, 
J = 5.7 Hz, 1H, Fur), 8.08 (t, J = 6.3 Hz, 2H, Ar), 7.94 (br s, 2H, NH2, exc D2O), 
7.93 (d, J = 5.5 Hz, 1H, Fur), 7.71 (dd, J = 13.4, 6.6 Hz, 1H, Ar), 7.65 – 7.52 
(m, 2H, Ar), 6.91 (d, J = 4.8 Hz, 1H, Fur), 5.01 (d, J = 5.8 Hz, 2H, CH2). IR (cm-
1): 3485, 3350, 2206, 1618 
 
2-Amino-4-(furan-2-yl)-6-((pyridin-3-ylmethyl)thio)pyridine-3,5-dicarbonitrile (13) 
Yield: 80%; mp: 228-230°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.77 (d, J = 
2.1 Hz, 1H, Fur), 8.45 (dd, J = 4.8, 1.5 Hz, 1H, Ar), 8.89 – 7.52 (br s, 2H, NH2, 
exc D2O), 8.10 (d, J = 1.7 Hz, 1H, Fur), 7.94 (d, J = 7.9 Hz, 1H, Ar), 7.38 (d, J = 
3.6 Hz, 1H, Ar), 7.34 (dd, J = 7.8, 4.8 Hz, 1H, Ar), 6.83 (dd, J = 3.6, 1.7 Hz, 1H, 
Fur), 4.49 (s, 2H, CH2); IR (cm-1): 3385, 3086, 2206 
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2-Amino-4-(furan-2-yl)-6-((pyridin-2-ylmethyl)thio)pyridine-3,5-dicarbonitrile (14) 
Yield: 44%; mp: 212-214°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.48 (d, J = 
4.7 Hz, 1H, Ar), 8.11 (br s, 2H, NH2, exc D2O), 8.00 (d, J = 1.5 Hz, 1H, Fur), 7.75 
(td, J = 7.7, 1.7 Hz, 1H, Ar), 7.60 (d, J = 7.8 Hz, 1H, Ar), 7.37 (d, J = 3.6 Hz, 1H, 
Fur), 7.34 – 7.24 (m, 1H, Ar), 6.80 (dd, J = 3.6, 1.7 Hz, 1H, Fur), 4.56 (s, 2H, CH2); 
13C NMR (100 MHz, DMSO-d6): 167.73, 160.59, 150.03, 145.54, 144.30, 137.29, 124.18, 123.00, 116.85, 
116.14, 113.29, 89.68, 82.11, 35.95; IR (cm-1): 3389, 3311, 3148, 2206 
 
2-Amino-4-(furan-2-yl)-6-(((2-phenylthiazol-4-yl)methyl)thio)pyridine-3,5-dicarbonitrile (15) 
Yield: 75%; mp: 202-204°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.12 
(br s, 2H, NH2, exc D2O), 8.10 (s, 1H, Fur), 7.93 (dd, J = 6.4, 2.7 Hz, 2H, 
Ar), 7.86 (s, 1H, CH thiazole), 7.64 – 7.42 (m, 3H, Ar), 7.39 (d, J = 3.6 
Hz, 1H, Fur), 6.83 (d, J = 1.9 Hz, 1H, Fur), 4.64 (s, 2H, CH2); IR (cm-1): 
3373, 3200, 3178, 3103, 2212 
 
2-Amino-6-(((2-aminothiazol-4-yl)methyl)thio)-4-(furan-2-yl)pyridine-3,5-dicarbonitrile (16) 
Yield: 79%; mp: 243-245°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.10 
(s, 1H, Fur),  8.06 (br s, 2H, NH2 Py, exc D2O), 7.39 (d, J = 3.5 Hz, 1H, Fur), 
6.98 (br s, 2H, NH2 thiazole, exc D2O), 6.84 (s, 1H, CH thiazole), 6.62 (s, 
1H, Fur), 4.30 (s, 2H, CH2); IR (cm-1): 3452, 3352, 3317, 3217, 3115, 2218 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(furan-3-yl)pyridine-3,5-dicarbonitrile (26) 
Yield: 53%; mp: 271-273°C dec. (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.83 
(br s,1H, NH imidazole, exc D2O), 8.26 (s, 1H, CH, Fur), 8.02 (br s, 2H, NH2, exc 
D2O), 7.92 (s, 1H, CH, Fur), 7.07 (br s, 1H, CH imidazole), 6.88 (s, 1H, CH, Fur), 
6.86 (br s, 1H, CH imidazole), 4.5 (s, 2H, CH2); IR (cm-1): 3328, 3220, 2211 
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2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(thiophen-3-yl)pyridine-3,5-dicarbonitrile (27) 
Yield: 73%; 233-235°C (ACN); 1H NMR (400 MHz, DMSO-d6): 11.83 (br s, 1H, 
NH imidazole, exc D2O), 8.05 (d, 1H, CH thiophene, J = 4 Hz), 8.04 (br s, 2H, 
NH2, exc D2O), 7.78 (t, 1H, CH thiophene, J = 4 Hz), 7.39 (d, 1H, CH thiophene, 
J = 4 Hz), 7.07 (br s, 1H, CH imidazole), 6.85 (br s, 1H, CH imidazole), 4.50 (s, 
2H, CH2); 13C NMR (100 MHz, DMSO-d6): 166.79, 160.36, 153.48, 142.99, 133.83, 129.32, 128.16, 127.92, 
115.88, 93.29, 86.01, 27.24; IR (cm-1): 3400,3321,2218 
 
2'-(((1H-Imidazol-2-yl)methyl)thio)-6'-amino-[3,4'-bipyridine]-3',5'-dicarbonitrile (28) 
Yield: 64%; mp: 238-240°C (ACN); 1H NMR (400 MHz, DMSO-d6): 12.18 (br s, 
1H, NH imidazole, exc D2O), 8.78 (d, 1H, CH Py, J = 4 Hz), 8.75 (s,1H, CH Py), 
8.25 (br s, 2H, NH2, exc D2O), 8.03 (d, 1H, CH Py, J = 8 Hz), 7.62 (t, 1H, CH Py J 
= 8 Hz), 7.02 (br s, 2H, CH imidazole), 4.54 (s, 2H, CH2); IR (cm-1): 3379, 3308, 
2212, 1658 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-[4,4'-bipyridine]-3,5-dicarbonitrile (29) 
Yield: 64%; mp: > 300°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.87 (br s, 1H, 
NH imidazole, exc D2O), 8.81 (d, 2H, CH Py, J = 8 Hz), 8.2 (br s, 2H, NH2, exc 
D2O), 7. 59 (d, 2H, CH Py, J = 8 Hz), 7.09 (s, 1H, CH imidazole), 6.86 (s, 1H, CH 
imidazole), 4.52 (s, 2H, CH2); IR (cm-1): 3312, 3175, 2210 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-benzylpyridine-3,5-dicarbonitrile (30) 
Yield: 70%; mp: 246-248°C dec (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.82 
(br s, 1H, NH imidazole, exc D2O), 8.14 (br s, 2H, NH2, exc D2O), 7.34 (d, 2H, 
Ar, J = 8 Hz), 7.24 (m, 3H, Ar), 6.95 (sl, 2H, CH imidazole), 4.47 (s, 2H, SCH2), 
4.05 (s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6): 166.73, 160.33, 159.10, 
142.89, 136.61, 129.38, 128.78, 127.64, 115.61, 86.95, 27.15; IR (cm-1): 3431, 3357, 2377 
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2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-chlorophenyl)pyridine-3,5-dicarbonitrile (31) 
Yield: 42%; mp: 229-231°C dec (EtOH); 1H NMR (400 MHz, DMSO-d6): 
11.87 (br s, 1H, NH imidazole, exc D2O), 8.2 (br s, 2H, NH2, exc D2O), 7.65 
(d, 2H, Ar, J = 8 Hz), 7.59 (d, 2H, Ar, J = 8 Hz), 7.08 (s, 1H, CH imidazole), 
6.85 (s, 1H, CH imidazole), 4.5 (s, 2H, CH2); IR (cm-1): 3336, 3244, 2220 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-fluorophenyl)pyridine-3,5-dicarbonitrile (32) 
Yield: 80%; mp: 223-225°C dec (EtOAc); 1H NMR (400 MHz, DMSO-d6): 11.9 
(br s, 1H, NH imidazole, exc D2O), 8.2 (br s, 2H, NH2, exc D2O), 7.6 (m, 2H, 
Ar), 7.45 (t, 2H, Ar, J = 8.8 Hz), 7.0 (br s, 2H, CH imidazole), 4.5 (s, 2H, CH2); 
IR (cm-1): 3314, 3145, 2229 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(p-tolyl)pyridine-3,5-dicarbonitrile (33) 
Yield: 67%; mp: 259-261°C dec (EtOH); 1H NMR (400 MHz, DMSO-d6): 
11.85 (br s, 1H, NH imidazole, exc D2O), 8.14 (br s, 2H, NH2, exc D2O), 7.4 
(d, 2H, Ar, J = 8 Hz), 7.38 (d, 2H, Ar, J = 8 Hz), 7.07 (br s, 1H, CH imidazole), 
6.86 (sl, 1H, CH imidazole), 4.5 (s, 2H, CH2), 2.39 (s, 3H, CH3); IR (cm-1): 
3318, 3129, 2213 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-(methylthio)phenyl)pyridine-3,5-dicarbonitrile (34) 
Yield: 95%; mp: 257-259°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 
11.87 (br s, 1H, NH imidazole, exc D2O), 8.12 (br s, 2H, NH2, exc D2O), 
7.47 (d, 2H, Ar, J = 8 Hz), 7.42 (d, 2H, Ar, J = 8 Hz), 7.08 (s, 1H, CH 
imidazole), 6.85 (s, 1H, CH imidazole), 4.5 (s, 2H, CH2), 2.51 (s, 3H, CH3); 
13C NMR (100 MHz, DMSO-d6): 166.65, 160.26, 158.33, 143.00, 142.31, 130.19, 129.43, 125.69, 115.81, 93.54, 
86.35, 27.23, 14.47; IR (cm-1): 3420, 3390, 2223 
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2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-methylpyridine-3,5-dicarbonitrile (35) 
Yield: 66%; mp: 267-269°C (EtOH); 1H NMR (400 MHz, DMSO): 11. 87 (br s, 1H, 
NH, exc D2O), 8.12 (br s, 2H, NH2, exc D2O), 7.02 (br s, 2H, 2CH imidazole), 4.51 
(s, 2H, CH2), 2.43 (s, 3H, CH3); IR (cm-1): 3455, 3363, 2473 
 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-dicarbonitrile 
(37) 
Yield: 63%; mp: 226-228°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
11.86 (br s, 1H, NH imidazole, exc D2O), 8.15 (br s, 2H, NH2, exc 
D2O), 7.46 (d, 2H, Ar, J = 8.2 Hz), 7.9 (d, 2H, Ar, J = 8 Hz); 7.0 (br s, 
2H, CH imidazole), 4.5 (s, 2H, CH2, SCH2), 3.9 (d, 2H, CH2, J = 8 Hz), 
1.26 (m, 1H, CH cyclopropyl), 0.63-0.53 (m, 4H, CH2 eq), 0.46 – 0.23 
(m, 2H, CH2 ax); 13C NMR (100 MHz, DMSO-d6): 166.59, 160.74, 160.32, 158.58, 155.20, 143.02, 130.64, 
126.03, 115.96, 115.91, 114.98, 93.64, 86.38, 72.75, 27.21, 10.53, 3.62; IR (cm-1): 3430, 3387, 2229 
 
2-(((1H-Imidazol-5-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-dicarbonitrile 
(38) 
Yield: 32%; mp: 186-188°C (EtOH); 1H NMR (400 MHz, DMSO-d6):  
11.97 (s, 1H, NH imidazole, exc D2O), 8.04 (s, 2H, NH2, exc D2O), 
7.59 (s, 1H, CH imidazole), 7.46 (d, J = 8.5 Hz, 2H, Ar), 7.18 (s, 1H, 
CH imidazole), 7.08 (d, J = 8.5 Hz, 2H, Ar), 4.40 (s, 2H, SCH2), 3.90 
(d, J = 6.9 Hz, 2H, OCH2), 1.26 (dd, J = 15.5, 11.2 Hz, 1H, CH 
cyclopropane), 0.73 – 0.47 (m, 2H, CH qe), 0.47 – 0.24 (m, 2H, ax); 13C NMR (100 MHz, DMSO-d6): 167.24, 
160.67, 160.17, 158.49, 134.33, 130.63, 126.15, 116.02, 114.94, 93.81, 86.04, 72.72, 10.52, 3.60; IR (cm-1): 
3318, 3205, 3080, 2212 
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2-Amino-4-(4-(cyclopropylmethoxy)phenyl)-6-(((4,5-dihydro-1H-imidazol-2-yl)methyl)thio)pyridine-3,5-
dicarbonitrile (39) 
Yield: 37%; mp: 260-262°C (2-propanol/EtOAc); 1H NMR (400 MHz, 
DMSO-d6):  7.40 (d, J = 8.5 Hz, 2H, Ar), 7.19 (s, 2H, NH2, exc D2O), 
7.12 (d, J = 8.1 Hz, 2H, Ar), 6.44 (s, 1H, NH, exc D2O), 5.82 (s, 2H, 
SCH2), 3.92 (d, J = 7.1 Hz, 2H, CH2), 3.77 (t, J = 9.3 Hz, 2H, CH2 
imidazoline), 3.23 (t, J = 10.4 Hz, 2H, CH2 imidazoline), 1.36 – 1.21 
(m, 1H, CH), 0.72 – 0.52 (m, 2H, CH2 eq), 0.50 – 0.29 (m, 2H, CH2 ax) 
 
2-(((1H-Benzo[d]imidazol-2-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-
dicarbonitrile (40) 
Yield: 64%; mp: >300°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 
12.3 (br s, 1H, NH, exc D2O), 7.9-8.4 (br s, 2H, NH2, exc D2O), 7.57 
(d, 1H, J= 7.8, Ar), 7.46-7.48 (m, 3H, Ar), 7.15-7.20 (m, 2H, Ar), 
7.09 (d, 2H, J= 8.72, Ar), 4.71 (s, 2H, CH2), 3.9 (d, 2H, CH2, J= 7.08), 
1.22-1.30 (m, 1H, CH), 0.57-0.62 (m, 2H, 2CH eq), 0.33-0.37 (m, 
2H, 2CH ax); IR (cm-1): 3396; 3331; 2210 
 
2-(((1H-Pyrazol-5-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-dicarbonitrile 
(41) 
Yield: 37%; mp: 133-136°C (EtOH/CHx); 1H NMR (400 MHz, DMSO-d6): 
12.7 (br s, 1H, NH, exc D2O), 8.0 (br s, 2H, NH2, exc D2O), 7.67 (br s, 
1H, CH pyrazole), 7.47 (d, 2H, J= 8.28, Ar), 7.09 (d, 2H, J= 8.48, Ar), 
6.32 (s, 1H, CH pyrazole), 4.49 (s, 2H, CH2), 3.91 (d, 2H, CH2, J= 6.88), 
1.22-1.26 (m, 1H, CH), 0.58-0.62 (m, 2H, 2CH eq), 0.36-0.40 (m, 2H, 
2CH ax) 
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2-(((1H-1,2,4-Triazol-1-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-
dicarbonitrile (42) 
Yield: 40%; mp: 235-237°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
8.99 (s, 1H), 8.75 – 7.78 (m, 2H, NH2, exc D2O), 8.04 (s, 1H, CH 
triazole), 7.47 (d, 2H, Ar, J = 8.7 Hz,), 7.08 (d, 2H, Ar, J = 8.8 Hz), 
6.03 (s, 2H, CH2), 3.90 (d, 2H, CH2, J = 7.1 Hz), 1.34 – 1.17 (m, 1H, 
CH cyclopropyl), 0.64 – 0.54 (m, 2H, CH2 eq), 0.38-0.32 (m, 2H CH2 
ax); IR (cm-1): 3311, 2212 
 
2-(((1H-1,2,4-Triazol-5-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-
dicarbonitrile (43) 
Yield: 72%; mp: 240-242°C (EtOH/Et2O); 1H NMR (400 MHz, DMSO-
d6): 13.9 (br s, 1H, NH, exc D2O), 8.3 (br s, 1H, CH triazole), 8.1 (sl, 2H, 
NH2, exc D2O), 7.48 (d, 2H, J= 7.80, Ar), 7.09 (d, 2H, J= 8.48, Ar), 4.59 
(s, 2H, SCH2), 3.91 (d, 2H, J= 7.08, OCH2), 1.23-1.29 (m, 1H, CH), 0.57-
0.62 (m, 2H, 2CH eq), 0.34-0.37 (m, 2H, 2CH ax); IR (cm-1): 3441; 3323; 
3207; 2212 
 
2-(((1H-Tetrazol-5-yl)methyl)thio)-6-amino-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-dicarbonitrile 
(44) 
Yield: 64%; mp: 225-227°C (EtOH/Et2O); 1H NMR (400 MHz, DMSO-
d6): 16.1 (br s, 1H, NH, exc D2O), 8.0 (br s, 2H, NH2, exc D2O), 7.47 (d, 
2H, J= 8.64, Ar), 7.09 (d, 2H, J= 8.64, Ar), 4.78 (s, 2H, SCH2), 3.91 (d, 
2H, OCH2, J= 7.04), 1.24-1.28 (m, 1H, CH), 0.58-0.61 (m, 2H, 2CH eq), 
0.34-0.37 (m, 2H, 2CH ax); IR (cm-1): 3442; 3323; 3224; 2225; 2208 
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2-Amino-6-(((2-aminothiazol-4-yl)methyl)thio)-4-(4-(cyclopropylmethoxy)phenyl)pyridine-3,5-
dicarbonitrile (45) 
Yield: 87%; mp: 238-240°C (EtOH/Et2O); 1H NMR (400 MHz, DMSO-
d6): 8.02 (br s, 2H, NH2, exc D2O), 7.46 (d, 2H, J= 8.68, Ar), 7.08 (d, 
2H, J= 8.72, Ar), 6.98 (br s, 2H, NH2, exc D2O), 6.63 (s, 1H, CH 
thiazole), 4.31 (s, 2H, SCH2), 3.90 (d, 2H, J= 7.04, OCH2), 1.23-1.29 
(m, 1H, CH), 0.57-0.62 (m, 2H, 2CH eq), 0.34-0.37 (m, 2H, 2CH ax); 
IR (cm-1): 3423; 3327; 3184-3170; 2216 
 
2-Amino-4-(4-(cyclopropylmethoxy)phenyl)-6-((pyridin-3-ylmethyl)thio)pyridine-3,5-dicarbonitrile (46) 
Yield: 80%; 190-192°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.7 (s, 
1H, Ar), 8.45 (s, 1H, Ar), 8.11 (br s, 2H, NH2, exc D2O), 7.94 (d, 1H, J= 
5.68, Ar), 7.42 (d, 2H, J= 6.8 Hz, Ar), 7.35-7.37 (m, 1H, Ar), 7.05 (d, 
2H, Ar, J= 6.9 Hz), 4.48 (s, 2H, SCH2), 3.86 (d, 2H, J= 7.0 Hz, OCH2), 
1.19-1.22 (m, 1H, CH), 0.57-0.59 (m, 2H, 2CH eq), 0.30-0.34 (m, 2H, 
2CH ax); IR (cm-1): 3369; 2212 
 
2-((6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)-N-methylacetamide (47) 
Yield: 71%; mp: 274-276°C (Acetone); 1H NMR (400 MHz, 
DMSO-d6):  8.18 – 7.85 (2 br s, 3H, NH2 + NH, exc D2O), 7.48 (d, 
J = 8.7 Hz, 2H, Ar), 7.10 (d, J = 8.7 Hz, 2H, Ar), 3.89 (s, 2H, SCH2), 
2.62 (d, J = 4.5 Hz, 2H, OCH2), 1.27 (m, 1H, CH), 0.61 (q, J = 6.3 
Hz, 2H, CH2 eq), 0.36 (q, J = 4.5 Hz, 2H, CH2 ax); 13C NMR (100 
MHz, DMSO-d6): 167.78, 166.54, 160.75, 160.16, 158.59, 130.64, 126.03, 115.90, 115.00, 93.69, 86.40, 72.75, 
33.72, 26.50, 10.55, 3.60 IR (cm-1): 3390; 3323; 3223; 2208 
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2-((6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)-N-(hydroxymethyl)- 
acetamide (48) 
Yield: 79%; mp: 202-204°C (MeOH); 1H NMR (400 MHz, DMSO-
d6): 8.69 (t, 1H, NH, J= 6.28 Hz, exc D2O); 7.8-8.2 (br s, 2H, NH2, 
exc D2O), 7.46-7.50 (m, 2H, Ar), 7.08-7.12 (m, 2H, Ar), 5.72 (t, 
1H, OH, J = 6.42 Hz, exc D2O), 4.53 (t, 2H, NCH2O, J= 5.96), 3.90-
3.92 (1 d + 1 s, 4H, 2CH2 overlapping), 1.21-1.31 (m, 1H, CH), 
0.58-0.62 (m, 2H, 2CH eq), 0.34-0.38 (m, 2H, 2CH ax); IR (cm-1): 
3394; 3319 bl; 3224; 2208; 1639 
 
2-((6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)-N-hydroxyacetamide (49) 
Yield: 60%; mp: 176-178°C (EtOH); 1H NMR (400 MHz, DMSO-
d6):  10.58 (br s, 1H, OH, exc D2O), 9.06 (br s, 1H, NH, exc D2O), 
8.01 (br s, 2H, NH2, exc D2O), 7.48 (d, J = 8.6 Hz, 2H, Ar), 7.10 (d, 
J = 8.6 Hz, 2H, Ar), 3.91 (d, J = 6.9 Hz, 2H, SCH2), 3.81 (s, 2H, CH2), 
1.32 – 1.19 (m, 1H, CH), 0.60 (m, 2H, CH2, eq), 0.42 – 0.29 (m, 
2H, CH2 ax); IR (cm-1): 3649, 3331, 3223, 2208 
 
Methyl 2-((6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)acetate (50) 
Yield: 41%; mp: 205-207°C (EtOH); 1H NMR (400 MHz, DMSO-d6):  
7.9 (br s, 2H, NH2, exc D2O), 7.48 (d, 2H, J= 8.8, Ar), 7.1 (d, 2H, J= 
8.84, Ar), 4.20 (s, 2H, SCH2), 3.91 (d, 2H, J= 7.04, OCH2), 3.69 (s, 3H, 
OCH3), 1.24-1.28 (m, 1H, CH), 0.58-0.62 (m, 2H, 2CH eq), 0.35-0.38 
(m, 2H, 2CH ax); IR (cm-1): 3446; 3342; 3224; 2210; 1739 
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Methyl 3-(((6-amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)methyl)benzoate 
(51) 
Yield: 58%; mp: 158-160°C (MeOH); 1H NMR (400 MHz, 
DMSO-d6): 8.10 (s, 1H, Ar), 7.90-8.35 (br s, 2H, NH2, exc 
D2O), 7.84-7.87 (m, 2H, Ar), 7.44-7.49 (m, 3H, Ar), 7.07 (d, 
2H, J= 8.8, Ar), 4.59 (s, 2H, SCH2), 3.90 (d, 2H, OCH2  J= 
7.04), 3.86 (s, 3H, OCH3), 1.23-1.27 (m, 1H, CH), 0.58-0.60 
(m, 2H, 2CH eq), 0.34-0.36 (m, 2H, 2CH ax); IR (cm-1): 3396; 
3331; 3230; 2210; 1707 
 
3-(((6-Amino-3,5-dicyano-4-(4-(cyclopropylmethoxy)phenyl)pyridin-2-yl)thio)methyl)benzamide (52) 
Yield: 47%; mp: 243-245°C (EtOAc/2-methoxyethanol); 1H 
NMR (400 MHz, DMSO-d6): 8.05 (br s, 2H, NH2, exc D2O), 
8.00 (s, 1H, Ar), 7.96 (s, 1H, NH amide, exc D2O), 7.77 (d, 1H, 
J= 7.80 Hz, Ar), 7.69 (d, 1H, J= 7.73 Hz, Ar), 7.47-7.38 (m, 4H, 
2Ar  + NH amide), 7.07 (d, 2H, J=  8.8, Ar), 4.54 (s, 2H, SCH2), 
3.90 (d, 2H, J= 7.04, OCH2), 1.22-1.28 (m, 1H, CH), 0.58-0.61 
(m, 2H, 2CH eq), 0.33-0.37 (m, 2H, 2CH ax); IR (cm-1): 3441; 3387; 3356; 3169; 2212; 1635 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-(cyclobutylmethoxy)phenyl)pyridine-3,5-dicarbonitrile 
(53) 
Yield: 20%; 214-216°C (EtOH); 1H NMR (400 MHz, DMSO-d6):  11.87 
(br s, 1H, NH imidazole, exc D2O), 8.10 (br s, 2H, NH2, exc D2O), 7.46 
(d, 2H, J= 7.76 Hz, Ar), 7.09 (d, 2H, J= 7.76 Hz, Ar), 7.08 (s, 1H, CH 
imidazole), 6.96 (s, 1H, CH imidazole), 4.49 (s, 2H, SCH2), 4.03 (d, 2H, 
OCH2, J= 5.96 Hz), 2.7-2.6 (m, 1H, CH cyclobutyl), 2.08-2.07 (m, 2H, 
CH2 cyclobutyl), 1.91-1.88 (m, 4H, 2CH2 cyclobutyl); IR (cm-1): 3385; 
3320; 3217; 2210 
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2-((6-Amino-3,5-dicyano-4-(4-(cyclobutylmethoxy)phenyl)pyridin-2-yl)thio)acetamide (54) 
Yield: 21%; mp: 244-246°C (EtOAc/CHx); 1H NMR (400 MHz, DMSO-
d6): 7.99 (br s, NH2, exc D2O), 7.50 (br s, 1H, NH2 amide, exc D2O), 
7.49 (d, 2H, J= 8.6 Hz, Ar), 7.26 (s, 1H, NH2 amide, exc D2O), 7.10 (d, 
2H, J= 8.6 Hz, Ar), 4.04 (d, 2H, OCH2, J= 6.68 Hz), 4.03 (s, 2H, SCH2), 
2.78- 2.67 (m, 1H, CH cyclobutyl), 1.99-1.96 (m, 2H, CH), 1-95-1.82 
(m, 4H, 2CH2 cyclobutyl); IR (cm-1): 3664, 3361, 3252, 2214, 1635 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-isobutoxyphenyl)pyridine-3,5-dicarbonitrile (55) 
Yield: 31%; mp: 230-232°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
11.84 (br s, 1H, NH imidazole, exc D2O), 8.14 (s, 2H, NH2, exc D2O), 
7.47 (d, 2H, J= 8.7 Hz, Ar), 7.10 (d, 2H, J= 8.6 Hz, Ar), 7.08 (s, 1H, CH 
imidazole), 6.85 (s, 1H, CH imidazole), 4.50 (s, 2H, SCH2), 3.84 (d, 2H, 
OCH2, J= 6.3 Hz), 2.09-2.02 (m, 1H, CH isopropyl), 1.00 (2 d, 6H, 2 CH3 
isopropyl, J= 6.7 Hz); IR (cm-1): 3387, 3315, 3215, 2208 
 
2-((6-Amino-3,5-dicyano-4-(4-isobutoxyphenyl)pyridin-2-yl)thio)acetamide (56) 
yield: 21%; mp: 233-235°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
7.99 (br s, 2H, NH2, exc D2O), 7.49 (s, 1H, NH2 amide, exc D2O), 7.48 
(d, 2H, J= 8.4 Hz, Ar), 7.25 (s, NH2 amide, exc D2O), 7.11 (d, 2H, J= 
8.8 Hz, Ar), 3.88 (s, 2H, SCH2), 3.84 (d, 2H, OCH2, J= 6.4 Hz), 2.08-
2.02 (m, 1H, CH isopropyl), 1.00 (d, 6H, J= 6.8 Hz, 2CH3 isopropyl); IR 
(cm-1): 3537; 3375; 3196; 2208; 1639 
  
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-ethoxyphenyl)pyridine-3,5-dicarbonitrile (57) 
Yield: 41%; mp: 242-244°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.84 
(br s, 1H, NH imidazole, exc D2O), 8.12 (s, 2H, NH2, exc D2O), 7.47 (d, 2H, 
J= 8.6 Hz, Ar), 7.09 (d, 2H, J= 8.7 Hz, Ar), 7.08 (s, 1H, CH imidazole), 6.85 
(s, 1H, CH imidazole), 4.49 (s, 2H, SCH2), 4.2 (q, 2H, J= 6.8 Hz, OCH2), 
1.36 (t, 3H, J= 6.8 Hz, CH3); 13C NMR (100 MHz, DMSO-d6): 166.60, 
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160.65, 160.32, 158.56, 143.01, 130.67, 126.06, 115.94, 115.89, 114.94, 93.66, 86.40, 63.83, 27.23, 15.06; 
IR (cm-1): 3506, 3398, 3159, 2212 
 
2-((6-Amino-3,5-dicyano-4-(4-ethoxyphenyl)pyridin-2-yl)thio)acetamide (58) 
Yield: 35%; mp: 235-237°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 7.98 
(br s, 2H, NH2, exc D2O), 7.50 (s, 1H, NH2 amide, exc D2O), 7.48 (d, 2H, 
J= 8.8 Hz, Ar), 7.23 (s, 1H, NH2 amide, exc D2O), 7.10 (d, 2H, J= 8.8 Hz, 
Ar), 4.12 (q, 2H, OCH2, J= 7.2 Hz), 3.88 (s, 2H, SCH2), 1.36 (t, 3H, J= 7.2 
Hz, CH3); IR (cm-1): 3396, 3180, 2210, 1637 
 
2-((6-Amino-3,5-dicyano-4-(4-ethoxyphenyl)pyridin-2-yl)thio)-N-methylacetamide (59) 
Yield: 32%; mp: 262-264°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
7.96 (br s, 1H, NH, exc D2O), 7.95 (br s, 2H, NH2, exc D2O), 7.48 (d, 
2H, J= 8.5 Hz, Ar), 7.09 (d, 2H, J= 8.4 Hz, Ar), 4.12 (q, 2H, J= 7.2 Hz, 
OCH2), 3.88 (s, 2H, CH2), 1.36 (t, 3H, J= 6.8 Hz, CH3); 13C NMR (100 
MHz, DMSO): 167.78, 166.54, 160.15, 158.57, 130.67, 126.05, 
115.93, 114.94, 63.83, 33.71, 26.56, 15.07; IR (cm-1): 3394, 3223, 2210, 1637 
 
2-(((1H-Pyrazol-5-yl)methyl)thio)-6-amino-4-(4-ethoxyphenyl)pyridine-3,5-dicarbonitrile (60) 
Yield: 29%; mp: 195-197°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 12.72 
(br s, 1H, NH pyrazole, exc D2O), 8.05 (s, 2H, NH2, exc D2O), 7.65 (s, 1H, 
CH pyrazole), 7.47 (d, 2H, J= 8.3 Hz, Ar), 7.09 (d, 2H, J= 8.4 Hz, Ar), 6.31 
(s, 1H, CH pyrazole), 4.48 (s, 2H, SCH2), 4.11 (q, 2H, J= 6.8 Hz, OCH2), 
1.36 (t, 3H, J= 6.8 Hz, CH3); IR (cm-1): 3456, 3319, 3215, 2218 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-4-(4-(allyloxy)phenyl)-6-aminopyridine-3,5-dicarbonitrile (61) 
Yield: 21%; mp: 216-218°C (EtOH/EtOAc); 1H NMR (400 MHz, 
DMSO-d6): 11.86 (s, 1H, NH imidazole, exc D2O), 8.09 (s, 2H, NH2, 
exc D2O), 7.48 (d, 2H, J= 8.5 Hz, Ar), 7.12 (d, 2H, J= 8.6 Hz, Ar), 
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7.07 (s,1H, CH imidazole), 6.85 (s, 1H, CH imidazole), 6.11-6.04 (m, 1H vinyl, CH), 5.40 (d, 1H, CH vinyl), 5.30 
(d, 1H, CH vinyl), 4.62 (d, 2H, J= 5.2 Hz, OCH2), 4.48 (s, 2H, SCH2) 
 
2-((4-(4-(Allyloxy)phenyl)-6-amino-3,5-dicyanopyridin-2-yl)thio)acetamide (62) 
Yield: 67%; mp: 204-206°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
8.00 (s, 2H, NH2, exc D2O), 7.50 (d, J = 8.6 Hz, 3H, Ar + NH amide, 
partially exc D2O), 7.26 (s, 1H, NH amide, exc D2O), 7.14 (d, J = 8.7 
Hz, 2H, Ar), 6.08 (ddd, J = 22.4, 10.5, 5.3 Hz, 1H, CH allyl), 5.45 (d, 
J = 17.3 Hz, 1H, CH2 allyl), 5.30 (d, J = 10.5 Hz, 1H, CH2 allyl), 4.67 (d, J = 5.1 Hz, 2H, OCH2), 3.89 (s, 2H, SCH2); 
IR (cm-1): 3325, 3215, 3184, 2212 
 
2-(((1H-Pyrazol-5-yl)methyl)thio)-4-(4-(allyloxy)phenyl)-6-aminopyridine-3,5-dicarbonitrile (63) 
Yield: 65%; mp: 129-131°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
12.75 (s, 1H, NH pyrazole, exc D2O), 8.06 (s, 2H, NH2, exc D2O), 7.59 
(s, 1H, CH pyrazole), 7.49 (d, J = 8.7 Hz, 2H, Ar), 7.13 (d, J = 8.7 Hz, 
2H, Ar), 6.32 (s, 1H, CH pyrazole), 6.18 – 5.95 (m, 1H, CH allyl), 5.45 
(d, J = 17.3 Hz, 1H, CH2 allyl), 5.30 (d, J = 10.4 Hz, 1H, CH2 allyl), 4.67 (d, J = 5.2 Hz, 2H, OCH2), 4.49 (s, 2H, 
SCH2); 13C NMR (100 MHz, DMSO): 160.25, 160.23, 158.49, 133.86, 130.67, 128.81, 126.41, 125.65, 118.35, 
115.95, 115.18, 111.08, 109.95, 105.12, 93.71, 86.31, 68.84; IR (cm-1): 3335, 3179, 2210 
 
2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-4-(4-((2-methylallyl)oxy)phenyl)pyridine-3,5-dicarbonitrile 
(64) 
Yield: 36%; mp: 224-226 (EtOH/EtOAc); 1H NMR (400 MHz, DMSO-
d6): 11.85 (br s, 1H imidazole, exc D2O), 8.08 (s, 2H, NH2, exc D2O), 
7.48 (d, 2H, J= 8.4 Hz, Ar), 7.12 (d, 2H, J= 8.4 Hz, Ar), 7.07 (s, 1H, CH 
imidazole), 6.85 (s, 1H, CH imidazole), 5.09 (s, 1H, CH2 propene), 
4.99 (d, 1H, CH2 propene), 4.56 (s, 2H, SCH2), 4.49 (s, 2H, OCH2), 
1.79 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): 167.19, 161.03, 160.95, 159.11, 143.71, 141.67, 131.75, 
131.28, 126.93, 116.58, 115.93, 115.80, 113.79, 94.22, 87.00, 72.14, 27.75, 20.32; IR (cm-1): 3404, 3377, 3336, 
2210 
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2-((6-Amino-3,5-dicyano-4-(4-((2-methylallyl)oxy)phenyl)pyridin-2-yl)thio)acetamide (65) 
Yield: 27%; mp: 224-226°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 
7.99 (s, NH2, exc D2O), 7.51 (s, 1H, NH2 amide, exc D2O), 7.50 (d, 
2H, J= 8.6 Hz, Ar), 7.25 (s, 1H, NH2 amide, exc D2O), 7.13 (d, 2H, J= 
8.6 Hz, Ar), 5.10 (s, 1H, CH2 propene), 4.99 (s, 1H, CH2 propene), 
4.57 (s, 2H, OCH2), 3.88 (s, 2H, SCH2), 1.08 (s, 3H, CH3); IR (cm-1): 
3481, 3334, 3234, 2212, 1681 
 
N-(4-(2-(((1H-Imidazol-2-yl)methyl)thio)-6-amino-3,5-dicyanopyridin-4-yl)phenyl)acetamide (66) (295) 
Yield: 61%; mp: 266-268°C (EtOH/CHx); 1H NMR (400 MHz, DMSO-
d6): 11.84 (br s, 1H, NH imidazole, exc D2O), 10.22 (s, 1H, NH amide, 
exc D2O), 8.11 (s, NH2, exc D2O), 7.73 (d, 2H, J= 8.3 Hz, Ar), 7.46 (d, 
2H, J= 8.4 Hz, Ar), 7.05 (s, 1H, CH imidazole), 6.86 (s, 1H, CH 
imidazole), 4.49 (s, 2H, CH2), 2.09 (s, 3H, CH3); IR (cm-1): 3387, 3211, 
2214, 1683 
 
2-((4-(4-Acetamidophenyl)-6-amino-3,5-dicyanopyridin-2-yl)thio)acetamide (67) 
Yield: 19%; 279-281°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 
10.21 (br s, 1H, NHCOCH3, exc D2O), 8.00 (s, 2H, NH2, exc D2O), 
7.74 (d, 2H, J= 7.6 Hz, Ar), 7.48 (d, 2H, J= 8.4 Hz, Ar), 7.47 (s, 1H, 
NH2 amide, exc D2O), 7.24 (s, 1H, NH2 amide, exc D2O), 3.88 (s, 2H, 
CH2), 2.09 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): 169.38, 
169.27, 166.67, 160.10, 158.52, 141.70, 129.72, 128.44, 119.12, 115.82, 93.65, 86.29, 33.78, 24.57; IR (cm-1): 
3419, 3367, 2208, 1647  
 
2-((6-Amino-3,5-dicyano-4-(4-hydroxyphenyl)pyridin-2-yl)thio)acetamide (142) 
Yield: 24%; (EtOH); 1H NMR (400 MHz, DMSO-d6): 10.08 (br s, 1H, OH, 
exc D2O), 7.97 (br s, 2H, NH2, exc D2O), 7.50 (br s, 1H, NH2 amide, exc 
D2O), 7.38 (d, 2H, Ar, J= 8.4 Hz), 7.24 (s, 1H, NH2 amide, exc D2O), 6.92 
(d, 2H, Ar, J= 8.4 Hz), 3.88 (s, 2H, CH2); IR (cm-1): 3331, 3176, 2214, 1658 
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Synthesis of 2-chloro-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile (85) 
 
Isoamylnitrite (9.05 mmol) was added to a suspension of equimolar amount of copper (II) chloride in ACN dry 
(5 ml) under nitrogen atmosphere and the reaction mixture was stirred 20 min at rt. Then, A (1.51 mmol) 
was added and the reaction was allowed to proceed for a weekend. 1N HCl  was then added and the resulting 
mixture was extracted with DCM (4 x 25 ml). The collected organic phases were washed with brine (2 x 20ml) 
and dried (NA2SO4). The solvent was removed under vacuum and the yellow residue triturated with Et2O, 
filtered and recrystallized by EtOH. Yield: 67 %; mp: 197-199°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.27 (s, 
1H,Fur), 7.66 (d, J = 3.6 Hz, 1H, Fur), 6.95 (d, J = 3.6 Hz, 1H, Fur), 3.70 (t, J = 6.3 Hz, 2H, CH2), 3.41(t, J = 6.3 Hz, 
2H, CH2); IR (cm-1): 2230 
 
General procedure for the synthesis of compounds (21-24) 
 
Procedure 
An ecess of the suitable primary amine (2.00 mmol) was added to a solution of 85 (1.00 mmol) in DMF dry 
(0.5 ml) and the mixture was stirred at rt for 5-16 h. At reaction completion, water (40 ml) was added in order 
to afford a solid which was filtered and washed with Et2O (5 ml). 
 
Examples 
2-(Cyclopropylamino)-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile (21) 
Yield: 91%; mp: 214-216°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.29 (br s, 
1H, NH, exc D2O), 8.10 (s, 1H, Fur), 7.37 (d, J = 3.4 Hz, 1H, Fur), 6.84 (s, 1H, Fur), 
5.01 (t, J = 5.4 Hz, 1H, OH, exc D2O), 3.70 (dd, J = 12.1, 6.2 Hz, 2H, O-CH2), 3.38 
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(t, J = 6.5 Hz, 2H, CH2), 2.97 – 2.84 (m, 1H, CH cyclopropyl), 0.80 (m, 2H, CH eq), 0.75 – 0.61 (m, 2H, CH ax); IR 
(cm-1): 3491, 3302, 2210 
 
2-(Cyclopentylamino)-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile (22) 
Yield: 89%; mp: 185-187°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.10 (s, 1H, 
Fur), 7.83 (d, J = 6.8 Hz, 1H, NH, exc D2O), 7.36 (d, J = 3.5 Hz, 1H, Fur), 6.82 (s, 
1H, Fur), 5.03 (t, J = 5.3 Hz, 1H, OH, exc D2O), 4.60 – 4.37 (m, 1H, CH 
cyclopentyl), 3.67 (dd, J = 12.1, 6.2 Hz, 2H, OCH2), 3.31 (t, J = 6.2 Hz, 2H, SCH2) 
1.96 (dd, J = 10.6, 6.4 Hz, 2H, CH2 cyclopentyl), 1.82 – 1.46 (m, 6H, 3CH2 
cyclopentyl); 13C NMR (100 MHz, DMSO-d6): 168.59, 157.83, 145.56, 144.17, 116.73, 116.31, 116.07, 113.23, 
89.74, 83.21, 59.98, 53.70, 33.33, 32.26, 24.29; IR (cm-1): 3466, 3348, 2210 
 
4-(Furan-2-yl)-2-((2-hydroxyethyl)thio)-6-((4-iodophenyl)amino)pyridine-3,5-dicarbonitrile (23) 
Yield: 99%; mp: 218-220°C (Acetone); 1H NMR (400 MHz, DMSO-d6): 9.93 (br 
s, 1H, NH, exc D2O), 8.15 (s, 1H, Fur), 7.72 (d, J = 8.5 Hz, 2H, Ar), 7.45 (d, J = 3.5 
Hz, 1H, Fur), 7.38 (d, J = 8.6 Hz, 2H, Ar), 6.96 – 6.78 (m, 1H, Fur), 4.96 (t, J = 5.8 
Hz, 1H, OH, exc D2O), 3.58 – 3.46 (m, 2H, OCH2), 3.16 (t, J = 6.1 Hz, 2H, SCH2); 
13C NMR (100 MHz, DMSO-d6): 178.96, 168.75, 156.80, 145.36, 144.60, 
138.22, 137.53, 126.43, 117.20, 115.92, 115.83, 113.36, 92.69, 89.73, 59.82, 33.60 ; IR (cm -1): 3394, 3296, 
2216 
 
2-(Benzylamino)-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridine-3,5-dicarbonitrile (24) 
Yield: 86%; mp: 171-173°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.80 (s, 1H, 
NH, exc D2O), 8.11 (s, 1H, Fur), 7.40 (d, J = 3.5 Hz, 1H, Fur), 7.38 – 7.29 (m, 4H, 
Ar), 7.25 (s, 1H, Ar), 6.85 (s, 1H, Fur), 4.98 (t, J = 5.4 Hz, 1H, OH, exc D2O), 4.70 
(d, J = 5.4 Hz, 2H, NHCH2), 3.48 (dd, J = 11.6, 5.9 Hz, 2H, OCH2), 3.16 (t, J = 6.1 
Hz, 2H, SCH2); 13C NMR (100 MHz, DMSO-d6): 168.81, 158.22, 145.51, 144.02, 139.43, 128.80, 127.35, 116.83, 
116.22, 116.08, 113.29, 90.03, 83.13, 59.74, 45.18, 33.42; IR (cm-1): 3344, 2208 
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Synthesis of N-(3,5-dicyano-4-(furan-2-yl)-6-(phenylthio)pyridin-2-yl)acetamide (86) 
 
A solution of compound 74 (0.94 mmol) and dry pyridine (0.23 mmol) in acetic anhydride (21.16 mmol, 2 ml) 
was refluxed for 28h. After removal of the solvent under vacuum, a brown solid was obtained which was 
recovered with Et2O and purified by silica gel column chromatography, eluting system CHX /EtOAc 7:3. Yield: 
41%; mp: 213-215°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 10.82 (s, 1H, NH, exc D2O), 8.23 (d, J = 1.2 Hz, 1H, 
Fur), 7.69 – 7.62 (m, 2H, Ar), 7.54 (m, J = 15.1, 4.6 Hz, 3H, Ar), 6.92 (dd, J = 3.7, 1.8 Hz, 1H, Fur), 1.92 (s, 3H, 
CH3); IR (cm-1): 3358, 3147, 2216, 1705 
 
Synthesis of N-(3,5-dicyano-4-(furan-2-yl)-6-mercaptopyridin-2-yl)acetamide (87) 
 
Sodium sulfide (1.19 mmol) was added to a solution of compound 86 (0.36 mmol) in dry DMF (0.5 ml), and 
the reaction mixture was heated at 80°C for 3h. Then, 0.1N HCl (25 ml) was added followed by addition of 
6N HCl  up to that a huge precipitate is formed. The solid was collected by filtration, washed with water (20 
ml) and Et2O (5 ml), and used for the next reaction without any further purification. Yield: 98%; 1H NMR (400 
MHz, DMSO-d6): 12.99 (s, 1H, SH, exc D2O), 8.19 (s, 1H, Fur), 7.50 (d, J = 3.4 Hz, 1H, Fur), 6.89 (s, 1H, Fur), 
2.23 (s, 3H, CH3)  
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Synthesis of N-(3,5-dicyano-4-(furan-2-yl)-6-((2-hydroxyethyl)thio)pyridin-2-yl)acetamide (25) 
 
 
Sodium hydrogencarbonate (0.53 mmol) and 2-bromoethanol (0.39 mmol) were sequentially added to a 
stirred solution of compound 87 (0.35 mmol) in dry DMF (1 ml). The reaction mixture was kept at rt for 3h 
and then water was added affording a light brown solid which was filtered and washed with water (10 ml) 
and Et2O (5 ml). The crude product was purified by preparative TLC using EtOAc as eluting system and then 
recrystallized. Yield: 20%; mp: 164-166°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 11.13 (s, 1H, NH, exc D2O), 
8.21 (s, 1H, Fur), 7.53 (d, J = 3.6 Hz, 1H, Fur), 6.90 (dd, J = 3.6, 1.7 Hz, 1H, Fur), 5.07 (s, 1H, OH, exc D2O), 3.70 
(t, J = 6.2 Hz, 2H, OCH2), 3.42 (t, J = 6.2 Hz, 2H, SCH2), 2.21 (s, 3H, CH3); 13C NMR (100 MHz, DMSO-d6): 169.37, 
168.55, 155.12, 144.96, 144.30, 118.22, 115.22, 115.09, 113.76, 113.27, 98.59, 94.79, 59.69, 33.87, 24.06; IR 
(cm-1): 3321, 2218, 1718 
 
Synthesis of 3,6-diamino-5-cyano-4-(4-(cyclopropylmethoxy)phenyl)thieno[2,3-b]pyridine-2-carboxamide 
(68) 
 
A solution of BAY-606583 (0.71 mmol) and potassium hydroxide (1.42 mmol) in absolute EtOH (10 ml) was 
refluxed for 3h. After completion of the reaction, iced-water (30 ml) was added and the mixture was 
neutralized with 5N HCl, then the green solid was filtered and washed with water (10 ml) and Et2O (5 ml). 
Yield: 85%; mp: 260-262°C (1,4-Dioxane); 1H NMR (400 MHz, DMSO-d6): 7.42 (d, 2H, J= 8 Hz, Ar); 7.28 (br s, 
2H, NH2, exc D2O); 7.12 (d, 2H, J= 8.4 Hz, Ar); 6.97 (br s, 2H, NH2, exc D2O); 5.70 (s, 2H, NH2 amide, exc D2O); 
3.91 (d, 2H, J= 6.8 Hz, OCH2); 1.28-1.27 (m, 1H, CH), 0.66-0.51 (m, 2H, CH2 eq), 0.44-0.27 (m, 2H, CH2 ax); 13C 
NMR (100 MHz, DMSO-d6): 167.23, 163.83, 160.08, 158.93, 152.75, 146.75, 130.05, 125.74, 116.43, 115.29, 
114.78, 93.36, 90.93, 72.71, 10.56; IR (cm-1): 3466, 3452, 3346, 3315, 3136, 2214, 1629. 
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Synthesis of 3,6-diamino-5-cyano-4-(4-(cyclobutylmethoxy)phenyl)thieno[2,3-b]pyridine-2-carboxamide 
(69) 
 
Equimolar amount of potassium carbonate and the suitable alkyl halide (4.61 mmol) were sequentially added 
to a solution of compound 142 (3.07 mmol) in dry acetone (20 ml). The mixture was heated at reflux for 98h. 
Then, the mixture was cooled to rt, filtered and the insoluble material was extracted with acetone (3 x 20 
ml). The collected organic phases were evaporated under vacuum affording a solid which was recovered with 
water (40ml) and the mixture was extracted with DCM (4 x 25 ml), washed with brine (2 x 25 ml) and dried 
(Na2SO4). The solid obtained after removal of the solvent was purified by preparative TLC, eluting system 
EtOAc/CHX 6:4. Yield: 18%; mp: 260-262°C (Dioxane); 1H NMR (400 MHz, CDCl3): 7.37 (d, 2H, J= 8.4 Hz, Ar); 
7.10 (d, 2H, J= 8.4 Hz, Ar); 5.90 (s, 2H, NH2 amide, exc D2O); 5.49 (s, 2H, NH2, exc D2O); 5.22 (s, 2H, NH2, exc 
D2O); 4.03 (d, 2H, J= 6.4 Hz, OCH2); 2.88-2.82 (m, 1H, CH); 2.20-2.17 (m, 2H, CH2); 2.05-1.90 (m, 4H, 2CH2); 13C 
NMR (100 MHz, DMSO-d6): 167.26, 163.82, 160.25, 158.92, 152.78, 146.78, 130.03, 125.72, 116,41, 115.31, 
114.75, 93.31, 90.91, 72.02, 34.39, 18.56; IR (cm-1): 3462, 3323, 3216, 3190, 2220, 1639 
 
Synthesis of 2-amino-4-(furan-2-yl)-6-methoxypyridine-3,5-dicarbonitrile (83) (374) 
 
A solution of sodium methoxide (30.45 mmol) in MeOH (20 ml) was rapidly added to a solution of 2-
furaldehyde (20.82 mmol), malononitrile (20.82 mmol) and tetrabutylammonium fluoride (2.08 mmol) in 
MeOH (10 ml) at rt. Then, further malononitrile (20.82 mmol) was added and the mixture was allowed to 
reflux for 3h. After completion, the reaction mixture was filtered over celite pad and the filtrate evaporated 
under vacuum. The crude residue was purified by silica gel column chromatography using DCM as eluent. 
Yield: 7%; mp: 205-207°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.09 (s, 1H, Fur), 8.05 (br s, 2H, NH2, exc D2O), 
7.38 (s, 1H, Fur), 6.83 (s, 1H, Fur), 3.97 (s, 3H, CH3); IR (cm-1): 3406, 3345, 3244, 2222 
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Synthesis of 2-amino-4-(furan-2-yl)-6-hydroxypyridine-3,5-dicarbonitrile (84) 
 
Compound 83 (1.41 mmol) was suspended in a mixture of glacial acetic acid (4 ml) and concentrated HCl (1 
ml) and heated at 100°C for 2 h. Then, the reaction mixture was cooled at rt affording a precipitate which 
was collected by filtration, washed with water (20 ml) and Et2O (5 ml) and dried in oven at 60°C. Yield: 81%; 
mp: 186-188°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.85 (br s, 1H, OH, exc D2O), 8.08 (d, J = 1.1 Hz, 1H, 
Fur), 7.72 (br s, 2H, NH2, exc D2O), 7.36 (d, J = 3.6 Hz, 1H, Fur), 6.82 (dd, J = 3.6, 1.7 Hz, 1H, Fur); IR (cm-1): 
3319, 3199, 2226, 2212 
 
Synthesis of 2-amino-4-(furan-2-yl)-6-(2-hydroxyethoxy)pyridine-3,5-dicarbonitrile (20) 
 
A sealed tube containing a mixture of compound 84 (0.53 mmol), 2-bromoethanol (0.58 mmol) and sodium 
hydrogencarbonate (0.79 mmol) in dry DMF (1 ml) was irradiated at 80°C in a microwave reactor for 3 h. 
After completion, water (30 ml) was added and the mixture was extracted with DCM (3 x 25 ml). The collected 
organic layers were washed with brine (2 x 20 ml), dried (Na2SO4) and evaporated under reduced pressure to 
yield a pale green solid that was purified by preparative TLC using DCM/MeOH 9:1 as eluent. Yield: 56%; mp: 
207-209°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.09 (s, 1H, Fur), 8.03 (br s, 2H, NH2, exc D2O), 7.38 (d, J = 
3.5 Hz, 1H, Fur), 6.93 – 6.69 (m, 2H, Fur), 4.91 (t, J = 5.3 Hz, 1H, OH, exc D2O), 4.54 – 4.17 (m, 2H, OCH2), 3.73 
(dd, J = 10.0, 5.2 Hz, 2H, CH2OH); 13C NMR (100 MHz, DMSO-d6): 166.70, 162.20, 146.50, 145.86, 116.47, 
116.36, 115.79, 113.19, 79.48, 69.52, 64.57, 59.40 
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Synthesis of 2-amino-6-chloro-4-phenylpyridine-3,5-dicarbonitrile (82) (301) 
 
Malononitrile (15.13 mmol) was added in small portions to a solution of trimethylorthobenzoate (7.53 mmol) 
in dry pyridine (0.6 ml). The mixture was heated at 100°C for 6 h and then cooled in ice bath. Concentrated 
HCl (2.7 ml) was carefully added and the mixture was heated again at 100°C for 2h. After cooling to rt, the 
resulting precipitate was collected by filtration, suspended in a saturated aqueous solution of sodium 
hydrogencarbonate, re-filtered and finally washed with water (10 ml). Yield: 61%; mp: >300°C (MeOH); 1H 
NMR (400 MHz, DMSO-d6): 7.57-7.61 (m, 5H, Ar), 8.27 (br s ,1H, NH2, exc D2O), 8.68 (br s, 1H, NH2, exc D2O); 
IR (cm-1): 3356, 3179, 2225, 1660, 1564 
 
General procedure for synthesis of 6-amino substituted compounds 19,36 
 
Procedure 
Equimolar amount of the suitable primary amine and triethylamine (2.00 mmol) were added to a solution of 
compound 82 (1.00 mmol) in a mixture THF/EtOH (2:1, 10.5 ml) and the reaction was refluxed for 1.5-6 h. 
Then, water (20 ml) was added affording a precipitate which was collected by filtration and washed with Et2O 
(5 ml).  
Examples 
 2-Amino-6-((2-hydroxyethyl)amino)-4-phenylpyridine-3,5-dicarbonitrile (19) 
Yield: 22%; mp: 230-231°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 7.55-7.53 (m, 
3H, Ar), 7.47-7.45 (m, 2H, Ar), 7.37 (br s, 2H, NH2, exc D2O), 7.20 (t, J = 5.1 Hz, 
1H, NH, exc D2O), 4.74 (t, J = 5.2 Hz, 1H, OH, exc D2O), 3.54 (q, J = 10.8 Hz, 2H, 
NHCH2), 3.47 (t, J = 5.8 Hz, 2H, OCH2); IR (cm-1): 3472, 3345, 3223, 2204. 
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2-(((1H-Imidazol-2-yl)methyl)amino)-6-amino-4-phenylpyridine-3,5-dicarbonitrile (36) 
Yield: 57%; mp: 208-210°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 11.64 (br s, 
1H, NH imidazole, exc D2O), 8.38 (br s, 2H, NH2, exc D2O), 7.88 (t, J = 5.5 Hz, 
1H, NH, exc D2O), 7.61-7.45 (m, 5H, Ar), 7.04 (s, 1H, CH imidazole), 6.83 (s, 1H, 
CH imidazole), 4.56 (d, J = 5.5 Hz, 2H, CH2); IR (cm-1): 3360, 3322, 3186, 2207. 
 
Synthesis of 2-amino-4-(furan-2-yl)-6-((2-hydroxyethyl)amino)pyridine-3,5-dicarbonitrile (17) 
 
A solution of compound 74 (0.47 mmol) and 2-aminoethanol (1.88 mmol) in DMF (2 ml) was heated at 100°C 
for 4h. After cooling at rt, water (10 ml) was added and the resulting precipitate was filtered and washed 
with water (10 ml) and Et2O (5 ml). Yield: 92%; mp: 230-232°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.03 (d, 
J = 0.96 Hz, 1H, Fur), 7.33 (br s, 2H, NH2, exc D2O), 7.24 (d, J = 0.56 Hz, 1H, Fur), 7.19 (t, J = 5.36 Hz, 1H, NH, 
exc D2O), 6.78 (dd, J = 3.5, 1.7 Hz, 1H, Fur), 4.76 (t, 1H, OH, exc D2O), 3.54 (q, J = 11 Hz, 2H, NHCH2), 3.47 (q, 
J = 11 Hz, 2H, OCH2); IR (cm-1): 3334, 2204. 
 
Synthesis of 2-amino-6-((2-hydroxyethyl)amino)-4-(thiophen-2-yl)pyridine-3,5-dicarbonitrile (18) 
 
A solution of compound 76 (0.60 mmol) and 2-aminoethanol (2.40 mmol) in DMF (2 ml) was heated at 100°C 
for 2h. After cooling at rt, water (10 ml) was added and the resulting precipitate was filtered, washed with 
water (10 ml) and Et2O (5 ml) and recrystallized from EtOH. Yield: 88%; 220-222°C (EtOH); 1H NMR (400 MHz, 
DMSO-d6): 7.87 (d, J = 4.7 Hz, 1H, CH thiophene), 7.47 (d, J = 1.6 Hz, 1H, CH thiophene), 7.42 (br s, 2H, NH2, 
exc D2O), 7.26-7.22 (m, 2H, NH + CH thiophene, partially exc D2O), 4.74 (t, J = 5.1 Hz, 1H, OH, exc D2O), 3.54 
(q, J = 10.9 Hz, 2H, NHCH2), 3.48 (q, J = 10.9, 2H, OCH2); IR (cm-1): 3491, 3451, 3338, 2202. 
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Synthesis of ethyl 2-cyano-3,3-bis(methylthio)acrylate (143) (375) 
 
Potassium carbonate (100 mmol) was added to a solution of ethyl cyanoacetate (100 mmol) in DMF dry (95 
ml) and the mixture was allowed to stir at rt for 3h under nitrogen atmosphere. Then, carbon disulfide (300 
mmol) was slowly dropped in the reaction mixture and the suspension stirred again for 2h before adding 
methyl iodide (200 mmol) and stirring at rt overnight. Then, addition of water (400 ml) while strong stirring 
yielded a solid that was collected by filtration and dried in desiccator. Yield: 88%; 1H NMR (400 MHz, DMSO-
d6): 4.21 (q, J = 7.1 Hz, 2H CH2), 2.73 (s, 3H, SCH3), 2.62 (s, 3H, SCH3), 1.25 (t, J = 7.1 Hz, 3H CH3); IR (cm-1): 
3262, 2207, 1697 
 
Synthesis of 4-(methylthio)-2-oxo-6-phenyl-2H-pyran-3-carbonitrile (144) (317) 
 
Compound 143 (4.87 mmol) and acetophenone (6.33 mmol) were sequentially added to a suspension of 
potassium hydroxide (5.84 mmol) in DMSO dry (20 ml). The reaction mixture was allowed to stir at rt for 5h. 
When the reaction was completed, iced water (70 ml) was added and the mixture was stirred for 2h to afford 
a yellow solid that was collected by filtration, washed with water (100 ml) and dried in oven at 60°C overnight. 
Yield: 56%; 1H NMR (400 MHz, DMSO-d6): 8.06 (d, J = 7.3 Hz, 2H, Ar), 7.74 – 7.49 (m, 3H, Ar), 7.26 (s, 1H, Ar), 
2.85 (s, 3H, SCH3). 
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Synthesis of 2-(5-phenyl-1H-pyrazol-3-yl)acetonitrile (145) (376) 
 
A solution of compound 144 (1.43 mmol) and hydrazine monohydrate (2.16 mmol) in pyridine (25 ml) was 
heated at reflux for 2.5h. The solvent was then removed under vacuum and the residue was recovered with 
CHCl3 (50 ml). The organic phase was washed with water (2 x 25 ml), dried (Na2SO4) and the solvent 
evaporated under reduced pressure. The brown residue was triturated with petroleum ether (5 ml) and EtOH 
(1 drop) and recovered by filtration. Yield: 71%; 1H NMR (400 MHz, DMSO-d6): 13.31 (br s, 1H, exc D2O, NH), 
7.74 (d, J = 7.5 Hz, 2H, Ar), 7.46 (t, J = 7.3 Hz, 2H, Ar), 7.41 – 7.32 (m, 1H, Ar), 6.68 (s, 1H, CH pyrazole), 4.00 
(s, 2H, CH2). IR (cm-1): 3135, 3113, 2250. 
 
Synthesis of tert-butyl 3-(cyanomethyl)-5-phenyl-1H-pyrazole-1-carboxylate (146) 
 
Dry TEA (5.97 mmol), dimethylaminopyridine (0.35 mmol) and BOC-anhydride (2.63 mmol) were added to a 
stirred solution of compound 145 (1.76 mmol) in dry ACN at 0°C. After reagent addition, the mixture was 
allowed to warm to rt and stirred for 1h. Then, brine (10 ml) was added and the mixture extracted with EtOAc 
(3 x 5 ml). The collected organic phases were dried (Na2SO4) and the solvent removed under vacuum, leading 
to a red residue which was triturated with Et2O and filtered to yield a light brown solid, used for the next step 
without any further purification. Yield: 86%; 1H NMR (400 MHz, DMSO-d6): 7.90 (d, J = 7.0 Hz, 2H, Ar), 7.53 – 
7.37 (m, 3H, Ar), 7.08 (s, 1H, CH pyrazole), 4.39 (s, 2H, CH2), 1.63 (s, 9H, CH3 t-Bu).  
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Synthesis of tert-butyl 3-(1-cyano-2,2-bis(methylthio)vinyl)-5-phenyl-1H-pyrazole-1-carboxylate (147) 
 
Compound 146 (3.52 mmol) was dissolved in dry DMSO (20 ml) at 0°C and carbon disulfide (7.94 mmol), 
methyl iodide (14.12 mmol) were added and followed by the portion wise addition of sodium hydride (7.06 
mmol, 60% in mineral oil) while keeping the temperature under 10°C. After 30min at 5°C, the mixture was 
warmed to rt and stirred for 3h. Then, the mixture was transferred into a 250 ml round bottomed flask and 
a saturated solution of ammonium chloride (20 ml) was added, followed by addition of cold water (150 ml). 
The mixture was stirred until an orange gluey solid is formed, then the aqueous layer was removed by 
decantation. The residue was suspended in 2-propanol and after few minutes of stirring an off-white solid 
precipitated which was collected by filtration. Yield: 61%; 1H NMR (400 MHz, DMSO-d6): 7.91 (d, J = 6.9 Hz, 
2H, Ar), 7.55-7.37 (m, 3H, Ar), 7.31 (s, 1H, CH pyrazole), 2.65 (s, 3H, SCH3), 2.39 (s, 3H, SCH3), 1.60 (s, 9H, CH3 
t-Bu). 
 
Synthesis of 3,3-bis(methylthio)-2-(5-phenyl-1H-pyrazol-3-yl)acrylonitrile (148) 
 
Compound 147 (0.77 mmol) was allowed to stir in of a 10% solution of trifluoroacetic acid in DCM dry (25 ml) 
for 1,5h. Then, the solvents were removed under reduced pressure affording a brown solid that was 
triturated with a saturated solution of sodium bicarbonate (25 ml), collected by filtration and dried in oven 
at 60°C. Yield: 93%; 1H NMR (400 MHz, DMSO-d6): 13.70 (br s, 1H, NH), 7.79 (d, J = 7.5 Hz, 2H, Ar), 7.47 (t, J = 
7.5 Hz, 2H, Ar), 7.38 (t, J = 7.4 Hz, 1H, Ar), 7.04 (s, 1H, CH pyrazole), 2.59 (s, 3H, SCH3), 2.50 (s, 3H, overlapping 
with DMSO-d6, SCH3). 
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Synthesis of 7-amino-5-(methylthio)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (149) 
 
A solution of compound 148 (2.78 mmol), cyanamide (8.35 mmol) and paratoluensulfonic acid (2.78 mmol) 
in NMP (3 ml) was irradiated with microwave at 160°C for 1h (4 x 15 min cycle). At the end of each irradiation 
cycle, cyanamide (8.35 mmol) was added. The reaction mixture was diluted with water (200 ml) and stirred 
for 5h to afford a solid that was collected by filtration and extracted with acetone (50 ml). The solvent was 
evaporated under reduced pressure affording a yellow solid that was recovered with petroleum ether (10 
ml). Yield: 89%; mp: 104-106°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.95 (br s, 1H, NH2, exc D2O), 8.52 (br 
s, 1H, NH2, exc D2O), 8.10 (d, J = 6.9 Hz, 2H, Ar), 7.48 (m, 3H, Ar), 6.96 (s, 1H, CH pyrazole), 2.63 (s, 3H, SCH3). 
IR (cm-1): 3319, 2204. 
 
 
Synthesis of 7-amino-5-(methylsulfonyl)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (150) 
 
3-Chloroperoxybenzoic acid (4.53 mmol) was added to a solution of compound 149 (1.81 mmol) in DCM dry 
(40 ml) at 0°C. The mixture was allowed to stir at 0 – 5°C for 2h and then at rt for further 5h. The solvent was 
then removed under vacuum at rt and a 5% sodium bicarbonate solution (25 ml) was added to the residue. 
The mixture was stirred for 20 min and the resulting solid was filtered and washed with water (20 ml) and 
petroleum ether (10 ml) affording a brown powder which was dried in oven at 60°C. Yield: 86%; (MeOH); 1H 
NMR (400 MHz, DMSO-d6): 9.35 (br s, 1H, NH2, exc D2O), 8.90 (br s, 1H, NH2, exc D2O), 8.18 (dd, J = 11.3, 4.4 
Hz, 2H, Ar), 7.61 – 7.41 (m, 4H, Ar + pyrazole), 3.36 (s, 3H, SO2CH3). 
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General procedure for the synthesis of compound (70-73) 
 
Procedure  
A solution of compound 150 (1.00 mmol), the suitable primary amine (7.1 mmol) and N,N-
diisopropylethylamine (4.1 mmol) in anhydrous dioxane (10 ml) was heated at 90°C for 24-48 h. After 
completion, the reaction mixture was allowed to cool at rt and water (40 ml) was added. Extraction was 
performed with EtOAc (3 x 20 ml) and the collected organic phases were washed with brine (2 x 20 ml), dried 
(Na2SO4), and evaporated under vacuum to yield the final compounds which were purified by silica gel 
column chromatography or by recrystallization.  
 
Examples 
7-Amino-5-(benzylamino)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (70) 
Yield: 84%; mp:245-247°C (EtOH); 1H NMR (400 MHz, DMSO-d6): 8.43 
(br s, 1H, NH2, exc D2O), 8.02 (dt, J = 3.3, 1.9 Hz, 2H, Ar), 7.98 (br s, 1H, 
NH2, exc D2O), 7.79 (t, J = 6.1 Hz, 1H, NH, exc D2O), 7.51 – 7.39 (m, 3H, 
Ar), 7.39 – 7.28 (m, 4H, Ar), 7.28 – 7.18 (m, 1H, Ar), 6.55 (s, 1H, CH), 4.63 
(d, J = 6.1 Hz, 2H, CH2); 13C NMR (100 MHz, DMSO-d6): 157.90, 155.73, 148.69, 144.17, 140.68, 132.47, 129.61, 
129.15, 128.66, 127.80, 127.10, 126.93, 118.03, 90.60, 60.25, 44.42; IR (cm-1): 3222, 3136, 2251 
 
7-Amino-5-((3-methoxybenzyl)amino)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (71) 
Yield: 79%; mp: 198-200°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 8.43 
(br s, 1H, NH2, exc D2O), 8.07 – 7.99 (m, 2H, Ar), 7.96 (br s, 1H, NH2, exc 
D2O), 7.75 (t, J = 6.2 Hz, 1H, NH, exc D2O), 7.53 – 7.37 (m, 3H, Ar), 7.29 
– 7.19 (m, 1H, Ar), 6.94 (d, J = 7.4 Hz, 2H, Ar), 6.80 (dd, J = 9.1, 1.6 Hz, 
1H, Ar), 6.55 (s, 1H, CH), 4.59 (d, J = 6.1 Hz, 2H, CH2), 3.74 (s, 3H, CH3); 
13C NMR (100 MHz, DMSO-d6): 159.68, 157.86, 155.73, 148.66, 144.14, 142.31, 132.46, 129.76, 129.60, 
129.16, 126.93, 119.96, 118.02, 113.59, 112.44, 90.62, 55.40, 44.37; IR (cm-1): 3203, 3100, 2251 
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7-Amino-5-((furan-2-ylmethyl)amino)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (72) 
Column chromatography eluent CHx 1 : EtOAc 1; Yield: 55%; mp: 206-
208°C (EtOAc); 1H NMR (400 MHz, DMSO-d6): 8.49 (br s, 1H, NH2, exc 
D2O), 8.19 – 7.86 (m, 3H, Ar + NH2, partially exc D2O), 7.67 (t, J = 5.9 Hz, 
1H, NH, exc D2O), 7.57 (d, J = 0.9 Hz, 1H, Fur), 7.52 – 7.36 (m, 3H, Ar), 
6.56 (s, 1H, CH), 6.40 (dd, J = 3.1, 1.8 Hz, 1H, Fur), 6.32 (d, J = 3.0 Hz, 1H, Fur), 4.59 (d, J = 5.8 Hz, 2H, CH2); 13C 
NMR (100 MHz, DMSO-d6): 157.64, 155.73, 153.45, 148.63, 144.05, 132.43, 129.61, 129.15, 126.92, 117.84, 
110.91, 107.46, 90.14, 38.09; IR (cm-1): 3304, 3188, 3150, 2199 
 
7-Amino-5-(phenethylamino)-2-phenylpyrazolo[1,5-c]pyrimidine-4-carbonitrile (73) 
Yield: 60%; mp: 232-234°C (MeOH); 1H NMR (400 MHz, DMSO-d6): 
8.43 (br s, 1H, NH2, exc D2O), 8.02 (d, J = 7.6 Hz, 2H, Ar), 7.97 (br s, 
1H, NH2, exc D2O), 7.45 (dt, J = 21.6, 7.1 Hz, 3H, Ar), 7.37 – 7.15 (m, 
6H, Ar + NH, partially exc D2O), 6.53 (s, 1H, CH), 3.61 (dd, J = 14.6, 6.2 
Hz, 2H, N-CH2), 2.95 – 2.82 (m, 2H, CH2-Ph); 13C NMR (100 MHz, DMSO-d6): 157.88, 155.65, 148.68, 144.21, 
139.97, 132.50, 129.57, 129.24, 129.13, 128.75, 126.90, 126.52, 118.09, 90.27, 43.20, 36.05; IR (cm-1): 3333, 
3157, 2193 
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10. Visiting period at Universität Bonn 
 
During my Ph.D. course I spent six months at Universität Bonn, Pharmazeutische Chemie I department in the 
group of Professor Christa E. Müller under the supervision of Dr. Thanigaimalai Pillayiar. For many years, the 
group of Professor Müller has been specialized on the study of GPCRs and in particular on purinergic signaling. 
Recently, one of the most important aim of the group has been the deorphanization of the so called orphan 
receptors. In particular, the completion of the human genome sequencing project has identified 
approximately 720 genes that belong to the GPCR superfamily. Approximately half of these genes are thought 
to encode sensory receptors. Of the remaining 360 receptors, the natural ligand has been identified for 
approximately 210 receptors, leaving 150 so-called orphan GPCRs with no known ligand or function (377). 
The identification of ligands active at orphan GPCRs has been achieved through the development of a number 
of experimental approaches, including the screening of putative small molecule and peptide ligands, reverse 
pharmacology, and the use of bioinformatics to predict candidate ligands (378). Following expression, 
candidate ligands are screened against the receptor to identify molecules capable of specific regulation of 
that receptor. Such ligands can include tissue extracts, expressed or purified proteins or small peptides, 
natural and synthetic small molecules, and lipids. Once a candidate ligand is identified, further studies are 
performed to confirm that the activity of the ligand is specific to the receptor. In recent years, small-molecule, 
peptide, protein, and lipid ligands have been identi- fied for many orphan GPCRs. However, approximately 
160 orphan GPCRs remain for which there is no known ligand. Efforts continue to identify ligands for these 
receptors, however, it is now necessary to investigate alternative strategies. Such studies may involve the 
identification of new ligands using bioinformatics to predict likely peptide or protein ligands. It may be that 
the remaining orphan GPCRs are atypical in that they do not signal through heterotrimeric G-proteins. If this 
is the case, then the assays used to date, which all rely upon G-protein activation of a signal transduction 
cascade, cannot be used for these receptors. In support of this hypothesis, there is an emerging literature 
describing G-protein-independent signaling by GPCRs. The identification of ligands at such receptors depends 
on the development of new assays. It is also possible that not all of these receptors will have ligands; 
receptors have been identified that act as trafficking factors, are believed to act as ligand sinks, and exhibit 
constitutive signaling in the absence of ligand. The challenge in the coming years is to identify the biological 
function of the remaining orphan GPCRs.  
MrgX-4 is an orphan G-protein coupled receptor (GPCR) that belongs to a family called MAS-related genes 
(Mgrs) (379). This GPCRs family takes its name from the first receptor discovered, MAS1 oncogene that is 
activated by binding angiotensin (1-7): it mediates a range of effect mostly opposed to the activation of 
angiotensin-II activated angiotensin receptor. MrgX-4 belongs to a class of receptors (MrgX1-7) which seems 
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to be selectively expressed in the small-diameter sensory neurons of dorsal root ganglia: this is one of the 
nowadays known evidences that lead to expect a promising involvement in neuropathic pain for this class of 
GPCRs. Besides, this family has not been found in rodents, making a deepening of the physiopatholgical role 
more complicated. MrgX receptors were cloned from rhesus monkey and functionally characterized 
alongside their human orthologues. Most of the human and rhesus MrgX receptors displayed high 
constitutive activity in a cellular proliferation assay. Proliferative responses mediated by human or rhesus 
MrgX-1, or rhesus MrgX-2 were partially blocked by pertussis toxin (PTX). Proliferative responses mediated 
by rhesus MrgX-3 and both human and rhesus MrgX-4 were PTX insensitive. These results indicate that 
human and rhesus MrgX-1 and MrgX-2 receptors activate both Gq- and Gi-regulated pathways, while MrgX-3 
and MrgX-4 receptors primarily stimulate Gq-regulated pathways (379). The aim of my work was synthesizing 
agonist at MrgX-4 through a synthetic pathway partially shown in figure I. Neither complete synthesis 
(scheme 23), nor the twelve synthesized compounds and related pharmacological data can be showed in this 
thesis, in order to safeguard a future patent application or future pubblications.  
 
 
Scheme 23 
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